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Abstract  
Micronutrient deficiencies are common in children living in low-income countries, more so 
in malnourished and HIV-infected children. The routinely practiced interventions, such as 
vitamin A supplementation and other micronutrients in recommended dietary allowances 
(RDA), may not be sufficient to correct all the micronutrient deficiencies. Gaps still exist in 
determining the optimal composition, dosing and duration of supplementation. Highly 
active antiretroviral therapy tends to improve micronutrient status of HIV-infected persons, 
but most probably not back to normal concentrations, especially in areas where daily food 
intake is not micronutrient-rich.  
Aims
The study aimed at determining the effect of multiple micronutrient supplementation on 
mortality, growth, diarrhoea and micronutrient concentrations of Ugandan HIV-infected 
children aged 1-5 years at paediatric HIV clinics.  
Methods
Using a randomised controlled design, 847 confirmed HIV-infected children were enrolled, 
stratified into the highly active antiretroviral (HAART) and HAART naïve groups, and 
assigned to either an intervention supplement or standard of care comparative arm. The 
intervention consisted of 10 multivitamins and 4 minerals (vitamins A, B1, B2, Niacin, B6, 
B12, folate, C, D and E, plus minerals selenium, zinc, copper and Iodine) in 2 RDA doses, 
whereas the comparative supplement contained 6 multivitamins in 1-RDA as the ‘standard 
of care’ at 7 paediatric HIV clinics in Uganda. At enrolment, current and previous history of 
illness, anthropometric measurements and a detailed systemic examination was done. The 
trial supplement was administered orally, once daily for 6 months. Compliance was 
measured by weighing the remaining supplement at each monthly visit. The participants 
attended the study clinics on scheduled visits monthly for 6 months, at 9 and 12 months, and 
for treatment whenever the child was sick. All study clinics had in-patient facilities where 
very sick children could be hospitalised. Blood was drawn for a complete blood count, 
CD4+ cell count, C-reactive protein (CRP) and micronutrient assays, at baseline and 6 
months visit. Study outcomes were measured at 12 months for mortality, 6 months for 
diarrhoea morbidity and the effect of supplementation on vitamin B12 and folate 
concentrations at 6months. Zinc status was reported as part of the baseline survey. For all 
the papers, data analysis was by arm and stratum. 
Results
Of the 847 children, 85 (10.0%) were on HAART whereas 762 (90.0%) were HAART-
naïve. Overall, 426 (50.3%) children, 43 on HAART and 383 HAART-naïve received the 
intervention whereas 421(49.7%), 42 on HAART and 379 HAART-naïve were treated with 
the comparative ‘standard of care’ supplement.  
 
The mortality rate in the participants was 6.3 % at one year of follow-up. Mortality from all 
causes was 25/426 (5.9%) with intervention and 28/421 (6.7%) in the comparative arm. 
There was no difference between arms; the risk ratio was 0.9 (95% CI; 0.5-1.5) using the 
Kaplan-Meier survival analysis. As expected, mortality was lower in the HAART stratum, 
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2/85 (2.4%). Mean survival time was similar in both groups. Generally, weight-for-height 
and weight-for-age improved except height-for-age z scores, and there was no difference 
between the 2 arms.  
 
There was no difference in the incidence and prevalence of diarrhoea in the 2 groups. The 
incidence of diarrhoea was 3.8 (95% CI; 3.4-4.3) in the intervention and 3.5 (95% CI; 3.1-
4.0) in the comparative arm per child-year. The rate ratio was 1.1(95%CI; 0.9-1.3). In the 
HAART stratum, the incidence of diarrhoea was 1.7 (95%CI; (1.0-2.7) in the intervention 
and 1.5 (95%CI; 0.9-2.6) in the comparative arm. Although these children had fewer 
episodes of diarrhoea, there was no difference between the 2 arms. The rate ratio was 1.1 
(95%CI; 0.5-2.3). 
 
More than half the children had low zinc concentrations. Of the 247 children analysed for 
zinc status, 134 (54.3%) had zinc concentrations of < 10 mol/L; 121/203 (59.6%) in the 
HAART naïve, and 13/44 (29.5%) in the HAAR-treated children, Odds ratio (OR) 3.5 
(95%CI; 1.7-7.1).  
 
At 6 months of supplementation, the children receiving the intervention had higher serum 
concentrations of vitamin B12 and folate compared to those who received the ‘standard of 
care’ supplement. In the intervention group, the median concentration (IQR) of vitamin B12 
at 6 months was 401.5 (264.3-518.8) pmol/L compared to the baseline of 285.5 (216.5-
371.8) pmol/L, p<0.001. The median (IQR) folate concentrations also increased from 17.3 
(13.5-26.6) nmol/L to 27.7 (21.1-33.4) nmol/L, p<0.001. Of the 214 children, 60 (28.0%) 
had low vitamin B12 (<221picomoles per litre) concentrations at baseline compared to 
42/214 (19.6%) at 6 months. Sixty two children (29.0%) had low folate (<13.4 nanomoles 
per litre) concentrations at baseline compared to 44/214 (20.6%) at 6 months. There was 
minimal reduction in the prorpotion of children with low vitamin B12 and folate 
concentrations. 
 
There was a general increase in haemoglobin with no differences between the 2 groups, nor 
was there any significant change in CD4+ cell count. The supplement was well tolerated 
with no adverse effects.  
Conclusion
A supplement of 2 RDAs of 14 micronutrients given to HIV-infected children for 6 months 
did not reduce mortality or diarrhoea morbidity, but improved vitamin B12 and folate 
concentrations compared to the comparative ‘standard of care’ arm. The supplement was 
well tolerated with no adverse effects. More than half of the children were zinc deficient, 
whereas one-third was vitamin B12 or folate deficiency. Routine supplementation with 
2RDAs of multiple micronutrients to HIV-infected children in Uganda is recommended to 
reduce the magnitude of micronutrient deficiencies. Further studies to determine the impact 
of prolonged supplementation, inclusion of iron (our supplement did not contain iron) and 
supplementation in a larger group of HAART treated children are also recommended.   
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Introduction 
Vitamins and minerals are commonly termed ‘micronutrients’, which are distinguished from 
‘macronutrients’ that are the energy-yielding compounds (proteins, carbohydrates and fat) 
in our diet. The topic of micronutrients is extremely broad and could be subject for a 
textbook-sized presentation. The scope of this thesis was a randomised clinical trial of 
supplementation of micronutrients to HIV-infected children in Uganda. In this introduction, 
I will try to bring the reader sufficiently up to date to understand the rationale for the study, 
but obviously there are a lot of things about micronutrients that have intentionally been left 
out to limit the size of this thesis. I hope the reader will find the selection adequate.  
Micronutrients – vitamins and minerals 
Micronutrients often constitute important building blocks in enzymes and other vital cellular 
structures, and they cannot be substituted by any other micronutrient or macronutrient; they 
are known as ‘essential nutrients’. The micronutrients - vitamins and trace elements - cannot 
be synthesised by the body in sufficient amounts to maintain normal metabolism, growth 
and health. Therefore adequate intake depends on their availability in the diet or other 
external sources. For any micronutrient, an individual’s requirements depends on a variety 
of factors, such as age, gender, physical activity, health status, physiological states (e.g. 
pregnancy) and the efficiency with which a person absorbs and metabolises micronutrients. 
Growing individuals, such as children and people with increased physiological demands 
(pregnant women), have a relatively greater need of vitamins and trace elements compared 
to others. For sick individuals, potential losses must also be factored in.  
 
The average normal requirements for an individual can be estimated using average 
requirements (EARs) of a population. Every nutrient has a distribution of requirement 
described by a median/mean and standard deviation. The EAR is the intake level of a 
nutrient at which the needs of 50% of the population in that age-group and gender are met. 
In order to cover for the requirements of the whole population, another measurement - the 
Recommended Daily Allowance (RDA)- is needed. RDA is defined as the daily dietary 
intake level of a nutrient considered sufficient by the Food and Nutrition Board, National 
Academy of Sciences, Institute of Medicine, Washington to meet the requirements of nearly 
all (97-98%) the healthy individuals in each life-stage and gender group.1 Mathematically, it 
is calculated based on the EAR in the following way. If the standard deviation (SD) of the 
EAR is available and the requirement for the nutrient is symmetrically distributed, the RDA 
is set at 2 SDs above the EAR: 
RDA = EAR + 2 SD (EAR) 
 
This level of intake statistically represents 97.5 percent of the requirements of the 
population (Figure 1). For some nutrients, data on the variability in requirements may be 
insufficient or unavailable to calculate a standard deviation, in which case a coefficient of 
variation (CV) for the EAR of 10% is assumed. Twice that amount added to the EAR is 
equivalent to the RDA. The resulting equation for the RDA is: 
 
RDA = 1.2 × EAR 
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Figure 1. Distribution of requirements for a single nutrient in population for a single gender 
and a specific age group. The distribution is commonly a Gaussian curve. Estimated 
Average Requirement (EAR) for this group and how the Recommended Dietary Allowance 
(RDA) is derived by adding 2 standard deviations (SDs). Source: Tarasuk, 2006. 
 
To illustrate how RDA varies with gender, age group and physiological states, the RDA for 
vitamin C are shown in Table 1. It is easy to see that the relative need is higher for growing 
individuals; a baby of 5 kg needs 50 mg of vitamin C compared to 90 mg in an adult who > 
10 times heavier. 
 
Micronutrients and biochemical functions 
A number of micronutrients act as co-enzymes for many metabolic processes in the body. 
The co-enzymes help our bodies to utilise the macronutrients (carbohydrates, proteins and 
fats) by breaking them down for energy production. 2, 3 The majority of the B vitamins are 
mainly involved in energy metabolism, lipid and nucleic acids synthesis.4 Vitamin B6 is a 
coenzyme in many enzyme reactions, particularly those responsible for amino-acid 
metabolism and transport. In addition, some of the micronutrients are involved in nucleic 
acid synthesis and formation of new cells. For instance, folate is required for synthesis of 
new red blood and gastrointestinal cells, and works with vitamin B12. Vitamin C plays a role 
in collagen formation and iron absorption, and has multiple other functions as a co-enzyme 
or co-factor.5, 6 In the metabolic processes the micronutrients co-operate, for instance, 
selenium promotes activity of vitamin E to prevent lipid oxidation and copper promotes iron 
metabolism. Some of the functions and symptoms of deficiency states of selected 
micronutrients are summarised in Table 2. 
 
Magnitude of micronutrient deficiencies in children 
Micronutrient deficiency has been coined ‘hidden hunger’, the reason being that, although it 
is not a gut-feeling, it may have devastating effects on an individual’s health and general 
wellbeing. It is also wide spread – affecting more than 2 billion people globally – especially 
those living in low-income countries. It arises from lack of micronutrient-rich foods such as 
vegetables, fruits, animal products and fortified foods. Children and pregnant women with a 
relatively greater need of vitamins and trace elements are most affected by this scarcity, 
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making them more vulnerable to micronutrient deficiencies. The risk of micronutrient 
deficiencies is further increased in those with severe acute malnutrition, chronic infections 
and human immunodeficiency virus (HIV) infection. These conditions singly or together 
lead to reduced immunity and an increased risk of infectious diseases and mortality.7  
Table 1. Recommended dietary allowance (RDA) for vitamin C according to gender 
age and physiological status. 
Life stage Age Males (mg/day) Females (mg/day) 
Infants 0-6 months   40   40 
Infants 7-12 months   50   50 
Children 1-3 years   15   15 
Children 4-8 years   25   25 
Children 9-13 years   45   45 
Adolescents 14-18 years   75   65 
Adults 19 years & older   90   75 
Smokers 19 years & older 125 110 
Pregnancy 18 years & younger     -   80 
Pregnancy 19 years & older     -   85 
Breastfeeding 18 years & younger     - 115 
Breastfeeding 19 years & older     - 120 
Source: Micronutrient Information Center, Linus Pauling Institute, Oregon State University, USA 
In order to understand how micronutrient deficiency leads to reduced immunity and 
recurrent infections, the following section summarises how the immune system works. It 
also deals with how HIV-infection and micronutrient deficiencies affect the immune system.  
Table 2. The main functions and deficiency states of selected micronutrients  
Micronutrient 
name
Main function Main deficiency symptoms 
Retinol
(Vitamin A) 
Maintain healthy surface linings of the eyes, 
the respiratory, urinary, and intestinal tracts, 
the skin and mucous membranes; night 
vision; bone development; antioxidant  
Bitot’s spots, xerophthalmia, corneal 
ulcers, scarring of the cornea and 
blindness; impaired dark adaptation. High 
incidence of respiratory illnesses and 
diarrhoea; increased mortality 
Thiamin
(Vitamin B1)
Carbohydrate metabolism, coenzyme for 
synthesis of nucleic acids  
Peripheral neuropathy, diminished 
sensation and weakness in the 
extremities. Muscle pain and tenderness, 
seizures (severe deficiency). Signs of 
congestive heart failure  
Riboflavin
(Vitamin B2)
Metabolism of fats, carbohydrates and 
proteins. Protection from reactive oxygen 
species 
Sore throat, stomatitis, cheilosis, 
inflammation and redness of the tongue, 
and seborrhoeic dermatitis. Normochromic 
normocytic anaemia 
Niacin 
(Vitamin B3)
Metabolism of carbohydrates, fats and 
proteins and synthesis of fatty acids and 
cholesterol  
Dermatitis, diarrhoea, bright red tongue, 
vomiting, and diarrhoea, apathy and 
fatigue
Pyridoxine
(Vitamin B6)
Coenzymes that catalyse gluconeogenesis, 
synthesis of neurotransmitters, heme, 
nucleic acids, conversion of homocysteine 
to cysteine, production of lymphocytes and 
IL-2
Peripheral neuropathy, irritability, 
confusion, seizures in severe deficiency. 
Inflammation of the tongue, sores or 
ulcers of the mouth, and angular 
stomatitis. Anaemia.  
Folic acid 
(Vitamin B9)
Metabolism of nucleic acids and amino 
acids, synthesis of DNA, RNA, conversion 
of homocysteine to methionine  
Continued on next page 
Megaloblastic anaemia and symptoms of 
anaemia (fatigue, weakness, and 
shortness of breath) 
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Micronutrient 
name
Main function Main deficiency symptoms 
Cobalamin 
(Vitamin B12)
Amino acid metabolism, methylation of a 
number of sites in DNA and RNA, 
production of energy from fats and proteins, 
hemoglobin synthesis.  
Megaloblastic anaemia, numbness and 
tingling of the extremities, difficulty 
walking, mood changes, tongue soreness, 
appetite loss, and constipation 
Ascorbic acid 
(Vitamin C) 
Synthesis of collagen, synthesis of carnitine 
which is essential for transport of fat into 
mitochondria for production of energy, 
metabolism of cholesterol to bile acids. 
Antioxidant, enhance chemotaxis and 
phagocytosis 
Bleeding and bruising easily, hair and 
tooth loss, and joint pain and swelling, 
fatigue
Cholecalciferol 
Vitamin D) 
Absorption of calcium and hardening of 
bones. DNA synthesis and transcription of 
genes, cellular differentiation, modulates 
immune cells e.g. dendritic cells and 
macrophages 
Rickets, muscle weakness and pain, 
frequent bacterial infections 
Alpha-
tocopherol  
(Vitamin E) 
Antioxidant, maintain integrity of cell 
membranes, affect the expression and 
activities of enzymes in immune and 
inflammatory cells 
Peripheral neuropathy, muscle weakness  
Iodine (I-)  Production of thyroid hormones, regulating 
metabolism and development, growth and 
development of the nervous system 
Fetal death, still-birth, birth defects, mental 
retardation, lower IQ and learning 
disabilities, poorer school performance, 
growth retardation, enlarged thyroid gland 
Selenium
(Se2+)
Regulates thyroid hormone (conversion of 
T4 to T3), a number of selenium dependent 
enzymes are antioxidants, facilitate cell 
growth and viability, promotes activity of 
vitamin E to reduce lipid oxidation 
Increased infections, cardiomyopathy in 
severe deficiency, increased oxidative 
stress may favour HIV viral replication  
Zinc (Zn2+) Growth and development, immune 
response, neurological function, and 
reproduction. Nearly 100 Zinc-dependent 
enzymes, stabilises the structure of a 
number of proteins. Antioxidant; stabilises 
structure and function of cell membranes, 
regulate gene expression, influences 
hormone release and nerve impulse 
transmission, apoptosis. Bioavailability of 
folate in diet increased by zinc dependent 
enzymes; metabolism of vitamin A 
Delayed growth and development, 
dermatitis, diarrhoea, increased 
susceptibility to infections, impaired wound 
healing, diminished appetite, impaired 
taste sensation 
Copper (Cu2+) Cellular energy production, formation of 
collagen and elastin, transport and 
mobilisation of iron from stores, synthesis of 
neurotransmitters, formation of myelin, 
formation of melanin, formation of 
antioxidant superoxide dismutase, regulate 
gene transcription, necessary for iron 
metabolism 
Anaemia unresponsive to iron therapy, 
reduced neutrophil count, loss of 
pigmentation, neurological symptoms, and 
impaired growth 
Iron (Fe2+) Oxygen transport and storage, 
electron transport and energy metabolism, 
antioxidant and beneficial pro-oxidant 
functions, oxygen sensing, DNA synthesis 
Microcytic-hypochromic anemia, brittle 
and spoon-shaped nails, sores at the 
corners of the mouth, taste bud atrophy, a 
sore tongue, pica (consumption of non-
food items), impaired intellectual 
development and immune function. 
Source of information: http://lpi.oregonstate.edu/infocenter/minerals:html and 
http://lpi.oregonstate.edu/infocenter/vitamin:html 
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The immune system
The immune system is a complex network of cells, tissues, proteins and organs that work 
together to defend the body from infectious micro-organisms and toxins. Our bodies are 
constantly exposed to germs or micro-organisms that cause diseases, however, the immune 
system continuously protect us from these invaders. In case they get in the body, the 
immune system tracks them down and eliminates them. There are 3 types of immunity – 
innate, adaptive and passive.  
 
Innate immunity comprises of the skin and mucous membranes, phagocytic cells, and 
physiological barriers, such as the acidity/alkalinity (pH) of body fluids and temperature. 
Adaptive (acquired) immunity develops when one becomes exposed to different illnesses. 
Passive immunity is acquired from the mother and lost in infancy.  
 
Most of the cells of the immune system responsible for the acquired immunity are white 
blood cells, the more important being lymphocytes, neutrophils and macrophages. We will 
focus on lymphocytes, which originate from stem cells in the bone marrow. One group 
migrates to the thymus for maturation, called T-lymphocytes or T-cells, while those 
maturing in the bone marrow are called B-lymphocytes or B-cells. Lymphocytes enter the 
bloodstream and become lodged in tissues and organs, such as the lymph nodes, spleen and 
tonsils.  
 
One subgroup of T-cells are called CD4 cells because they express a glycoprotein called 
CD4 (cluster of differentiation 4) on the surface. CD4 cells coordinate the overall immune 
system and are the ‘generals’ of the immune army. The CD4 receptor helps the T-cell to 
recognise antigen fragments. In addition to destroying an antigen or infected cells, T-cells 
communicate or signal other cells, e.g. phagocytes, to destroy the invaders. T-cells can also 
react by secreting chemicals (cytokines and chemokines) that activate the surrounding 
immune cells. 
 
Following exposure to antigens, B-cells produce antibodies. These are specific proteins 
(immunoglobulins) that lock onto the antigen and tag the antigen for destruction. After 
binding to the antigen, antibodies initiate the complement system, a group of specialised 
proteins that helps to remove antigen-antibody complexes. These antibodies remain in the 
body in case the antigen is re-introduced. This B-cell-dependent part of the immune system 
is most efficient in eliminating bacteria. For other microorganisms - viruses, fungi and 
special bacteria such as mycobacterium - T-cell mediated immunity is mostly involved. 
Other white cells e.g. macrophages and neutrophils, circulating in blood, survey the body 
and engulf antigens they encounter. They destroy the antigen by making toxic molecules, 
such as reactive oxygen intermediate molecules.  
 
Another type of T-lymphocyte that exhibits the innate ability to detect and attack an intruder 
on its own exists, i.e. the natural killer (NK) cell. NK cells produce a substance called 
interferon that prevents viruses from replicating. They also release poisonous chemicals, 
e.g. nitric oxide, that can destroy the antigens from within.  
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HIV and the immune system 
When the HIV enters the body, it attaches to CD4 cells, the commander of the other white 
blood cells in immunological processes. The virus multiplies within the cell and eventually 
lyses it. The new virions that are released infect other CD4 cells, eventually reducing the 
number of CD4 cells present. The immune system tries to fight infections by producing 
antibodies, but they are ineffective without CD4 to organise and regulate their function.  
 
Assessment of the immune competence of HIV-infected subjects relies on measuring their 
CD4 cell count. For an adult, antiretroviral treatment is usually initiated when the CD4-
count has dropped to or below 350 cells/l. In children, it is more common to use CD4%, 
which is the proportion of CD4 cells in the total lymphocyte count. A value > 30% is 
considered normal, and a child with a percent of < 20% is immune deficient, severely so 
below 15%.  
  
Micronutrients and the immune system
Cells of the immune system have a high replication rate, which means that they have a high 
demand for building blocks for new cells. Macronutrient and/or micronutrient malnutrition 
therefore rapidly affects both the antigen-specific and non-specific components of the 
immune system to cause a general ‘down-tuning’ of the system, changes that are in fact 
similar to immunodeficiency induced by HIV-infection. Micronutrient deficiencies are 
associated with lymphoid atrophy, reduced T-cell function and alterations in mucosal and 
other barrier surfaces.8 It is difficult to assign individual micronutrients to specific functions 
in the immune system because their functions are interrelated and complement each other. 
For example, vitamins A, C, B, D, and E support the production of white blood cells, 
cytokines and antibodies, whereas some of these and other micronutrients strengthen the 
natural barriers and are strong antioxidants. 5, 9-14 During acute infections, there is increased 
utilisation of micronutrients to enhance the activity of the immune system or destroy free 
radicals. This results in the reduction of the blood concentrations of these micronutrients. 
Although the reduced concentrations may be due to redistribution, it is more probable that 
this loss has to be compensated by increased intake.  
Effect of HIV-infection on micronutrient status and vice-versa 
HIV attacks and directly destroys CD4 cells in the immune system, resulting in a decline of 
CD4 cells over several years until it reaches a critical point when infections of different 
kinds appear. This in turn affects the nutritional status by reducing dietary intake, impairing 
nutrient absorption and increasing nutrient utilisation15 (Figure 2). Reduced dietary intake 
may be due to loss of appetite, and oral and oesophageal sores that affect the individual’s 
desire and ability to eat.16 Many of the opportunistic gut infections, such as microsporidia, 
cryptosporidia, Giardia destroy the absorptive surface of the intestines, leading to 
malabsorption and increased loss of micronutrients from the gut lumen.17 Diarrhoea per se, 
without significant destruction of the absorptive surface, leads to nutrient loss. HIV itself 
may cause epithelial damage to the intestinal walls causing malabsorption.18 Sometimes 
macronutrient malabsorption is accompanied by micronutrient malabsorption. For example, 
fat malabsorption affects the absorption of fat-soluble vitamins (A, D and E).19 HIV-
infection is associated with an increased basal metabolic rate, increased energy expenditure 
and protein catabolism.20 Micronutrients are required to maintain all these processes along 
with increased immunological demands. 
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Figure 2. ‘The vicious cycle of malnutrition and HIV’. Source: 
http://www.allvoices.com/contributed-news/6435380-vicious-cycle-of-malnutrition-and-hiv
 
Frequent or opportunistic infections are associated with increased oxidative stress and 
utilisation of antioxidant micronutrients, such as vitamins A, C, E, zinc, copper and 
selenium, resulting in reduced serum concentrations of these micronutrients. 21 The role of 
micronutrients in HIV-infection is mediated through the immune system, antioxidant status 
or possibly their antiviral effects.  
Single or multiple micronutrient supplements? 
In order to address micronutrient deficiencies, a plethora of micronutrient interventions have 
been explored. We have tried to review the literature on randomised micronutrient 
supplementation studies from 1980 to 2005 excluding those on adults, pregnant women, 
neonates, genetic disorders, cognitive function and food fortification. A few of the studies 
are summarised in Table 3. Not all studies from the same region reporting similar results 
have been included. Also studies using spreads or sprinkles to deliver the micronutrients 
have not been included in the summary table. Studies that were reported after 2005 have 
been included in the discussion. While most of the earlier studies concentrated on vitamin 
A, the majority of more recent studies addressed zinc supplementation. They tended to vary 
in their characteristics; some were community studies that included ‘healthy’ children, 
whereas others were hospital-based and followed participants in the communities. Most of 
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the studies were in children aged 6-59 months, although some included younger infants and 
school-age children. Most vitamin A and zinc community studies involved very large 
numbers of children. There were very few studies on other micronutrients or multiple 
micronutrients. For those who added multivitamins or other micronutrients, they were 
disease-targeted for treatment of diarrhoea 22-24 and given for a short period. The dosing 
schedule for vitamin A was almost consistent in most of the studies, while dosing schedules 
for zinc and the other micronutrients were not. Across these studies, the duration of 
supplementation varied from a few days to 24 months. Based on the different case scenarios 
and the settings, the outcomes were bound to vary. The main outcomes reported were 
growth, morbidity and mortality. In the majority of zinc studies, supplementation or adjunct 
therapy resulted in a significant reduction in diarrhoea morbidity, and vitamin A 
supplementation trials significantly reduced morbidity and mortality (from all causes).  
 
The literature for the HIV-infected children is scant. The few studies that had been 
conducted before 2005 are summarised in Table 4, which excludes studies reporting the 
effect of maternal supplementation on infant and child outcomes. These studies were 
characterised by small numbers and almost all of them were concerned with vitamin A. 
Their findings were similar to those reported in other children - reduction in mortality from 
all causes with vitamin A and diarrhoea morbidity with zinc.  
 
Table 3. Previous micronutrient supplementation studies in children, 1994 to 2005. 
 
Authors Country Participant’s 
age 
Number Intervention 
and dosage 
Duration 
of 
follow-
up 
Findings 
Benn CS, 
200525 
Guinea-
Bissau 
6 months – 5 
years 
 
4983 Vitamin A: 
recommended 
dose or half 
dose, single 
dose 
 9 
months 
Mortality lower in 
children who took 
half dose 
Brooks WA, 
200526 
Bangladesh 2 – 12 
months 
1665 Zinc 70mg 
once/weekly 
for 12 months 
12 
months 
Reduce mortality 
and pneumonia 
Penny ME, 
200427 
Peru 6 – 35 
months with 
persistent 
diarrhoea 
246  Zinc OR zinc 
+multiple micro 
at 1-2RDAs 
OR Placebo 
6 months Higher serum zinc, 
less diarrhoea and 
respiratory illness in 
zinc alone group 
Brooks WA, 
200428 
Bangladesh 2 – 23 
months 
with severe 
pneumonia 
270 Zinc or placebo During 
hospitali
sation 
Reduced duration 
of severe 
pneumonia 
Bhandari N, 
200229 
Dakshinpuri, 
New Delhi 
6 – 30 
months 
2482 Zinc gluconate  4 months Reduced incidence 
of diarrhoea 
Baqui AH, 
200230 
Bangladesh 3 – 59 
months 
8070 Zinc, cluster 
randomisation 
2 years  Shorter duration of 
diarrhoea, reduced 
incidence, reduced 
ARIs and 
admissions 
Rahman 
MM, 200231 
Bangladesh 12 – 35 
months 
653 Zinc OR Vit A 
OR zinc + vit A 
OR placebo for 
14 days 
 
6 months No effect on weight 
and length  
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Authors Country Participant’s 
age
Number Intervention 
and dosage 
Duration 
of
follow-
up
Findings
Muller O, 
200132
Burkina 
Faso
6 – 31 
months
709 Zinc 6 
days/week for 
6 months or 
placebo
6 months No effect on malaria 
episodes, reduced 
diarrhoea 
Varandas L 
200133
Mozambique 6 – 72 mo 
with severe 
malaria 
570 Vitamin A OR 
placebo
6 weeks Slight reduction in 
malaria mortality, 
not significant 
Umeta M, 
200034
Ethiopia 6 – 12 
months
2000 Zinc 10mg 6 
days/ week for 
6 months or 
placebo
6 months Zinc increased 
growth in both 
stunted and non-
stunted children, 
reduced illness due 
to diarrhoea, cough 
and fever 
Shankar AH, 
199935
Papua New 
Guinea 
6 – 60 
months
274 Zinc 6 
days/week for 
46 weeks 
months
 No effect on malaria
Roy SK, 
199936
Bangladesh 3 – 24 
months with 
acute
diarrhoea 
65 Zinc with 
multivitamins
versus zinc-
free
multivitamin
2 months Fewer episodes of 
diarrhoea and 
respiratory illness, 
improved growth 
Penny ME, 
199922
Peru 6 – 36 
months
412 Zinc OR zinc 
+multiple micro 
at 1-2RDAs 
OR Placebo 
2 weeks Zn reduced 
duration of 
diarrhoea episodes 
Sempértegui 
F, 199937
Ecuador 6 – 36 
months
400 Vitamin A or 
placebo,
weekly low 
dose vitamin A 
10
months
No impact on 
diarrhoea, reduced 
ALRT infections in 
underweight 
children
Rivera JA, 
199838
Guatemala 6 – 9 months 89 Zinc or placebo 7 months Improved linear 
growth in those who 
were stunted 
Semba RD, 
199739
Indonesia 9 months 394 Vit A / placebo 
single dose 
with measles 
vaccine 
6 months No difference in 
sero-conversion 
Benn CS, 
199740
Guinea-
Bissau 
9 months  397 Vit A single 
dose with 
measles 
vaccine 
9 months Vit A had no effect 
on antibody 
response 
Barreto ML, 
199441
Brazil 6 – 48 
months
1240 Vitamin A, 3 
cycles OR 
Placebo 
12
months
Reduced incidence 
of diarrhoea, no 
effect on incidence 
of ARI 
Bhandari N, 
199442
India 12 – 60 
months
900 Vitamin A 
200000 IU 
versus placebo 
3 months Reduced incidence 
of measles and not 
diarrhoea and not 
ARI
In all the trials, including HIV-infected and uninfected, the results were not consistent, even 
when studies were from the same region. For instance, zinc supplementation reduced 
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respiratory illness in some studies but not in others. The effect was observed in some cases 
who were deficient in the supplemented micronutrient. 
The lack of effect of some of the interventions on some key child survival indicators, such 
as growth, may be evidence of the need to consider giving multiple micronutrients rather 
than single micronutrient supplementation. It has been argued that if you provide one 
vitamin or mineral to a person that is deficient in several, this intervention may not have any 
beneficial effect because of the overall deficiency.
Table 4. Previous micronutrient intervention studies in HIV-infected children. 
Author  Country Participants Number Intervention & 
dosage 
Follow-
up
Outcome 
Semba
RD,
200543
Uganda HIV-infected 
children at 15 
months of age 
181 Vit A / placebo 
supplementatio
n quarterly  
21
months
Reduced all cause of 
mortality by 46% 
Bobat R, 
200544
South
Africa 
HIV-infected 
children 6 to 60 
months
96 HIV-
infected
children
Zinc or placebo 6 months Did not increase viral 
load, reduced 
diarrhoea morbidity 
Villamor E, 
200245
Tanzania 6 – 60 months 
with pneumonia 
687
(malaria 
115, HIV 
47)
Vitamin A or 
placebo
1 year Improved linear 
growth in stunted 
children
and weight gain in 
infants with malaria 
and HIV 
Hanekom 
WA,
200046
North
America
Children
receiving
influenza 
vaccine 
59 Vit A / placebo  
Single dose  
2 weeks Decreased HIV viral 
load
Fawzi
WW,
199947
Tanzania Children 
admitted with 
severe 
pneumonia 
6 months – 5 
years
687 (58 
HIV-
infected
children)
Vit A / placebo 
quarterly 
24
months
Halved all cause 
mortality, reduced 
risk of severe watery 
diarrhoea. All cause 
mortality reduced by 
63% in 58 HIV-
infected children 
Coutsoudi
s A, 
199548
South
Africa 
Infants born to 
118 HIV-
infected women 
28 HIV-
infected
infants
Vit A / placebo 
supplementatio
n quarterly from 
1 month 
15
months
Reduced all cause 
mortality by a third, 
no effect on mortality 
in a sub group of 
HIV-infected children 
but halved episodes 
of diarrhoea 
Hence, there has therefore been a move towards use of multiple micronutrient supplements. 
However, the dilemma of how many micronutrients should be given and the doses to a 
deficient population remains controversial among many researchers and clinicians.  
UNICEF, United Nations University (UNU), World Health Organization (WHO) and other 
partners held a consultative workshop in 1998 to discuss and propose a formulation for a 
multi-micronutrient supplement to be used in low-income countries.49, 50 The supplement, 
called UNIMAP, for UN Multiple Micronutrient Preparation, contained 15 micronutrients 
(vitamin A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, and Fe, Zn, Cu, I, and Se) at 
approximately the RDAs for pregnant women. The selection of the micronutrients was 
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based on previous reports on nutritional deficiencies, consequences of deficiency states to 
the mother and infant and known biological interactions between the different 
micronutrients.51-53 Second, the dose, toxicity of some micronutrients, the cost, size of the 
pill and possible adverse effects were considered. The physiological doses were based on 
the US and Canadian recommendations 54 as being the most recent and best documented at 
that time. 
 
The use of this UNIMAP supplement was to be piloted in several countries until subsequent 
research could substantiate its safety, efficacy and effectiveness. From a programme point 
of view, it was more efficient to combine several micronutrients into one supplement and 
consider other vulnerable groups, such as children. Some of the earlier studies showed no 
impact of the multi-micronutrient supplement on birth weight and infant mortality, except 
for one which showed a slight increase in birth weight. 55-58 A trial using 2RDAs showed a 
significant increase in birth weight.59  
 
By 2003/4 when we designed this trial, there were no published studies on the effects of 
prolonged use of multiple micronutrient supplementation as the main intervention in young 
children. We therefore decided to conduct such a study using similar micronutrients 
suggested by UNICEF and partners, but we made one important change in excluding iron. 
The reason was that some studies had indicated that iron-supplementation could be harmful 
in HIV-infected persons. In HIV-infected adults living in developed countries, high iron 
stores, such as ferritin (after adjusting for acute infections) have been associated with 
increased mortality and rapid progression of HIV.60-62 This was also supported by in vitro 
studies which showed that iron chelation was associated with reduced HIV replication.63  
 
One or several RDAs of each micronutrient? 
How much of each micronutrient should be provided to HIV-infected children? The 
recommended dietary allowance ideally is supposed to meet the nutrient requirement of 
97.5% of healthy individuals in a life-stage and gender group in a population.64 It was 
questionable if this would be adequate in HIV-infected children, the majority of whom had 
frequent illnesses associated with poor appetite, reduced intake and increased losses. In 
addition, the common diet in Uganda is not micronutrient-dense and most children do not 
routinely consume animal products, vegetables and fruits.65 We therefore concluded that we 
should give more than one RDA based on an anticipated deficiency and increased needs, but 
how much more? We considered 1) earlier studies that had reported using larger doses of 
micronutrients66, 67, and 2) the upper tolerable levels of intake and potential adverse effects 
for each of the micronutrients. Upper tolerable level (UL) defines the highest level of 
consumption where the risk of adverse effects or toxicity is zero (Fig 3).1,68  
 
Some vitamins e.g. vitamin A, may be harmful in larger doses. Furthermore, our supplement 
was to be given over extended periods of time (6 months). After consideration of these 
different factors, we decided to give 2RDA of each of the micronutrients, having no real 
data to support the use of different multiples of the RDA.  
 
Furthermore, we decided to use the RDA of a 4-year old category, the group with the higher 
requirement, to warrant the highest probability that every child’s requirements were met. 
We ensured that the doses of the individual micronutrients were not above the tolerable 
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upper levels at 2RDA doses. We also noticed that there were minor variations between the 
1-3 and 4-8 age categories, and some doses were similar, such as iodine and vitamin D.  
 
 
Figure 3. Theoretical curve of risk of adverse effects in relation to the level of intake of a 
particular nutrient. Above the upper tolerable level of intake (UL) there is a risk of adverse 
effects. Source: Renwich (2006) 
Uganda
The context under which the study was conducted is described below. 
 
Uganda is a landlocked country in East Africa lying on the equator. Lake Victoria covers a 
substantial portion of the southern part of the country. The climate is tropical which means a 
warm climate throughout the year with 2 rainy seasons in most of the country that remains 
permanently green throughout the year. Agriculture is the main economic activity relying on 
a few crops: maize, sweet potatoes, plantain, maize, sorghum, millet and pulses; vegetables 
and fruits tend to be seasonal. Livestock, poultry and fish also exist, but animal foods are 
rarely consumed on a regular basis. The northern part of the country is semi-arid and 
sometimes experiences prolonged drought, leading to crop failure and food insecurity.  
 
The population of Uganda 
Uganda has 32.7 million inhabitants and is one of the fastest growing populations69 in the 
world at a rate of 3.3% (2009) compared to the world’s average of 1.2%. Half the 
population is < 15 years of age. An estimated 20% of the population live in the urban areas, 
the main being the capital, Kampala. Uganda is generally a poor country with almost a third 
of the population living on less than one United States dollar per day.70 The country is 
divided into 4 main regions (Central, Western, Eastern, and Northern) along the main ethnic 
groups, and into administrative units of 50,000 to 500,000 people called districts, of which 
there are currently 111 (i.e. in 2011). 
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The healthcare system of Uganda 
The health system has 4 levels of health centres, district hospitals, regional and national 
referral hospitals. On top of the referral pyramid is the national referral level with 2 
hospitals: the Mulago hospital for general care and Butabika hospital for psychiatric care, 
both located in the capital. The next level comprises of 13 regional referral hospitals, 3-4 in 
each of the main regions. At this level, the staffing ideally includes a paediatrician, a 
surgeon, a physician and a gynaecologist. This level is followed by the district hospitals 
which supervise the lower health levels: health centres IV (mini-hospitals), III (inpatient 
care), II (only outpatient care). The lowest level is ‘Health Centre I’; it has no physical 
structures but is a village health team comprised of selected members of the community. 
Healthcare seeking does not follow this hierarchical order. Patients can present to the 
regional or national referral hospital for care without referral. Similar to most low-income 
countries, the reality is understaffing, frequent stock-outs and lack of adequate diagnostics. 
Frequent shortages in electricity and black-outs are also common, but the higher levels are 
usually better off. The Ministry of Health is mainly responsible for setting policies, 
standards and guidelines, soliciting for funding and supervision.  
The private sector contributes 50% of healthcare delivery in Uganda. This includes the 
private-for-profit and the private not-for-profit, the latter mainly consisting of the faith-
based organisations. Uganda uses a multi-sectorial approach to the control of AIDS 
(MACA) whose principle is that persons individually or collectively have a responsibility to 
fight the epidemic. The approach emphasizes the involvement of private and public actors, 
individuals and groups from highest political level to the grassroots.71
Figure 4. Under 5 mortality in Uganda: progress from 1990 to 2008 towards MDG 4 and 
main causes of under-5 deaths. Source: Countdown 2015.
http://www.who.int/child_adolescent_health/documents/9789241599573/en/index.html
Health indicators of Uganda 
Uganda is making progress towards the millennium development goal number 4 of lowering 
the under-5 mortality by two-thirds between 1990 to 2015; however, this is not at the 
required pace (Figure 4). 
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Common causes of death in Uganda 
Most of the common causes of death in children, as seen in Figure 4 are preventable, such 
as malaria, diarrhoea, pneumonia, HIV, malnutrition and neonatal causes. As in many low-
income countries, malnutrition significantly contributes to morbidity and mortality (Figure 4 
and Table 5). 
 
Nutritional interventions in Uganda 
Children aged 6 to 59 months receive a dose of vitamin A as routine supplementation. The 
coverage has been improving using the national child health days twice a year. Apart from 
this, there are no large-scale programs to prevent child malnutrition. Those in place are 
donor-initiated projects and most probably have a limited life-time. The proportion of 
children with diarrhoea who receive zinc as part of treatment is unknown. The choice of 
treatment given depends on how knowledgeable the health worker is. Sometimes 
multivitamin and rarely mineral supplementation is given as treatment to sick children at the 
discretion of the health worker.  
 
HIV care services for children in Uganda 
By 2005 Uganda was beginning to scale up paediatric HIV services following the "3 by 5" 
initiative, launched by UNAIDS and WHO in 2003; this aimed at improving access to 
antiretroviral therapy in low- and middle-income countries.72 The major components of the 
HIV treatment package at that time included HIV testing and counselling services, treatment 
of common and opportunistic infections, nutritional counselling and routine multivitamin 
supplementation, with very few and severely ill children accessing anti-retroviral therapy. 
Most of the children had frequent visits to the clinics because of recurrent illness related to 
their poor immunological and nutritional state. 
 
Table 5. Anthropometric and nutritional status of Ugandan children under 5 years of 
age. 
  
Category Prevalence (%) 
Wasting   6 
Stunting 38 
Underweight 16 
Vitamin A deficiency (<0.7 mmol/L) 20 
All anaemia combined (Hb <11g/dl) 73 
- Mild (Hb 10.0-10.9 g/dl) 22 
- Moderate (Hb 7.0-9.9 g/dl) 43 
- Severe (Hb <7.0 g/dl)   7 
Zinc deficiency  20-69% 
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Rationale for the study of this thesis 
There still is insufficient knowledge and evidence to guide appropriate micronutrient 
supplementation, especially in the most vulnerable groups. We know the diets for most 
Ugandan children comprise mainly of carbohydrate foods and plant proteins, which are 
unlikely to contain enough micronutrients for growth and cater for illness. And there is 
evidence to show that malnourished or HIV-infected persons have higher micronutrient 
requirements. We also know that more than one in two of the Ugandan HIV-infected 
children are malnourished,73, 74 but how much more is required compared to the healthy 
population remains unclear. 
 
Research-wise, previous micronutrient supplementation studies have largely focused on 
single or few micronutrient interventions probably because it is easier to attribute an 
outcome to a single micronutrient than many.  
 
Implementation-wise, vitamin A supplementation is routinely given to all children under 5 
years of age and an addition of multivitamins is given to HIV-infected children in Uganda. 
WHO recommends use of micronutrients in one RDA for HIV-infected persons, but it is not 
known whether the multivitamin supplements given at the HIV clinics and the doses are 
adequate to meet the requirements of these children 
 
Highly active anti-retroviral therapy (HAART) is associated with a sustained increase in 
growth in HIV-infected children.75 It is also known that HAART leads to improvement in 
micronutrient status76 but it still may not correct all the deficiencies.  
 
Theoretically, providing several micronutrients on a regular basis would improve child 
health; however, there is little evidence to support or refute this. In reality the best option 
would be to provide a supplement that would address all the micronutrient needs of the 
individual.  
 
In order to try and fill in the knowledge gaps above, we hypothesised that providing 2RDAs 
of multiple micronutrients would reduce mortality (all causes), improve growth and reduce 
the frequency of illness compared to the ‘standard of care’ multivitamins. In the process, we 
also assessed the micronutrient status of the children by measuring some of the 
micronutrients in the blood.  
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Aims of the thesis  
The overall aim of this thesis has been to assess whether a multiple micronutrient 
supplement could improve survival and weight gain, and also reduce morbidity of HIV-
infected children living in Uganda compared to the ‘standard of care multivitamin 
supplement’.  
Primary objective 
1. To assess whether multiple micronutrient supplementation could decrease 
mortality in Ugandan HIV-infected children aged 1-5 years (paper I) 
Secondary objectives 
2. To assess the effect of multiple micronutrient supplementation on incidence and 
prevalence of diarrhoea among HIV-infected children aged 1-5 years (paper II) 
3. To assess the magnitude of zinc deficiency among HIV-infected children aged 1-
5 years (paper III) 
4. To assess the effect of multiple micronutrient supplementation on serum 
concentrations of vitamin B12 and folate among HIV-infected children aged 1-5 
years (paper IV) 
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Subjects and methods 
This thesis presents data from a randomised clinical trial of a multiple micronutrient 
supplement containing 14 micronutrients to HIV-infected children attending paediatric HIV 
clinics at 7 sites in Uganda. As it mainly describes a randomised clinical trial (RCT), we 
have followed the Consolidated Standards of Reporting Trials (CONSORT) checklist in the 
presentation of the methodology. The CONSORT group is one of the many initiatives to 
standardise reporting of scientific studies, and has produced the CONSORT Statement, 
which is an evidence-based minimum set of recommendations for reporting RCTs.77  
Study sites
The studies were conducted in 7 sites (Figure 4). Three sites were located in the capital city 
(Kampala), while the other 4 sites were regional referral hospitals. The main site was 
Mulago hospital, the national referral hospital, situated in Kampala. Mulago has the oldest 
and biggest paediatric HIV clinic. The other sites in the capital city were Mildmay Centre, 
which is a non-governmental organisation based in the United Kingdom, and Nsambya 
Hospital, which is a faith-based private hospital. The 4 sites outside the capital city were 
Mbale hospital in the east, Lira in the north, Mbarara in the southwest and Masaka hospital 
in the south of the central region. 
19
167
38500
53
21
49
 
Figure 5. Map of Uganda showing the 7 study sites with numbers from each site. 
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The number of participants at the different sites varied since the paediatric HIV clinics were 
at different levels of development. Most of the regional sites were in their initial stages of 
setting up paediatric HIV clinics and had small numbers of patients registered in care. Most 
of the participants were from Mulago hospital, followed by the Mildmay Centre. All the 
study sites had in-patient wards where the children could be hospitalised if they became 
very ill. 
Design
The study was a randomised controlled trial conducted between 2005 and 2008 at 7 
paediatric HIV clinics in Uganda. Participants were allocated to the intervention or 
comparative ‘standard of care’ supplement in a ratio of 1:1. The participants were stratified 
into those receiving highly active anti-retroviral treatment (HAART), 10% and those not yet 
on HAART, 90% of the participants.  
 
Papers I and II compared the outcomes in the intervention and comparative arm. In paper III 
a cross-sectional design was used to report baseline zinc status, whereas paper IV assessed 
the effect of the intervention on micronutrient concentrations.  
Participants
Children aged 1-5 at the study clinics were screened for eligibility. The study profile shows 
the number of children screened, included, excluded and the number of children at different 
end-points (Figure 6).  
 
Eligibility criteria 
 
Inclusion criteria 
HIV-infected children 
 Aged 1-5 years  
 HIV status previously confirmed by 2 ELISAs for children  18 months, and DNA 
PCR for those <18 months  
 Unlikely to change residence during the course of the study  
 Residing within 15 kilometres from the study clinics  
 
Exclusion criteria  
 Enrolled in other studies  
 Mother or caretaker declined consent  
 Unlikely to return to the clinic for regular follow-up, based on their previous record 
of non-adherence to clinic appointments 
 
Clinical procedures 
All eligible children had a detailed medical history followed by physical examination by 
one of the study doctors. Measurements included anthropometry, temperature, respiratory 
rate, and a systemic examination.  
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Follow-up  
 
Children were followed monthly (routine visit) for the first 6 months during 
supplementation, and at 9 and 12 months (Figure 7). All clinical measurements made at 
baseline were repeated at monthly visits, except the laboratory tests were done at 0 and 6 
months. Mothers/ caretakers were encouraged to attend a regular clinic managed by the 
study teams whenever the child was ill (inter-current visits). Transport was refunded to 
every mother/ caretaker attending a scheduled visit. Children who did not turn up for the 
scheduled visits were traced initially by telephone for those who had telephone contacts or 
by home visits on the 7th day.  
Stratified: 
847
ART stratum 
Randomized: 85
Lost to follow up: 1
Withdrew: 0
Transferred: 1
Total excluded: 785
- Other studies: 218
- Inconsistent carers: 172
- Distance >15km: 348
- Declined to consent: 47
Screened for eligibility:
1632
Survived:
41 
Died:
0
Survived:
38
Died:
2
Intervention arm:
43
Comparative arm: 
42
Non-ART stratum 
Randomized: 762
Lost to follow up: 66
Withdrew: 5
Transferred: 8
Survived:
279
Died:
25
Survived:
284
Died:
26
Intervention arm: 
383
Comparative arm: 
379
Lost to follow up: 0
Withdrew: 0
Transferred: 2
Lost to follow up: 57
Withdrew: 6
Transferred: 6
Tested for zinc 44
Tested for 
B12 and folate: 19
Tested for 
B12 and folate: 25
Tested for 
B12 and folate: 85
Tested for 
B12 and folate: 85
Tested for zinc 203
 
Figure 6. Trial profile of the study. Analysis in Papers I and II is based on the blue boxes, 
paper III on the purple boxes and paper IV on the yellow boxes.  
 
Laboratory procedures 
Blood samples (5-7 ml) were collected twice, at enrolment and 6 months (Figure 7) by 
venepuncture from the cubital fossa or dorsum of the hand using sterile techniques. A 2 ml 
sample was placed in a Beckton Dickinson Vacutainer® EDTA tube (purple-top) and 3-5 
ml in a trace-element-free Vacutainer® (blue-top) tube. The EDTA samples were analyzed 
for a complete blood count using a Coulter counter (AcT 5Diff instrument Beckman 
Coulter), and CD4 cell count using a FACScan instrument and MultiSET software (Beckton 
Dickinson). Haematological analysis was performed by the Centre for Disease Control 
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(CDC) laboratory in Entebbe, Uganda, for the Kampala sites and at the Joint Clinical 
Research Centre (JCRC) laboratories at the rural sites.  
 
Table 6. Study sites and number of participants recruited per site. 
 
Study site Location Management Total bed 
capacity 
Number of 
HIV-infected 
children 
screened 
Number 
enrolled 
Mulago 
Hospital 
 
Central 
(Kampala) 
Government/ 
public and free
1500 1050 500 
Mildmay 
Centre 
Central 
(Kampala) 
NGO/free 
services for 
children 
Mainly 
outpatient 
services/ 30 
beds for 
children 
232 167 
St Francis 
Hospital 
(Nsambya) 
 
Central 
(Kampala) 
Private faith-
based not-for-
profit 
361  86 38 
Masaka 
Regional 
Referral 
Hospital 
 
South of 
central region 
(Masaka 
town) 
Government/ 
public and free 
330 78 53 
Lira regional 
Referral 
Hospital 
 
North (Lira 
town) 
Government/ 
public and free 
254 68 49 
Mbale 
Regional 
Referral 
Hospital 
East (Mbale 
town) 
Government/ 
public and free 
400 63 21 
Mbarara 
Regional 
Referral 
Hospital 
Southwest 
(Mbarara 
town) 
Government/ 
public and free 
300 55 19 
 
The samples collected in trace element-free tubes were allowed to clot, centrifuged at 
2000g, and the serum transferred to trace element-free cryo-tubes, kept and transferred in 
cool boxes within 3 hours to a -20°C refrigerator until they were shipped to the Clinical 
Chemistry Laboratory of Haukeland University Hospital, in Bergen, Norway, for 
biochemical analysis.  
 
For trace element analysis, the samples were digested using a microwave oven, nitric acid 
and concentrated hydrogen peroxide,78 and analysed using Inductively Coupled Atomic 
Emission Spectrophotometry (ICP-AES). Vitamin B12 was measured using Modular E 
(Roche) automatic analyzer by an electrochemiluminescence immunoassay, and folate on 
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Modular E (Roche) automatic analyzer using a competitive protein-binding assay. A 
coefficient of variation of 5% was used for the zinc, vitamin B12 and folate concentrations. 
Qualitative C-reactive protein (CRP) was measured at the study site before sample storage, 
using the latex immunoassay on one drop of serum (Human Gesellschaft fur Biochemica 
und Diagnostica mbH, Germany).  
0 1 2 3 4 5 6 7 8 9 10 11 12
Months of follow-up
Scheduled follow-up visits
Supplementation
Enrolment visit 
incl. blood sample
End-of-study
visit 
6-months visit 
incl. blood sample
 
Figure 7. Plan of supplementation, follow-up and scheduled procedures at each visit. 
 
Cut-off points for micronutrient concentrations 
Because no Ugandan child reference values for zinc, vitamin B12 and folate concentrations 
have been established, we used cut-off values established by other researches. Low zinc was 
defined as a serum concentration of < 10.0 mol/L.79, 80 Vitamin B12 concentrations were 
considered low if < 221picomoles per litre (pmol/L), and folate concentrations were 
considered low if < 13.4 nanomoles per litre (nmol/L).81-83 C-reactive protein (CRP) was 
positive if there was distinct agglutination on the latex immunoassay strip, which was 
consistent with a CRP of  6 mg/L. Anaemia was defined as a haemoglobin < 11 g/dl, using 
the WHO classification of anaemia in children aged 6 months to 5 years.84 
Intervention 
The trial supplement was a mixture of 10 vitamins and 4 trace elements in 2RDA doses 
(Table 7). The comparative supplement contained 6 vitamins that was ‘standard of care’ in 
1RDA doses. The rationale for this composition has been previously provided.  
 
The intervention was in form of a powder reconstituted with 10-20 ml of milk or water into 
a solution before being given to the child. The first dose was given at the clinic under 
guidance of the health worker, but subsequent doses were administered from home by the 
mother. Compliance was measured by weighing the remaining supplement when the 
children and mother returned for the monthly routine follow-up visits. The container held 
140 g and the child was expected to consume 120 g. The daily dose was 4 g equivalent to a 
levelled scoop supplied by the manufacturer. The additional doses were to cater for spillage 
or in case the mother was not able to return on the exact day of follow-up. Supplements 
were given daily for 6 months (Figure 7).  
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Administration of the intervention 
At the baseline visit, the study nurse demonstrated to the mother/caretaker how to measure a 
dose using a levelled scoop. Ten to 20 ml of milk or water was used to prepare a solution 
from the micronutrient powder. The mother prepared and gave the first dose under 
observation. Subsequent doses were administered at home. 
 
Table 7. The formulation for the intervention supplements. 
 
Micronutrient Multivitamins  
‘Standard of care’ 
1RDA 
Multiple micronutrients 
2 RDA 
Vitamin A (mcg) 400 800 
VitaminB1 (mg) 0.6 1.2 
Vitamin B2 (mg) 0.6 1.2 
Niacin (mg) 8 16 
Vitamin B6 (mg) - 1.2 
Vitamin B12 (mcg) - 2.4 
Folate (mcg) - 400 
Vitamin C (mg) 25 50 
Vitamin D (IU) 200 400 
Vitamin E (mg) - 14 
Selenium (mcg) - 60 
Zinc (mg) - 10 
Copper (mcg) - 800 
Iodine (mcg) - 180 
Iron (mg) - - 
 
   
Figure 8. Containers with the trial supplement. 
 
Measuring compliance 
At the monthly visit, mothers/caretakers came with the previous container of the 
supplement. The remaining amount was measured using a light-weight weighing scale to 
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ascertain how much supplement had been used. The actual amount of supplement taken 
against the expected was regarded as the compliance measure. Mothers answered a 
questionnaire on whether any doses had been missed and the reasons for non-compliance. 
Outcomes
The study outcomes are summarised in Table 8, including information on when and how 
they were assessed.
Primary outcome: mortality (Paper I) 
The primary outcome of the study was mortality. Participants were followed monthly on 
routine visits up to 6 months during supplementation, then at 9 and 12 months when the 
study ended. In addition to the routine visits mothers came to the study clinics for inter-
current visits whenever the child was ill to be treated by the study doctor. If they required 
hospitalisation, they were admitted to the same hospital. Information about a death was 
communicated verbally to the study team or from hospital records when a child died in 
hospital. Those who were alive were censored at 12 months and those lost to follow-up 
immediately after the last visit. 
Table 8. Outcomes of the study. 
 Sample 
size
How assessed When 
measured 
Outcome
Effect of multiple 
micronutrient
supplementation on 
survival (Paper I) 
847 Participants 
followed up for 
12 months, 
deaths recorded
At 12 
months
Mortality
Effect of multiple 
micronutrient
supplementation on 
diarrhoea (Paper II)
800 for 
incidence;
613 for 
prevalence
Episodes of 
diarrhoea
counted on 
routine visits and 
2 weeks before. 
Point prevalence 
at 6 months 
At 6 months Diarrhoea 
incidence and 
prevalence
Baseline zinc status 
(Paper III) 
247  Measured serum 
zinc by ICP-AES 
At baseline Prevalence of 
zinc deficiency 
Effect of multiple 
micronutrient
supplementation on 
vitamin B12 and folate 
concentrations (Paper 
IV)
214  Measured serum 
vitamin B12 and 
folate
At baseline 
and 6 
months
Vitamin B12 and 
folate
concentrations
Secondary outcome: incidence and prevalence of diarrhoea (Paper II) 
Episodes of diarrhoea occurring during supplementation, from the time of enrolment to 6 
months were recorded. The time for assessing this outcome was limited to 2 weeks of 
observation for every routine visit, since we could not conduct surveillance visits in the 
homes. Episodes therefore included children who had diarrhoea at the routine visits, 
episodes occurring within the past 2 weeks, and any inter-current visits due to diarrhoea. 
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Episodes per person-time (weeks) of observation were calculated. For prevalence, the 
proportion of children presenting with diarrhoea at 6 months was determined.  
 
Outcome 3: the proportion of children with a zinc concentration of <10.0 mol/L 
(Paper III) 
Zinc concentration was measured on serum samples collected at enrolment and reported in a 
sub-sample of 247 children. The proportion of children with serum zinc <10.0 mol/L was 
regarded as zinc deficiency.  
 
Outcome 4: Vitamin B1 and folate concentrations pre- and post-supplementation 
(Paper IV) 
Vitamin B12 and folate concentrations were measured both at baseline and at 6 months in a 
sub sample of 214 children. Vitamin B12 concentration was considered low if <221 pmol/L 
and folate <13.4 nmol/L. 
Sample size 
The estimated sample size of 411 children in each arm was based on data from 2 studies. 
The first assumption was a mortality rate in the comparative arm of 24% in one year, based 
on the mortality rate in a study conducted in Mulago Hospital, Kampala, before HAART 
was available to HIV-infected children in Uganda.73 The second assumption – that all-cause 
mortality would be reduced to 14.4% (a 40% reduction) was based on a study of Tanzanian 
children aged 6 months to 5 years where supplementation with vitamin A was associated 
with a 49% reduction in overall mortality and a 63% reduction among HIV-infected 
children.47 The 40% reduction level was used as we anticipated improved general care of 
HIV-infected children with time. Finally, we used a precision of 5%, and 95% confidence 
interval. The power estimate was 90% and we assumed a 10% loss to follow-up. The 
calculated sample size was 373 children plus 38 for 10% attrition rate (Total 411). 
 
Table 9. Basis for the sample size calculation. 
 
 Proportion 
(%) 
Sample 
size 
Mortality in Ugandan HIV-infected children  
pre-HAART (Berhane et al 1997) 
 
24  
Assumptions: 
Mortality in study 
Effect size 
Power 
Precision 
Loss to follow-up 
 
14.4 
40 
90 
  5 
10 
 
373 
 
 
 
38 
Total sample size in each arm 
 
 411 
Supporting evidence for mortality reduction 
Vitamin A in Tanzania children (Fawzi 1999) – All cases 
Vitamin A in Tanzania children (Fawzi 1999) – HIV-infected 
children) 
 
49 
63 
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Randomisation
The participants were randomly assigned to either twice the recommended dietary 
allowance of 14 multiple micronutrients or the 6 multivitamin ‘standard of care’ 
supplement. To ensure equal distribution, randomisation was done by an independent 
researcher in permuted blocks of 4 to 20, using the Stata software and sent to the 
manufactures (NUTRISET) in France.  
Allocation concealment or masking 
The supplements were packed in sequentially numbered identical containers (Figure 8). 
Each participant number had 6 containers to be used in 6 months. The 2 strata were 
identified as S1 (HAART stratum) or S2 (non-HAART stratum) followed by a serial 
number. Following screening, an eligible participant underwent all the study procedures 
after which the next number of the supplement was issued by the study nurse. The 
intervention and standard of care supplements were both similar in colour, consistency, and 
odour, and were packaged in identical containers. The study staff, mothers/caretakers and 
investigators were all masked to treatment assignment. Serial interviews with the study staff 
indicated that they could never tell the difference between the two. The investigators had no 
access to the randomisation code until completion of the study. 
Quality control 
Each site had a minimum staffing of 3 members; a doctor, nurse/HIV counsellor and a 
laboratory person. At Mulago Hospital and Mildmay Centre, there were more doctors and 
an extra nurse. At each of the sites one of the investigators trained the staff and one 
paediatrician on the protocol and study procedures for 3 days before commencement of the 
study. Data collection materials were piloted and refined. At the Kampala sites where there 
were 2 doctors, they checked each others work so that mistakes could be corrected there and 
then. The principal investigator checked the questionnaires at the end of the day except on 
the days when she travelled to the regional sites. A paediatrician was in charge of 
supervising the junior doctors for the regional sites, and the PI supervised once in 2 weeks. 
The laboratories for sample analysis had been chosen because of their expertise and 
renowned experience. They had external quality control programmes in place.  
Data management 
Semi-structured case report forms (CRFs) were used to collect information at baseline, 
monthly visits, and inter-current visits, as well as at 6, 9 and 12 months. Information 
captured on the CRFs included physical findings, illnesses/admissions during the study 
period, medications given and laboratory investigations. An adverse event form was filled if 
one occurred. One of the investigators or site supervisors checked the forms daily for 
completeness. Any missing data or corrections were addressed. The CRFs were collected, 
cross-checked, placed in individual participant folders and kept by one of the investigators 
at a central office.   
 
The data was entered at regular intervals and stored in Epidata version 3.1. at the Kampala 
office. The data-base was only accessible to the PI and the data entry person. In order to 
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minimise errors inbuilt consistency checks and restrictions were used on some of the 
variables. The data was transported into SPSS (version 15.0), frequencies run, and 
inconsistencies and outliers checked. The data was further cleaned with the assistance of 
case report notes kept at the central office. De-linking of the patients names was done before 
statistical analysis.  
 
Statistical analysis 
Statistical analysis was performed using SPSS version 15.0 (Table 10). Categorical 
characteristics were summarised into proportions while continuous variables were analysed 
using means and standard deviations. Baseline characteristics were compared in the 2 
treatment groups using proportions, and differences were tested with the Chi-square or 
Fisher's exact test. Sub-group analysis was based on whether the children belonged to the 
HAART or HAART-naïve stratum.  
 
In Paper I, Kaplan-Meier curves and the log-rank test were used to compare survival in the 
2 arms. For Paper II, the incidence of diarrhoea was determined using rates, and rate ratios 
were used to compare differences in the 2 arms. In Paper III, frequencies were run and 
clinical characteristics were compared among zinc deficient (zinc <10.0 mol/L) and non-
deficient children using Fisher’s exact test and odds ratios. In Paper IV, medians and their 
inter-quartile ranges were used to summarise the data. The median concentrations were 
compared using the Wilcoxon signed rank test.  
 
Table 10. Statistical analysis for the papers. 
 
 Design Sample size Statistical analysis 
Paper I Randomised 
controlled design 
847 children 
 
 
Kaplan Meier survival curves, 
Cox regression 
Paper II Randomised 
controlled design 
800 for incidence; 
613 for 
prevalence at 6 
months  
Rates and rate ratios,  
descriptive analysis,  
binary logistic regression, 
Fisher’s exact test for comparisons 
Paper III Cross-sectional  247 children Cross tabulations,  
Fisher’s exact test, 
binary logistic regression 
Paper IV Randomised 
controlled design  
214 pairs Wilcoxon signed rank test, logistic 
regression 
Ethical considerations 
Permission to carry out the study was granted by Makerere University School of Medicine 
Research and Ethics Committee, the boards of management at the hospitals, the Uganda 
National Council for Science and Technology, and the Western Regional Ethics and 
Research Committee of Norway. Informed written consent was obtained from 
caretakers/mothers before their children could participate in the study. Counselling on 
adherence to treatment and anti-retroviral therapy was offered to all the parents/caretakers 
and their children. Whenever a child was eligible and ready to start anti-retroviral drugs, 
they were allowed to do so but remained in their pre-determined treatment arm. 
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Results 
The results are presented in the 4 papers attached at the end of the recommendations. In this 
section, we have tried to summarise them for the reader.  
Characteristics of the participants 
The participants were 1-5 years of age, their mean age (Standard deviation, SD) being 33.4 
(13.6) months. The majority were over 2 years of age. Boys and girls were equally 
represented. The baseline characteristics were similar in the intervention and comparative 
arm (Table 11).  
 
Table 11. Baseline characteristics of HIV-infected children aged 1-5 years at paediatric HIV clinics in 
Uganda. 
 
Baseline 
Characteristics 
ART stratum (N=85) 
 
Non-ART stratum (N=762) 
 
 Intervention; 
    n/N  (%) 
Comparative 
arm; n/N (%) 
p- 
value 
Intervention; 
      n/N    (%)  
Comparative 
arm; n/N  (%) 
p-
value 
Age <24 months 1/43 (   2.3) 3/42 (   7.1) 0.36 123/383 (32.1) 122/379 (32.2) 1.00
Sex : Male 20/43 ( 46.5) 23/42 ( 54.8) 0.52 201/383 (52.5) 182/379 (48.0) 0.25
Site: Kampala 40/43 ( 93.0) 40/42 ( 95.2) 1.00 313/383 (81.7) 311/379 (82.1) 0.93
Carer: Mother 24/43 ( 55.8) 21/42 ( 50.0) 0.67 278/383 (72.6) 278/379 (73.4) 0.87
Diarrhoea at 
enrolment 
1/43 (   2.3) 2/42 (   4.8) 0.62 42/383 (11.0) 51/379 (13.5) 0.32
Persistent diarr-
hoea at enrolm. 
0/43 (   0.0) 0/42 (   0.0) - 11/383 (26.8) 11/379 (23.4) 0.81
Diarrhoea in 
past 2 wks 
0/43 (   0.0) 0/42 (   0.0) - 13/383 (  3.4) 14/379 (  3.7) 0.85
Fever at 
enrolment 
9/43 ( 20.9) 8/42 ( 19.0) 1.00 76/383 (19.8) 81/379 (21.4) 0.65
Cough at 
enrolment 
27/43 ( 62.8) 26/42 ( 61.9) 1.00 220/383 (57.4)  219/379 (57.8) 0.94
Cotrimoxazole 
prophylaxis 
43/43(100.0) 42/42(100.0) - 340/383 (88.8) 334/379 (88.1) 0.82
Routine 
multivitamins 
18/43 ( 41.9) 13/42 ( 31.0) 0.37 241/383 (62.9) 219/379 (57.8) 0.16
Vitamin A in past 
6 months 
20/43 ( 46.5) 16/42 ( 38.1) 0.51 183/383 (47.8) 175/379 (46.2) 0.66
WHO stage III or 
IV 
- - - 124/383 (33.4) 114/379 (30.1) 0.53
CD4+ <25% 17/39 ( 43.6) 17/36 ( 47.2) 0.81 211/325 (64.9) 215/328 (65.5) 0.87
WHZ <-2  2/41 (   4.9) 3/42 (   7.1) 1.00 53/366(14.5) 50/367 ( 13.6) 0.75
HAZ <-2 22/40 ( 55.0) 23/41 ( 56.1) 1.00 190/358(53.1) 197/359 ( 54.9) 0.65
WAZ <-2 5/40 ( 12.5) 6/41 ( 14.6) 1.00 110/364 (30.2) 125/363 (34.4) 0.24
*CRP >6mg/L 15/31 ( 48.4) 11/30 ( 36.7) 0.44 122/260 (46.9) 119/247 (48.2) 0.79
*Zinc <10 mol/L 5/31 ( 16.1) 14/29 ( 48.3) 0.01 86/143 (60.1) 84/133 (63.2) 0.62
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Effect of multiple micronutrient supplementation on mortality 
The overall mortality at 12 months of follow-up was 53/847 (6.3%). In the intervention arm 
25/426 (5.9%) and in the comparative arm 28/421 (6.7%) children died. There was no 
difference between arms; the risk ratio was 0.9 (95% CI; 0.5-1.5) using the Kaplan-Meier 
survival analysis (Figure 9). However, those on HAART were less likely to die. In the 
HAART stratum, two out of the 85 (2.4%) children died compared with 51/762 (6.7%) in 
the non-HAART stratum. The numbers in the HAART stratum were too few to draw 
comparisons. In the non-HAART stratum, similar proportions of children in the intervention 
and comparative arm died, 25/383 (6.5%) in one arm and 26/379 (6.9%) in the other. The 
risk ratio was 1.0 (95% CI; 0.6-1.6). The mean survival time was similar in the 2 groups of 
children.  
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Figure 9. Survival in the two arms using Kaplan-Meier curves.  
 
Presence of fever, hospitalization at enrolment visit, WHO Stage 3 or 4, and being 
underweight independently predicted early mortality. The common causes of death were 
pneumonia (accounting for 20/53, 37.7 %), acute febrile illness/malaria (11/53, 20.8%) and 
diarrhoea (6/53, 11.3%).  
 
When the anthropometric measurements and the CD4+ cell count at 12 months were 
compared, no difference was found between the 2 groups.  
 
Adverse effects related to the supplement were reported in 16 children (1.9%) and these 
included vomiting in 12 and diarrhoea in 4 children. A third of the 12 children vomited 
within 30 minutes of administering the supplement. There were equal numbers in each arm. 
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Effect of multiple micronutrient supplementation on diarrhoea morbidity 
Of the 847 children randomised, 800 children contributed data on the incidence of diarrhoea 
(Table 12). Forty-seven children (25 in the intervention and 22 in the comparative arm) 
dropped out before their first routine follow-up visit. Of the 710 children who completed 6 
months of follow-up, 613 were assessed for prevalence of diarrhoea at the 6 month visit. 
There were 516 episodes of diarrhoea in 7,336 person weeks, 270/3706 in the MMS and 
246/3630 in the MV group. The incidence rate was 3.8 (95% CI; 3.4-4.3) in the MMS and 
3.5 (95% CI; 3.1- 4.0) in the MV group per child year. The rate ratio was 1.1 (0.9-1.3), 
meaning that there was no difference in the incidence of diarrhoea. In the HAART stratum 
the incidence of diarrhoea was low but not different between the intervention and 
comparative arm.  
 
Table 12. Incidence of diarrhoea in the intervention arm (MMS) compared to the 
comparative arm (MV). 
 
The prevalence of diarrhoea at the 6 month visit was also similar in the 2 groups. Further 
analysis of the factors that were likely to predict diarrhoea revealed that age was the only 
significant factor.  
Zinc status of HIV-infected children aged 1-5 years 
Serum zinc concentration was assessed at baseline for a sub-sample of 247 children (Paper 
III). Of these, 134 (54.3%) had a serum zinc concentration of <10mol/L, which we 
considered low. The mean (SD) serum zinc concentration was 10.0 (2.9) mol/L, with a 
range of 5.6-29.5 mol/L. There was no linear relationship between age, weight-for-height 
z-score, haemoglobin and zinc status. The mean serum zinc among children on HAART was 
12.2 (SD 4.1) compared to 9.6 (SD 2.5) among those not receiving HAART, a statistically 
significant difference (OR 2.6; 95%CI; 1.6-3.5; Table 13). 
 
Table 13. Serum zinc concentrations in the HAART and HAART naïve children 
 Zinc <10 mol/L Zinc 10 mol/L p-value 
On HAART (n=44)   13 (29.5%) 31 (70.5%) <0.001 
HAART naïve (n=203) 121 (59.6%) 82 (40.4%)  
 
Group Arm Number of 
participants 
with at least 
one follow-up  
Episodes 
of 
diarrhoea 
Obs.  
period 
(weeks) 
Rate per 
child/year 
(95% CI) 
Rate ratio 
(95% CI) 
P 
value
Overall MMS 
MV 
 
401 
399 
270 
246 
3706 
3630 
3.8 (3.4 – 4.3) 
3.5 (3.1 – 4.0) 
1.1 (0.9 – 1.3) 0.43 
Non-
HAART 
stratum 
MMS 
MV 
359 
358 
255 
233 
3246 
3190 
4.0 (3.6 – 4.6) 
3.8 (3.4 – 4.3) 
1.1 (0.9 – 1.2) 0.44 
HAART 
stratum 
MMS 
MV 
 
42 
41 
15 
13 
460 
440 
1.7 (1.0 – 2.7) 
1.5 (0.9 – 2.6) 
1.1 (0.5 – 2.3) 0.94 
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Significant independent predictors of low zinc were: being HAART naïve and reported 
fever. The characteristics likely to be associated with low zinc concentration are presented 
in Table 14. 
 
Table 14. Factors associated with low serum zinc concentration in 247 HIV-infected 
Ugandan children aged 1-5 years. 
 
 Low zinc
<10μmol/L
        n/N        (%)
Unadjusted OR 
(95%CI)
Adjusted OR 
(95%CI) 
On HAART  
No HAART  
13/  44 (29.5)
121/203 (59.6)
3.5 (1.7 – 7.1) 3.7 (1.8 – 7.7) 
Reported fever  
No fever  
30/  44 (68.2)
 104/203 (51.2)
2.0 (1.0 – 4.1) 2.2 (1.1 – 4.6) 
 
WHO stage 3 or 4  
WHO stage 1 or 2  
42/  62 (67.7)
92/185 (49.7)
2.1 (1.2 – 3.9) 1.5 (0.8 – 2.9) 
 
WAZ score <-2  
WAZ score -2  
38/  56 (67.9)
96/191 (50.3)
2.1 (1.1 – 3.9) 1.2 (0.6 – 2.6) 
 
CRP <6 mg/L  
CRP 6 mg/L  
72/147 (49.0)
62/100 (62.0)
1.7 (1.0 – 2.9) 1.6 (0.9 – 2.7) 
 
Effect of multiple micronutrient supplementation on vitamin B12 and 
folate concentrations  
We compared the serum concentrations of vitamin B12 and folate at baseline and at 6 
months in a sub-sample of 214 children. There were almost equal numbers in both the 
intervention and comparative arm. At baseline, 60/214 children (28.0%) had a low vitamin 
B12 concentration of <221.0 pmol/L and 62/214 (29.0%) had a low concentration of folate 
of <13.4 nmol/L. At 6 months, the children in the intervention arm had an increase in the 
concentrations of both vitamin B12 and folate, whereas the ‘standard of care’ arm showed 
almost no change with time. The mean difference in concentration of vitamin B12 was 106.5 
(182.7) and that of folate was 7.8 (13.7) in the intervention arm, with minimal change in the 
comparative arm (Table 15, Figure 10).  
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Figure 10. Mean serum concentrations of vitamin B12 and folate at baseline and at 6 
months of supplementation. 
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The differences between the intervention and comparative arm were maintained in the 2 
strata. Vitamin B12 status was not associated with baseline characteristics, whereas folate 
status was likely to be lower in the male and children of <24 months of age.  
 
Table 15. Biochemical and haematological measurements at baseline and at 6 
months of supplementation by intervention group. 
 Multiple micronutrient 
supplementation group (n=104) 
Comparative ‘standard of care’ 
multivitamins group (n=110) 
 
Measurement 
 
Median (IQR) p-value Median (IQR) p-value 
Vitamin B12 (pmol/L) 
 - Baseline 
 - 6 months 
 - Change 
 
 
285.5 (216.5 – 371.8) 
401.5 (264.3 – 518.8) 
  90.5 (  -0.8 – 203.5) 
 
<0.001 
 
280.0 (211.5 – 386.3) 
288.5 (198.8 –391.0) 
  10.0 ( -73.8 –   83.8) 
 
0.78 
Folate (nmol/L) 
- Baseline 
 - 6 months 
 - Change 
 
 
17.3 (13.5 – 26.6) 
27.7 (21.1 – 33.4) 
  8.0 ( -0.3 – 17.1) 
 
<0.001 
 
15.7 (11.9 – 22.1) 
16.5 (11.7 – 22.1) 
 -0.6 ( -3.5 –  5.8) 
 
0.44 
Haemoglobin (g/dl) 
- Baseline 
 - 6 months 
 - Change 
 
 
10.0 ( 8.7 – 11.2) 
10.9 ( 9.4 – 11.7) 
  0.3 (-0.4 – 0.9) 
 
0.04 
 
  9.8 ( 8.8 – 11.2) 
10.6 ( 9.6 – 11.7) 
  0.6 (-0.2 –   1.4) 
 
<0.001 
CD4+ count (cells/μL) 
 - Baseline 
 - 6 months 
 - Change 
 
1201 (  822 – 1556) 
1039 (  725 – 1358) 
 -137 (-348 –   254) 
 
0.16 
 
1033 (  728 – 1406) 
1043 (  704 – 1484) 
    35 (-278 –    352) 
 
0.52 
Wilcoxon Signed Ranks test was used to measure the difference between baseline and 6 months. 
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Discussion 
This clinical trial of 2RDA multiple micronutrient supplementation in HIV-infected children 
demonstrated that this supplement was well tolerated by all subjects. However, there was no 
reduction in mortality compared to the ‘standard of care’ (of multivitamin supplement) at 
one year of follow-up, 6 months post-supplementation. The intervention neither improved 
growth nor reduced diarrhoea morbidity. Biochemical measurements showed that over half 
of the children were zinc deficient and close to one-third had low concentrations of vitamin 
B12 and folate. The deficiencies decreased following 6 months of supplementation but one-
fifth of the children remained with low concentrations of vitamin B12 and folate. Children 
who had received the intervention were more likely to have higher serum concentrations of 
micronutrients. 
Implications of the major findings 
The main findings of this study and the potential explanations are summarised in Table 16.  
 
Table 16. Main findings and their potential explanations. 
 
Main findings Potential explanations 
No reduction in mortality 
No difference in growth 
 
 Too short a supplementation period 
 Too low dose, higher dosing required 
 No placebo, comparative arm also 
had some impact  
 Too small difference in doses 
between intervention and 
comparative supplement 
 Too many other interventions in HIV 
No reduction in diarrhoea morbidity  Too short a supplementation period 
 Excluded peak age for diarrhoea 
morbidity, therefore fewer episodes 
 Other interventions 
Low micronutrient concentrations in blood  Micronutrient deficiency 
 Redistribution of zinc 
Improved micronutrient status following 
supplementation 
 Response to supplementation 
 The standard formulation did not 
contain folic acid and vitamin B12 
 Evidence of deficiency 
 
2RDAs of 14 micronutrients is safe 
The study supplement with 14 micronutrients in the amount of 2RDAs per day was well 
tolerated. Diarrhoea and vomiting were reported by mothers or caretakers in ~2 in 100 
children. The occurrence of gastrointestinal symptoms was variable in duration with a few 
episodes of vomiting within 30 minutes of administering the supplement. There were equal 
numbers in each arm indicating that these symptoms were unlikely to be due to the 
intervention supplement. Sometimes the children were taking multiple drugs and it may not 
be easy to attribute gastrointestinal symptoms to the intervention.   
 
Multiple micronutrient supplementation in HIV-infected children 
 
 43
The risk of harm due to dietary supplements normally depends on the safe intake range. At 
the lower end of intake, the risk of compromised health increases due to deficiency and at 
higher doses the risk of compromised health due to toxicity increases (Figure 3). The safe 
intake range tends to vary with each micronutrient and may be narrow for some of them. 
From a safety point of view, 3 groups of nutrients can be identified, water-soluble vitamins, 
fat-soluble vitamins and minerals.  
 
For the water-soluble vitamins, it is generally believed that higher doses are well tolerated 
since they are easily excreted. For example, vitamin C can be given in mega-doses without 
fear of toxicity other than osmotic diarrhoea. The margin is comparable or greater for most 
of the water-soluble vitamins.85 
 
The fat-soluble vitamins tend to have a narrow safe intake range, such as vitamin A.86 
Single nutrient studies show that vitamin A accumulates in fatty tissues and the liver; 
toxicity occurs when the amount of vitamin A exceeds the capacity of retinol-binding 
protein to bind it. Excess vitamin A binds instead to lipoproteins, causing changes in 
biological membranes. Excess vitamin A in the liver may result in elevated liver cell 
enzymes as an indicator of potential liver damage.  
 
The mineral supplements present a more varied picture. For example, selenium has a narrow 
range of safe intake such that using it in a more soluble form may increase uptake and the 
risk of toxicity. Our supplement also contained zinc whose adverse effects have been 
reported on in several studies. Although vomiting was reported in a few participants, there 
was no difference in the 2 groups. Previous studies reported that vomiting was twice as 
likely to occur in zinc-treated children, with no serious adverse events.87 The human body 
tends to regulate the absorption and retention of zinc such that toxic levels do not 
accumulate in the body.88 Zinc toxicity occurs following consumption of multiples of RDA; 
other minerals such as calcium and iron can be given in higher doses to most people without 
toxicity.  
 
Our supplement contained only 2 RDAs and within the safety margin for all the 
micronutrients included. Other studies that have used multiple micronutrient supplements in 
the HIV-infected population have reported no adverse events.89, 90  
 
No effect on mortality 
Multiple micronutrient supplementation was not associated with reduced mortality 
compared to the ‘standard of care’ supplement. Were there any signs or tendencies that the 
intervention arm did better than the comparative arm? With a very generous and kind 
interpretation of the Kaplan-Meier curve, it could be argued that there is a tendency for the 
survival curves to diverge during the first 6 months with supplements, and a convergence 
could be observed after cessation (Figure 9). Would these curves have been different if the 
supplementation had been continued for a longer time, and with a larger dose difference 
between the arms? We can only speculate on this, but the actual data does not support any 
conclusion about a difference between the arms. We are also unlikely to ever get a better 
answer to this question because HAART has now become the standard of care for HIV-
infected children. As expected, mortality was lower in children receiving HAART. Whether 
HIV-infected children on HAART require an MMS supplement is discussed below.  
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The care of HIV-infected children has improved with time as more knowledge is gathered 
about the disease. For example improved diagnosis and management of opportunistic 
infections improves the quality of life and reduces mortality.91 Although these factors could 
have been equally shared in the 2 arms, they reduced the overall mortality thus reducing the 
power of the study.  
 
Generally large studies are required for studying effects on mortality, as it is a relatively rare 
event. In the planning of this study we were facing very high mortality rates in this 
particular sub-population of HIV-infected children and we had indications that multiple 
micronutrients could dramatically improve their survival. At the time of calculating the 
sample size, an intervention effect size of 40% was used, anticipating a higher mortality 
than actually found. Fortunately, the overall mortality was much lower, only 6.3% 
compared to the anticipated 14.4%. The assumption for reduction of mortality was based on 
a small sample of HIV-infected children in Tanzania47 in the absence of any large 
micronutrient supplementation studies reported in Africa at the time. The mortality in 
paediatric HIV was also much higher73, 92, 93 than what we currently see. Although we 
factored in the impact of general improved care in the sample size, nevertheless, the study 
was underpowered for the mortality outcome, a limitation that has been acknowledged. 
 
No effect on diarrhoea morbidity 
The incidence of diarrhoea was 3-4 episodes per year in the non-HAART stratum, which is 
a quite common incidence among children in Africa.94 Our study population was HIV-
infected in whom we would thus expect a higher incidence. But the incidence was not 
elevated, and there was no difference between the intervention and comparative arm. Are 
there any explanatory factors?  
 
It is possible that prophylaxis with cotrimoxazole could have reduced diarrhoea morbidity in 
the study population. A study of HIV-infected adults in Uganda showed a significant 
reduction in diarrhoea morbidity following cotrimoxazole prophylaxis,95 although its impact 
on prevention of diarrhoea in HIV-infected children had been inconclusive in other 
studies.96 
 
The different causes of diarrhoea could have influenced the results if not equally distributed 
in the 2 arms. The intervention could have had an impact on severity and duration of 
diarrhoea, factors not explored in our study.  
 
Both the intervention and comparative supplements contained vitamin A, whose impact 
could have been similar on mucosal immunity and diarrhoea morbidity. Vitamin A 
supplementation reduces the severity of pathogen-induced diarrhoea, evidenced by reduced 
faecal concentrations of the monocyte chemoattractant protein-1, indicating that vitamin A 
has an anti-inflammatory effect in the gut.97 However, the effect of vitamin A on mucosal 
immune response may be modified by the type of pathogen, resulting in no detectable 
difference in patients with different pathogenic infections.98  
 
The intervention contained zinc, which reduces diarrhoea episodes and severity in HIV-
infected, non-infected children and adults.44, 99, 100 The effect could have been more 
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pronounced in those who were zinc deficient as shown in one of the adult studies 100. It is 
therefore surprising that a zinc-containing supplement had no effect on diarrhoea incidence. 
The only plausible explanation is that the Uganda diet contains high concentrations of 
phytates from dietary plant material, including cereals, corn and rice; these chelate zinc and 
inhibit its absorption,101 thereby minimising the difference between the 2 arms. 
 
Some opportunistic gut infections are associated with damage to the intestinal villi102 and 
this damage may not be repaired by micronutrients. Alternatively, the supplementation dose 
and period may not have been enough to facilitate complete repair.  
 
Another intervention that may have influenced diarrhoea morbidity was the promotion at the 
time of the study of use of point-of-use chlorination and storage of water using safe water 
systems.103 Some of the study participants received ‘water guard’ for chlorination of water 
and safe water storage containers. Unfortunately, no data was collected on this intervention.  
 
Does this mean that this supplement has no real influence on diarrhoeal morbidity or did we 
fail to detect a true relation? It could be argued that the supplementation time was not long 
enough to create an effect on diarrhoea morbidity. Further, it could be argued that we did 
not include the peak age for diarrhoea (6 to 12 months) and subsequently fewer episodes 
were registered. However, the lack of effect is likely to be a reflection of the truth, since we 
have not identified any strong biasing factors and there was no tendency of difference 
between the arms.  
 
The non-effect on diarrhoeal morbidity compares well with other recent multiple 
micronutrient supplementation studies among children in other low income countries that 
gave the supplement for 6 months.104, 105  
 
Low serum micronutrient concentration – is it always equal to deficiency?  
Ideally a measure of body stores of a micronutrient should determine its amount in the body. 
In most cases we use blood concentrations as proxy indicators of micronutrient status 
supposing that the blood concentration truly reflects body stores.  
 
We know that during acute infections, serum concentrations of some micronutrients change, 
for example vitamin A and zinc tend to reduce whereas serum ferritin increases.106, 107 If a 
sample is taken in such a situation and the micronutrient concentration is low, it is unclear 
whether this decrease is a real deficiency or the result of some redistribution. This becomes 
particularly difficult to evaluate when there is no follow-up measurement. In order to 
attribute a change to inflammation, another test that measures acute phase proteins is 
recommended. An example is CRP which was measured in our study. Indeed, zinc 
concentrations were related to fever or a positive CRP. Though not very reliable, serum zinc 
is the best measure of zinc status that is available to date.  
 
For some micronutrients, their deficiency states can be reliably measured through their 
metabolic functions. For example, vitamin B12 and folate deficiency are associated with 
increased concentrations of methylmalonic acid and homocysteine.108 Although we did not 
measure these metabolites, some studies in low-income countries indicated that low 
concentrations of folate and vitamin B12 were commonly associated with elevated 
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methylmalonic acid and homocysteine, indicating true deficiency.82 Therefore the low 
concentrations in our study could actually imply true deficiency. 
 
In a study of HIV-infected children in New York, all the participants had normal or elevated 
vitamin B12 and folate status,109 despite not receiving multivitamins. There are definitely 
major differences in the diet of children in the United States of America compared to 
Ugandan children. Our study included younger children, the majority of whom were 
symptomatic and not on HAART compared to the New York study of older and HAART 
treated children.  
 
Improved micronutrient status after supplementation 
The increase in vitamin B12 and folate at 6 months implies that this was probably a true 
deficiency that responded to supplementation. Our study indirectly shows that the Ugandan 
children do not get adequate levels of vitamin B12 and folate in the diet or in the form of 
supplements. The ‘standard of care’ supplement did not contain vitamin B12 or folate. The 
fact that some children did not show normalisation of vitamin B12 and folate concentrations 
following supplementation with 2RDAs of multiple micronutrients (containing vitamin B12 
and folate) could indicate that they require higher doses of at least some of the 
micronutrients or perhaps a longer duration of supplementation.  
 
The children who did not show normalisation of their blood micronutrient concentrations 
are probably those who were more deficient or had multiple deficiencies. At the same time, 
they could have been the ones that benefited more than others. This argument is supported 
by previous reports that have shown that supplementation is more likely to be beneficial to 
micronutrient deficient children.110-112  
 
Table 17. Main findings and their implications. 
 
Main findings Implications 
2RDA well tolerated  
 
 2RDA safe  
No reduction in mortality 
No difference in growth 
 
 MMS in 2 RDA for 6 months does not reduce mortality 
 MMS in 2 RDA for 6 months does not improve growth 
 The comparative arm also had some effect and decreased the 
difference  
 
No reduction in incidence 
of diarrhoea  
 MMS in 2 RDA does not reduce diarrhoea incidence 
Low micronutrient 
concentrations in blood 
 A high prevalence of micronutrient deficiencies 
 Possibly redistribution of zinc in infections 
Improved micronutrient 
status following 
supplementation 
 MMS in 2 RDA raises vitamin B12 and folate concentrations 
 Possible increase of the other micronutrients 
 An indirect evidence of deficiency 
Not all children 
normalised their blood 
concentrations of 
analysed micronutrients 
 MMS in 2 RDA for 6 months not enough to raise 
concentrations to normal levels 
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We found no association between CD4+ cell count with vitamin B12 or folate 
concentrations. This was rather surprising, since adult studies have shown that low vitamin 
B12 is associated with low CD4+ lymphocyte count and faster HIV disease progression.113-
115 Low folate concentrations have not been previously associated with HIV disease 
progression. 115 There have been no similar studies in HIV-infected children residing in low-
income countries to make comparisons. We have no clear explanation for the lack of 
association in this study.  
 
Generally there was an increase in haemoglobin, with no significant differences in both 
arms. This is probably due to the fact that all participants increased in age during the trial. 
Although the supplement did not contain iron, it could potentially have had an impact on 
iron absorption (from the diet) or metabolism and other micronutrients involved in 
haemopoiesis.  
 
Should HIV-infected children receive MMS?  
Our findings demonstrate that the HIV-infected children were micronutrient deficient and 
not in only one micronutrient but probably several. It is also clear that the supplementation 
improved the concentrations of some of these micronutrients. On the other hand, our 
supplement neither reduced mortality nor diarrhoeal morbidity, so what should we 
recommend?  
 
Based on general physiological knowledge that it is healthier for a subject to be replete in 
micronutrients than deficient, and on the finding that a large group of these children had low 
micronutrient concentrations and improved with supplementation, we recommend all 
Ugandan HIV-infected children to receive a multiple micronutrient supplement, even if it 
has no proven effect on mortality or morbidity. We also recommend that the multiple 
micronutrient supplement should be at least 2 RDAs.  
 
Which composition of MMS should it be? 
Because we need a considerable number of micronutrients and their assessment is often 
difficult, it is a good strategy to include as many as possible in a supplement.  
 
Whether iron should be included remains contentious. In malaria endemic areas it was 
previously argued that iron supplementation increases malaria parasitaemia and severity.116 
Subsequent studies failed to show increased malaria morbidity.117, 118 With adequate malaria 
diagnosis and treatment iron supplementation is associated with increased iron status and 
haemoglobin. 
 
Previous studies in HIV-infected patients indicated that iron could be associated with 
increased HIV replication, more rapid disease progression and poor outcomes.61, 62 With or 
without HIV infection iron is utilised by most pathogens and influences their virulence.119 
Most of the available literature is based on adult studies, not on HIV-infected children living 
in malaria-endemic areas. In Cochrane’s 2009 review, there were no randomised trials of 
iron supplementation in HIV-infected children120 and we have not found any to-date.  
 
The arguments in support of including iron in the supplement are: 1) HIV and iron 
deficiency appear in the same regions of the world, 2) many children with anaemia are 
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treated with iron, irrespective of their HIV status, without any reported serious adverse 
effects, 3) several studies from malaria endemic areas indicate that iron supplementation 
during malaria illness does not increase parasitaemia or cause severe anaemia, and 4) iron 
supplementation in malaria endemic areas has been associated with improved haemoglobin 
and growth.118 
 
Recommendation for HAART treated versus HAART naïve children?  
Although the HAART children were better off, a significant number had low micronutrient 
concentrations. Since the diets for most children in Uganda are not micronutrient dense, we 
would recommend the same supplement and similar dosing for children receiving HAART. 
This proposal is supported by other studies; for example, a multiple micronutrient 
supplement administered to HIV-infected adults on HAART for at least 3 months improved 
their CD4 cell count within 12 weeks of follow-up compared to a placebo.121 Other studies 
of one or two micronutrients resulted in improved antioxidant defence.122  
 
How should the supplementation be administered? 
Mothers were very comfortable with administering the powder form of the supplement. 
They equated it with giving powdered milk. However, a few mothers had problems 
administering the supplement for example, when having to travel with the child. In order to 
produce a relatively stable multiple micronutrient supplement that is easy to administer and 
store, we would recommend use of dispersible tables, preferably in blister packs.  
Methodological considerations 
A randomised controlled trial is a strong research design in studies of cause and effect 
associations. Any difference between the participants is supposed to be equally distributed 
between the arms and therefore the risk of bias is minimal; for instance, it is unlikely that 
one of the groups is richer or better educated than the other. In our study, randomisation 
took part in all the participating clinics which eliminates the risk of bias from the different 
sites.  
 
Despite having used a ‘gold standard’ design, there are some issues that could have 
influenced the outcomes. The first is the intervention: we relied on the mothers for 
supervision and administration of the supplement. The best option would have been directly 
observed therapy, which was not possible in this study. We assessed compliance, which was 
similar in both arms, indicating that any effect would be equally distributed.  
 
Second, we also relied on the mothers reporting one of the main outcomes: diarrhoea. We 
could also have missed diarrhoea episodes that occurred outside the clinic setting and were 
never reported, since we were unable to use home visits for ethical reasons. A record of 
morbidity would have been more complete had regular community visits been possible. 
This effect was minimised by encouraging mothers to return to the clinic on any day of the 
week whenever the child was sick. In addition, we restricted our analysis to 2 weeks of 
observation when we could fairly rely on the mother’s recall for diarrhoea.  
 
Third, micronutrient assays were only performed for children residing in Kampala city, and 
therefore it was not possible to assess differences with other sites. We could generally 
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conclude that our micronutrient results depict the micronutrient status of the children in 
Kampala.  
 
Fourth, this thesis does not report any data on dietary habits of the study children, and 
therefore unable to tell whether this could have had an impact on the outcome. But again, 
with randomisation, it is unlikely to have any large hidden confounding element in the 
dietary habits.  
 
Fifth, adult studies have shown that the time of blood collection and feeding influence 
micronutrient concentrations especially zinc.123 However, it is unfair to starve children for 
purposes of blood collection. In addition, we were unable to conduct absorption studies to 
examine the impact of malabsorption on baseline micronutrient and post-supplementation 
status.  
 
Sixth, due to the restrictions in blood volumes, we were unable to conduct other tests that 
may have confirmed vitamin B12 deficiency, such as methyl- malonic acid or homocysteine, 
and confirmed folate deficiency by red-cell folic acid status. Low micronutrient status 
remains a useful indicator in guiding detailed investigations for specific micronutrient 
deficiencies. 
 
Seventh, the loss to follow-up was high, but similar between the 2 arms, and not very 
different from what other follow-up studies of HIV-infected subjects have reported.124 The 
loss to follow-up in the rural sites was higher than in the capital city. We enrolled children 
who were living in internally displaced camps in the northern region; however, some of 
them relocated to their distant homes while still in the study and were therefore lost to 
follow-up. Those lost to follow-up were likely to be more sick, but with almost similar 
numbers in the two arms, and therefore less likely to influence the comparisons.  
 
Strengths of this thesis 
Our study had a larger sample size compared to other micronutrient supplementation studies 
in HIV-infected children. The study employed a ‘gold standard’ design with successful 
randomisation and blinding/masking. There are no published studies that had measured 
micronutrient concentrations or published the impact of micronutrient supplementation in 
Ugandan HIV-infected children.  
 
Generalisability 
The routinely available supplement for HIV-infected children in Uganda is mainly based on 
a few multivitamins. Our studies show that a significant proportion of the HIV-infected 
children have low concentrations of zinc, vitamin B12 and folate and that supplementation 
results in increased concentrations. These findings would apply to other HIV-infected 
children living in low-income countries in similar settings. The poor nutritional state, the 
micronutrient status and other baseline characteristics seemed similar to other African 
countries. The lack of effect on diarrhoea morbidity and mortality could also apply to 
similar settings, which is supported by the fact that other recent studies using multiple 
micronutrients in Africa, with supplementation for 6 months did not show an effect on child 
morbidity.104, 105 
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Conclusions and recommendations 
Twice the recommended dietary allowance of 14 micronutrients compared with 1 RDA 6 
multivitamins given as the ‘standard of care’ for 6 months did not significantly alter 
mortality, diarrhoea morbidity, but improved vitamin B12 and folate concentrations. The 
HAART-treated children had higher zinc concentrations and were less likely to die. A third 
to a half of the children had low serum concentrations of zinc, vitamin B12 and folate, and 
probably other micronutrients were deficient.  
 
Recommendation for practice  
We recommend that all HIV-infected children in Uganda be supplemented with 2RDAs of 
multiple micronutrients based on the following reasons:  
1) Our study has shown that Ugandan HIV-infected children are micronutrient deficient, 
not only in one micronutrient, but probably several.  
2) Supplementation with 2RDAs improved concentrations of some of the analysed 
micronutrients, whereas the standard of care had no effect.  
3) The Uganda diet for most children is carbohydrate and plant protein based and not 
micronutrient dense.  
4) Most of the Uganda cereal foods and grains are locally processed and not fortified.  
5) HIV-infected children are more likely to have increased micronutrient requirements 
because of increased morbidity and demands due to growth.  
 
 
Recommendation for future research 
Future studies in similar settings should consider: 
1) Assessing the efficacy of different dosing schemes in HIV-infected children (various 
dosing schedules and types of micronutrients to include in a supplement)  
2) Assessing the efficacy of prolonged supplementation. 
3) Assess efficacy of an iron containing regimen of micronutrients. 
4) Consider micronutrient intake at doses for risk reduction of disease, not only for the 
healthy population. 
5) Assess efficacy in HAART-treated children. 
More evidence is required regarding the best dosage schedules since RDAs are calculated 
for a healthy population. 
 
Recommendation for policy 
Currently the WHO recommends one RDA of multiple micronutrients daily to HIV-infected 
people. Our study has provided some evidence that 2RDA of multiple micronutrients is 
safe, and improves vitamin B12 and folate concentrations in Ugandan HIV-infected children, 
whereas 1RDA of a few multivitamins had no effect. A change of policy from 1RDA to 
2RDA is recommended.  
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Errata  
- Page 19, table 3, last row:
was:   200 000      
corrected to:  200 000 IU (International Units) 
- Page 23, line 8: 
was:   ‘Health Centre I’; it has physical structures 
corrected to:  ‘Health Centre I’; it has no physical structures 
- Page 33, 3rd paragraph, last sentence:  
Was:   Those who were alive or lost to follow-up were censored at 12 months. 
Corrected to:  Those who were alive were censored at 12 months and those lost to follow-up 
immediately after the last visit. 
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ResearchEffect of multiple micronutrient supplementation 
on survival of HIV-infected children in Uganda: a 
randomized, controlled trial
Grace Ndeezi*1,2, Thorkild Tylleskär2, Christopher M Ndugwa1 and James K Tumwine1
Abstract
Background: Micronutrient deficiencies compromise the survival of HIV-infected children in low-income countries. 
We assessed the effect of multiple micronutrient supplementation on the mortality of HIV-infected children in Uganda.
Methods: In a randomized, controlled trial, 847 children aged one to five years and attending HIV clinics in Uganda 
were stratified by antiretroviral therapy (ART, n = 85 versus no ART, n = 762). The children were randomized to six 
months of either: twice the recommended dietary allowance of 14 micronutrients as the intervention arm (vitamins A, 
B1, B2, niacin, B6, B12, C, D and E, folate, zinc, copper, iodine and selenium); or the standard recommended dietary 
allowance of six multivitamins (vitamins A, D2, B1, B2, C and niacin) as a comparative "standard-of-care" arm. Mortality 
was analyzed at 12 months of follow up using Kaplan Meier curves and the log rank test.
Results: Mortality at 12 months was 25 out of 426 (5.9%) children in the intervention arm and 28 out of 421 (6.7%) in 
the comparative arms: risk ratio 0.9 (95% CI 0.5 - 1.5). Two out of 85 (2.4%) children in the ART stratum died compared 
with 51 out of 762 (6.7%) in the non-ART stratum. Of those who died in the non-ART stratum, 25 of 383 (6.5%) were in 
the intervention arm and 26 of 379 (6.9%) in the comparative arm; risk ratio 1.0 (95% CI 0.6 - 1.6). There was no 
significant difference in survival at 12 months (p = 0.64, log rank test). In addition, there was no significant difference in 
mean weight-for-height at 12 months; 0.70 ± 1.43 (95% CI 0.52 - 0.88) for the intervention versus 0.59 ± 1.15 (95% CI 
0.45 - 0.75) in the comparative arm. The mean CD4 cell count; 1024 ± 592 (95% CI 942 - 1107) versus 1060 ± 553 (95% 
CI 985 - 1136) was also similar between the two groups.
Conclusions: Twice the recommended dietary allowance of 14 micronutrients compared with a standard 
recommended dietary allowance of six multivitamins for six months was well tolerated, but it did not significantly alter 
mortality, growth or CD4 counts. Future intervention studies should carefully consider: (1) the composition and dosing 
of the supplements; and (2) the power needed to detect a difference between arms.
Trial Registration: ClinicalTrials.gov Identifier: NCT00122941
Background
Mortality in HIV-infected children living in low-income
countries is still high compared with high-income coun-
tries [1,2]. Malnutrition in children under five years of
age is highly prevalent and both macro and micronutrient
deficiencies are likely to co-exist [3-6], especially among
HIV-infected children.
Micronutrients are important for maintaining optimal
functioning of the individual's immune response. Sele-
nium and vitamin E are involved in the maintenance of
the oxidant defence system, while zinc and vitamin A play
a significant role in maintaining cellular integrity [7].
Vitamin B12 is important in the formation of proteins and
proper functioning of a large number of enzymes and the
immune system [8]. Deficiency of the important compo-
nents of the endogenous anti-oxidant defence system
leads to accumulation of oxidative stress, including oxida-
tive damage [9]. Vitamin A and zinc deficiencies are asso-
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ciated with increased susceptibility to infections,
increased severity of illness and mortality [10,11].
Studies in HIV-infected children have demonstrated
that multiple, large doses of vitamin A reduces diarrhoea
episodes, increases CD4 count and reduces all-cause
mortality [12-14]. Zinc supplementation in children
whose HIV status was not known in Asia and Latin
America reduced the incidence, duration and severity of
diarrhoea and pneumonia episodes [15]. In a study of effi-
cacy and safety of zinc, mortality was lower in the zinc-
supplemented group [16]. Most of these studies were sin-
gle micronutrient interventions, yet deficiencies are less
likely to exist singly: hence the efforts to provide multiple
micronutrients as opposed to single nutrient supple-
ments in both children and adults studies [17-21].
To achieve normal plasma levels of micronutrients,
HIV-infected adults required multiples of the recom-
mended dietary allowance (RDA) compared with HIV-
negative men. Those consuming adequate recommended
intake had a relatively high prevalence of deficiencies
compared with uninfected adults with similar intake [22].
Multivitamin supplementation using multiples of the
RDA resulted in reduction of progression to Stage 4 dis-
ease and mortality in pregnant and lactating women in
Tanzania [13].
Supplementation with multiple micronutrients had no
effect on mortality in one study of adults with HIV [23],
while it reduced mortality in another trial that used mul-
tiples of RDAs in patients with CD4 counts of less than
200/mm3 [18]. Hitherto, there are no published studies
that have examined the effect of multiple micronutrient
supplementation on mortality of HIV-infected children.
The objective of this study was to assess the efficacy of
a supplement containing twice the RDA (2 RDA) of 14
multiple micronutrients on mortality of HIV-infected
children in Uganda, and to document any adverse effects
associated with this dosing of multiple micronutrients.
We hypothesized that daily administration of twice the
recommended dietary allowance of multiple micronutri-
ents to HIV-infected children aged one to five years for
six months would reduce all-cause mortality from 24% to
14.4% in one year.
Methods
Study design, site and population
This was a randomized, controlled, double-blind, hospi-
tal-based trial of a supplement containing twice the RDA
(2 RDA) of 14 micronutrients (minerals and vitamins)
versus a formula of six multivitamins at the standard
RDA (1 RDA) dose administered to HIV-infected chil-
dren for a period of six months and followed up to 12
months. The trial was conducted between June 2005 and
June 2008 in Uganda at: the Paediatric HIV clinics of the
national referral hospital (Mulago); two private, not-for-
profit centres (Nsambya Hospital and Mildmay Centre)
in Kampala, the capital city; and four regional hospitals
(Mbale, Mbarara, Masaka, Lira).
At each site, a paediatrician was in charge of the study
and worked with a nurse and laboratory technician, who
had undergone training on study procedures. The princi-
pal investigator initiated the study at all the sites and
supervised data collection once a week at the Kampala
(central) sites and once every four weeks at the regional
hospitals (rural sites). Similar operating procedures were
followed.
The principal investigator or another paediatrician
enrolled children aged one to five years whose mothers or
caretakers gave informed written consent to participate
and who had attended the clinic at least once. The moth-
ers or caretakers also had to adhere to a regular study fol-
low-up schedule for one year. Their HIV status had
earlier been confirmed by either an antibody test or
DNA-PCR if younger than 18 months of age. These chil-
dren were stratified into two groups: those receiving anti-
retroviral drugs (ARVs) and those not yet started on
antiretroviral therapy (ART). Children enrolled in other
studies, those residing more than 15 kilometres from the
clinic and those whose parents or caretakers were antici-
pating moving from the study area were excluded.
The study was approved by Makerere University Col-
lege of Health Sciences Research and Ethics Committee,
the participating hospitals, the Uganda National Council
for Science and Technology and the Regional Committee
for Medical Research Ethics, Western Norway. Counsel-
ling for initiation of ART and adherence was offered to all
the participants, while ongoing adherence counselling
was provided to those who were already receiving ART.
Initiation of ART, treatment for concurrent illnesses and
prophylaxis was offered according to the World Health
Organization (WHO) and national paediatric HIV man-
agement guidelines.
Micronutrient supplements
The trial supplements were manufactured in the form of
a white powder, packaged in plastic containers and seri-
ally labelled according to strata (S1 or S2). The interven-
tion supplement consisted of twice the recommended
dietary allowance (2 RDA) of vitamins A, B1, B2, niacin,
B6, B12, C, D and E, folate, zinc, copper, iodine and sele-
nium; the comparative "standard-of-care" supplement
consisted of the RDA (1 RDA) of vitamins A, C, D, B1, B2
and niacin (Table 1).
The comparative "standard-of-care" supplement was
designed to be similar to the regular multivitamin tablet
supplied as the standard of care at paediatric HIV clinics
in Uganda. Upon administration to the child, both sup-
plements were dissolved in milk or water. The nurse dem-
onstrated how to prepare a dose and allowed the mother
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to prepare and administer the first dose in the clinic. Each
participant received 140g (one container) per month,
which was equivalent to 35 doses.
Randomization and blinding
The eligible participants were randomized to either the
intervention or "standard-of-care" in two strata. A WHO
officer in Geneva, who was not part of the study team,
generated the randomization code in permuted blocks of
4 to 20 using the Stata software. The list was sent to
NUTRISET (France), which manufactured the trial sup-
plements and packaged them in serially labeled identical
containers. The consistency of the powder, colour and
smell were similar. All investigators, staff and parents or
caretakers were blinded to treatment assignment. The
randomization code was made available to the investiga-
tors upon completion of data collection.
Clinical and laboratory assessment
Mothers or caretakers were interviewed about the chil-
dren's previous medical, nutritional history and present-
ing symptoms. The participants underwent a detailed
physical examination, including anthropometry and
WHO staging for paediatric HIV/AIDS. Weight was
taken using a scale (uniscale 01-410-15) to the nearest
0.1kg, and height was taken to the nearest 0.1 centimetre
using a portable infant-child length-height measuring
board (Shorr productions, Olney, Maryland, USA). A
plastic tape was used to measure mid-arm circumference
to the neatest 0.1cm. HIV/AIDS clinical disease staging
was decided using clinical signs against the WHO classi-
fication for paediatric HIV [24].
Two millilitres (ml) of blood was collected in a 5ml
EDTA vacutainer tube (Becton Dickinson, Franklin
Lakes, N.J.) by venipuncture from the cubital fossa or
dorsum of the hand, and was analyzed for a complete
blood count (Act 5Diff instrument Beckman Coulter )
and CD4 cell count (FACScan instrument and MultiSET
software Beckton Dickinson). C-reactive protein (CRP)
was analyzed using a qualitative method (Human Gesell-
schaft fur Biochemica und Diagnostica mbH, Germany).
Agglutination indicated a C-reactive protein of more than
6mg/L and this was reported as a positive CRP. An addi-
tional 3-5ml blood sample was collected and serum was
analyzed for zinc and other trace elements using induc-
tively coupled atomic emission spectrometry (ICP-AES)
[25].
Participants were followed at the clinics monthly for
the first six months, and at nine and 12 months. A record
of illness, anthropometry, physical examination findings,
investigations and treatment was kept for each visit. Par-
ents or caretakers were requested to report to the clinic
whenever the child got sick, was admitted to hospital or
died. Those admitted were followed until discharge, and
if they died, information was recorded on a mortality and
adverse event form. Information on missed doses of the
supplement was recorded on each monthly visit for six
months.
Compliance was assessed by measuring the remaining
supplement using a light-weight weighing scale (Philips
HR 2389/B 9.OV/DC). Each study participant was
expected to take 4g of the supplement per day (one
scoop) and this was equivalent to 120g in 30 days. A pro-
Table 1: The formulation of intervention supplement and the comparative "standard-of-care" supplement used in the 
supplementation trial of HIV-infected children, Uganda
Micronutrient Intervention arm 2 RDA Comparative arm "standard-of-care" 1 RDA
Vitamin A (mcg) 800 400
VitaminB1 (mg) 1.2 0.6
Vitamin B2 (mg) 1.2 0.6
Niacin (mg) 1.6 0.8
Vitamin B6 (mg) 1.2 -
Vitamin B12 (mcg) 2.4 -
Vitamin C (mg) 50 25
Vitamin D (IU) 400 200
Vitamin E (mg) 14 -
Folate (mcg) 400 -
Selenium (mcg) 60 -
Zinc (mg) 10 -
Copper (mcg) 800 -
Iodine (mcg) 180 -
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portion of the amount of supplement taken against the
expected was used as a measure of compliance. Overall
compliance was assessed at the end of six months,
whereby the average compliance was derived by adding
the compliance rates on all the six scheduled visits.
After six months, no study supplements were given, but
the children received the regular multivitamin supple-
ments from the clinic as the standard of care. Follow up
to 12 months was to ascertain whether there was any sus-
tained effect of the intervention. Children who were not
brought for scheduled visits were traced by telephone or
physically by the health visitor. Those who missed more
than two scheduled visits and could not be traced were
declared lost.
Outcomes
Information on mortality was collected from verbal
reports by the parents or caretakers or from hospital
records. Those who died at home were reported by tele-
phone or through tracing. Side effects attributed to the
supplement were assessed and recorded at the monthly
visits. A serious adverse event (SAE) form was completed
if an adverse event had occurred. Conditions that
resulted in hospitalization, required medical intervention
to prevent a serious outcome, or were life threatening or
fatal were regarded and reported as SAEs. The paediatri-
cian decided on the relationship to the intervention using
a set of conditions or known side effects of micronutri-
ents. All SAEs warranted stoppage of the trial supplement
when closely related to the intervention.
Statistical issues
The estimated sample size of 411 children in each arm
was based on data from two studies. The first assumption
was a mortality rate in the comparative arm of 24% in one
year, based on the mortality rate in a study conducted in
Mulago Hospital, Kampala, before highly active antiretro-
viral therapy (HAART) was available to HIV-infected
children [26]. The mortality among HIV-infected chil-
dren occurring between the ages of 12 and 25 months
was close to 24%. We assumed a similar mortality in the
whole age span of one to five years.
The second assumption - that all-cause mortality would
be reduced to 14.4% (a 40% reduction) - was based on a
study in Tanzanian children aged six months to five years
where supplementation with vitamin A was associated
with a 49% reduction in overall mortality and 63% among
HIV-infected children [13]. We decided to use the 40%
reduction level as we anticipated improved general care
of HIV-infected children over time. Finally, we used a
precision of 5%, and 95% confidence interval. The power
estimate was 90% with an assumption of 10% loss to fol-
low up.
Weight-for-height (WHZ), height-for-age (HAZ) and
weight-for-age (WAZ) z-scores were computed using the
WHO International Growth References [27]. Sub-group
analysis was based on whether the children were receiv-
ing ART or not.
Statistical analysis was performed using SPSS version
15.0. Baseline characteristics were compared in the two
treatment groups using proportions, and differences were
tested with the Chi-square or Fisher's Exact test. To
determine the association between patients' characteris-
tics and mortality, logistic regression was used. Risk
ratios and 95% confidence intervals were used to test the
strength of association. Comparisons of treatment effi-
cacy were analyzed on intention-to-treat basis in the two
arms. Kaplan Meier curves and the log rank test were
used to compare survival in the two arms.
Results
A total of 1632 children aged 12 to 59 months attending
paediatric HIV clinics at the study sites were screened for
eligibility (Figure 1). Out of the 847 children enrolled, 704
(83.1%) were from the study sites in Kampala (the capital
city); the rest were from the rural sites.
Baseline characteristics of participants
Almost equal proportions of children were assigned to
the two arms in both strata. More than half of the chil-
dren (470/847, 56%) were aged less than 36 months. Table
2 shows the baseline characteristics and these were com-
parable in the two groups.
Follow up
All the study participants took 85% or more of the study
supplements. Adverse effects were reported in 16 chil-
dren (1.9%) and these included vomiting in 12 children
and diarrhoea in four children. Of the 12 children who
vomited, 6/426 (1.4%) were in the intervention arm and
6/421(1.4%) in the comparative arm. These symptoms
were minor and did not warrant stopping the supple-
ment. There were no other adverse effects attributed to
the intervention.
By 12 months, 124 (14.6%) children were lost to follow
up: 67/426 (15.7%) in the intervention arm and 57/
421(13.5%) in the comparative arm. Most of the partici-
pants lost to follow up (90/124; 72.5%) were from the cen-
tral region (Kampala sites). However, the proportion of
loss to follow up was higher in the regional than the cen-
tral sites (23.8% vs. 12.8%; p < 0.01). Children who were
not receiving cotrimoxazole routinely (22.7% vs. 13.7%; p
= 0.04), CRP positive (13.5% vs. 9.0%; p = 0.00) and those
who were underweight (19.9% vs. 12.1%; p = 0.01) were
also more likely to be lost to follow up. The other charac-
teristics were similar to those who completed the study.
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Mortality
The overall mortality at 12 months of follow up was 53/
847 (6.3%). In the intervention arm, the mortality was 25/
426 (5.9%) and in the comparative arm 28/421 (6.7%).
The difference between the arms was not statistically sig-
nificant; risk ratio 0.9 (95% CI 0.5 - 1.5). In the ART stra-
tum, two out of the 85 (2.4%) children died compared
with 51/762 (6.7%) in the non-ART stratum. Of those
who died in the non-ART stratum, 25/383 (6.5%) were in
Figure 1 Trial profile.
Stratified: 
847
ART stratum 
Randomized: 85
Lost to follow up: 1
Withdrew: 0
Transferred: 1
Total excluded: 785
- Other studies: 218
- Inconsistent carers: 172
- Distance >15km: 348
- Declined to consent: 47
Screened for eligibility:
1632
Survived:
41 
Died:
0
Survived:
38
Died:
2
Intervention arm:
43
Comparative arm: 
42
Non-ART stratum 
Randomized: 762
Lost to follow up: 66
Withdrew: 5
Transferred: 8
Survived:
279
Died:
25
Survived:
284
Died:
26
Intervention arm: 
383
Comparative arm: 
379
Lost to follow up: 0
Withdrew: 0
Transferred: 2
Lost to follow up: 57
Withdrew: 6
Transferred: 6
Table 2: Baseline characteristics of the 847 Ugandan HIV-infected children aged 1-5 years enrolled in the micronutrient 
supplementation trial by ART stratum
Characteristics ART stratum (n = 85) Non-ART stratum (n = 762)
Intervention arm
n = 43 (%)
Comparative arm
n = 42 (%)
p-value Intervention arm
n = 383 (%)
Comparative arm
n = 379 (%)
p-value
Age <36 months 8 (8.6) 16 (38.1) 0.06 219 (57.2) 227 (59.9) 0.46
Male 20 (46.5) 23 (54.8) 0.52 201 (52.5) 182 (48.0) 0.25
Caretaker: mother 24 (55.8) 21 (50.0) 0.67 278 (72.6) 278 (73.4) 0.87
Study site: Kampala 40 (93.0) 40 (95.2) 1.00 313 (81.7) 311 (82.1) 0.93
Fever 9 (20.9) 8 (19.0) 1.00 76 (19.8) 81 (21.4) 0.65
Diarrhoea 1 (2.3) 2 (4.8) 0.62 42 (11.0) 51 (13.5) 0.32
Cough 27 (62.8) 26 (61.9) 1.00 220 (57.4) 219 (57.8) 0.94
Persistent diarrhoea 0 (0.0) 0 (0.0) - 11 (26.8) 11 (23.4) 0.81
Cotrimoxazole prophylaxis 43 (100.0) 42 (100.0) - 340 (88.8) 334 (88.1) 0.82
Routine multivitamins 18 (41.9) 13 (31.0) 0.37 241 (62.9) 219 (57.8) 0.16
Vitamin A in past 6 months 20 (46.5) 16 (38.1) 0.51 183 (47.8) 175 (46.2) 0.66
WHO Stage 3 or 4 - - - 124 (33.4) 114 (30.1) 0.53
WHZ less than -2 z score 2 (4.6) 3 (7.1) 1.00 53 (13.8) 50 (13.2) 0.75
HAZ less than -2 z score 22 (51.2) 23 (54.7) 1.00 190 (49.6) 197 (51.9) 0.65
WAZ less than -2 z score 5 (11.6) 6 (14.3) 1.00 110 (8.7) 125 (32.9) 0.24
Current hospitalization 1 (0.02) 3 (7.1) 0.36 27 (7.0) 16 (4.2) 0.12
Ever hospitalized 25 (58.1) 27 (64.3) 0.66 226 (59.0) 200 (52.8) 0.09
CRP positive (n = 565) 15 (24.6) 11 (18.0) 0.65 122 (24.1) 119 (23.5) 0.70
CD4% <20 (n = 720) 10 (27.0) 8 (24.2) 1.00 124 (38.4) 136 (41.6) 0.42
Zinc <10 μmol/L (n = 336) 5 (26.3) 14 (73.7) 0.01 86 (50.6) 84 (49.4) 0.62
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the intervention arm and 26/379 (6.9%) in the compara-
tive arm; risk ratio 1.0 (95% CI 0.6 - 1.6).
Figure 2 shows the Kaplan Meier probability of survival
by arm. There was no significant difference in survival at
12 months of follow up (log rank statistic 0.22, 1df, p-
value 0.64). The mean survival time was 10.6 months
(95% CI 10.3 - 10.9) in the intervention arm and 10.7 (95%
CI 10.4 - 11.0) in the comparative arm. The mean survival
time was 11.6 months in the ART (95% CI 11.3 - 12.0)
stratum and 10.5 (95% CI 10.3 - 10.8) in the non-ART
stratum.
On bivariate analysis for baseline characteristics, pres-
ence of fever, diarrhoea, cough, hospitalization at enrol-
ment, low anthropometric indices below minus 2 z-
scores, and WHO Stage 3 or 4 disease were associated
with a shorter time of survival (Table 3). Those who were
taking cotrimoxazole routinely within one month before
the study had better survival. Other baseline characteris-
tics and routine multivitamin supplementation were not
significantly associated with mortality. At multivariate
analysis, presence of fever, hospitalization at enrolment
visit, WHO Stage 3 or 4, and being underweight indepen-
dently predicted early mortality.
The most common cause of death was pneumonia
accounting for 20/53 (37.7% )of the deaths: eight of the 20
children died of severe pneumonia, six of severe acute
malnutrition with severe pneumonia, three of pnemocys-
tis jiroveci pneumonia and a further three died of measles
with severe pneumonia. Acute febrile illness and malaria
accounted for 11/53 (20.8%) of the deaths, including eigth
deaths due to acute febrile illness/malaria, two to cerebral
malaria and one child died of malaria with severe anae-
mia.
Other causes of death were acute diarrhoea with dehy-
dration (6/53; 11.3%), persistent diarrhoea with dehydra-
tion (3/53; 5.7%), measles with other complications (3/53;
5.7%), severe acute malnutrition with tuberculosis (2/53;
3.8%), pyogenic meningitis (2/53; 3.8%), cryptococcal
meningitis (1/53; 1.9%), and Kaposi's sarcoma (1/53;
1.9%). In 4/53 (7.5%) children, the cause of death could
not be established. Seven children died outside the hospi-
tal, including the four whose cause of death could not be
ascertained.
Effect of multiple micronutrient supplementation on 
anthropometry and CD4 cell count
Multiple micronutrient supplementation had no effect on
anthropometry as shown in table 4. CD4 cell count was
available for 399 surviving children at one year of follow
up. Of 195 children who had received twice the RDA of
multiple micronutrients, 55 (28.2%) had CD4 cell counts
<20% compared with 46/204 (22.5%) who received the
standard of care. This difference was not significant (OR
0.74; 95% CI 0.74 - 1.17), implying that the intervention
did not have an impact on CD4 count.
Discussion
Twice the recommended dietary allowance of 14 micro-
nutrients given to HIV-infected children daily for six
months showed no significant difference in all-cause
mortality at 12 months of follow up compared with the
"standard-of-care" of the RDA of six multivitamins. This
lack of effect may be real. However, it might also be due
to other factors.
The first possible reason for "no effect" is that we did
not provide a true placebo since multivitamin supple-
mentation was the standard of care in the paediatric HIV
clinics in Uganda.
The second reason is the supplement composition and
the dosage. In this study, we included 14 of the micronu-
trients judged to be vital and these were provided in the 2
RDA arm. This was done to minimize the risk of toxicity.
But perhaps the individual vitamins and minerals should
have been dosed higher, at least for those whose thera-
peutic window was wide [28]. In our supplement, we did
not include iron, based on earlier studies that suggested
that iron was potentially detrimental in HIV patients [29].
The third issue is the duration of supplementation and
follow up, which have been variable in several studies.
Although not significant, there is a divergence of the sur-
vival curves during the first six months with supplements
and a convergence during follow up without supplemen-
tation. Would a longer supplementation time in a larger
cohort have demonstrated an effect?Figure 2 Kaplan-Meier survival curves of the two arms of the sup-plementation trial in HIV-infected children at 12 months of follow 
up.
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The fourth issue is that the study was designed at a time
when the mortality due to HIV was high and few children
had an opportunity to receive ART [30]. The mortality
figures in these clinics improved continuously over time
due to improved care and access to antiretroviral therapy.
This led to a lower mortality in the study than anticipated
at the design stage.
As previously reported in sub-Saharan Africa, the mor-
tality was lower in children who were already receiving
ART at the time of enrolment compared with those who
were not. This was comparable to mortality reported in
children receiving HAART by other researchers in sub-
Saharan Africa [31]. The factors associated with mortality
in the regression model included low weight for age,
advanced HIV disease (WHO Stage 3 and 4) and hospi-
talization at enrolment. These findings are not surprising
since other studies have reported that malnutrition and
symptomatic HIV disease are associated with increased
mortality [13,14,32].
There was no difference in the impact of 2 RDA multi-
ple micronutrients or the standard of care on anthropo-
metric measurements and CD4 cell count. This lack of
difference could be due to the same factors discussed
here.
There were no major adverse events observed from our
study, and this was similar to what other micronutrient
supplementation studies have reported [16,19,33].
The loss to follow up was higher than anticipated and
this could have influenced the study outcome. The chil-
dren lost to follow up were more likely to be underweight
than those who completed the study. Similarly, there were
a higher proportion of CRP-positive children among
those lost to follow up than among those who completed
the study. The implications of these two findings are not
clear, but indicate that those lost to follow up were more
ill than those who completed the study [34].
At one of the regional sites, we included children who
were living in internally displaced camps in northern
Uganda (Lira), and some of these relocated to distant
areas while still in the study. However, the overall loss to
follow up was comparable to what other micronutrient
supplementation studies in the HIV population have
reported [35].
Conclusions
Twice the recommended dietary allowance of 14 micro-
nutrients compared with 1 RDA of six multivitamins
given as the "standard of care" for six months was well
tolerated with no serious adverse events reported, but did
Table 3: Factors associated with mortality in HIV-infected children aged 1-5 years enrolled in the micronutrient 
supplementation trial in Uganda
Baseline characteristic Unadjusted hazard ratio (95%CI) p-value Adjusted hazard ratio (95%CI) p-value
Fever 3.7 (2.1 - 6.3) <0.001 2.1 (1.1 - 3.9) 0.02
Diarrhoea 2.0 (1.0 - 3.9) 0.05 1.4 (0.6 - 2.9) 0.42
Cough 2.1 (1.1 - 3.8) 0.02 1.8 (0.9 - 3.5) 0.08
Hospitalization (current) 6.9 (3.6 - 13) <0.001 2.6 (1.2 - 5.7) 0.02
Routine cotrimoxazole 0.4 (0.2 - 0.8) 0.01 0.4 (0.2 - 0.9) 0.03
Vitamin A in past 6 months 1.4 (0.8 - 2.4) 0.02 1.3 (0.7 - 2.3) 0.39
WHZ score <-2 3.3 (1.8 - 6.0) <0.001 0.8 (0.4 - 1.7) 0.62
WAZ score <-2 5.4 (3.0 - 9.8) <0.001 2.6 (1.2 - 5.8) 0.02
WHO Stage 3 or 4 5.1 (2.9 - 9.0) <0.001 2.9 (1.5 - 5.6) <0.01
Table 4: The effect of multiple micronutrient supplementation on anthropometry and CD4 cell count in HIV-infected 
children aged 1-5 years
Measurement at 12 months Intervention arm 2 RDA of 14
micronutrients
Comparative arm 1 RDA of 6 multivitamins
"standard-of-care"
Mean (SD) 95% CI Mean (SD) 95% CI p value
Weight-for-height (WHZ) 0.70 (1.43) 0.52 to 0.88 0.59 (1.15) 0.45 to 0.75 0.39
Height-for-age (HAZ) -2.17 (1.60) -2.37 to -1.95 -2.42 (1.50) -2.61 to -2.23 0.08
Weight-for-age (WAZ) -0.78 (1.30) -0.96 to -0.62 -0.97 (1.03) -1.11 to -0.84 0.07
CD4 count 1024 ( 592) 942 to 1107 1060 ( 553) 985 to 1136 0.53
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not significantly alter mortality, growth or CD4 counts in
HIV-infected children aged one to five years. Patients on
HAART had a considerably lower mortality compared to
those without. Future intervention studies should care-
fully consider: (1) the composition and dosing of the sup-
plements; and (2) the power needed to detect a difference
between arms.
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Table 1. Errata in the text and Table 1. 
Paper Location Reads Should be 
Paper I Table 1, Niacin Intervention 1.6 16 
 Table 1, Niacin Comparative arm 0.8 8.0 
 Results section, line 
3 
704 705 
 
Table 2. Errata in table 2.  
Paper  Location ART stratum 
Paper 1  Intervention 
arm reads,    
n (%) 
Intervention 
arm, should be  
n (%) 
Comparative 
arm, reads 
Comparative arm, 
should be n (%) 
Table 2 Age < 36 
months 
8 (  8.6) 8 (18.6)  
 WHZ less 
than -2  
2 (  4.6) 2/41 (  4.9)  
 HAZ less 
than -2 
22 (51.2) 22/40 (55.0) 23 (54.7) 23/41 (56.1)
 WAZ less 
than -2 
5 (11.6) 5/40 (12.5) 6 (14.3) 6/41 (14.6)
 CRP 
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 WAZ less 
than -2 
110 (  8.7) 110/364 (30.2) 125 (32.9) 125/363 (34.4)
 CRP 
positive 
122 (24.1) 122/260 (46.9) 119 (23.5) 119/247 (48.2)
 Zinc < 10 
mol/L 
86 (50.6) 86/143 (60.1) 84 (49.4) 84/133 (63.2)
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Abstract 
Objectives 
To determine the effect of multiple micronutrient supplementation on incidence and prevalence 
of diarrhoea in Ugandan HIV infected children aged 1-5 years. 
Methods 
We enrolled 847 HIV-infected Ugandan children in a trial of a supplement containing 14 
micronutrients (MMS) given in twice the recommended dietary allowances (RDA) versus a 6 
multivitamin (MV) supplement given in one RDA as the ‘standard of care’. The participants were 
stratified into the highly active antiretroviral therapy (HAART) group of 85/847 (10.0%) and the 
non-HAART of 762/847 (90%) participants. The supplements were given daily for 6 months. 
Episodes of diarrhoea assessed at routine visits, sick visits and those reported within 2 weeks 
prior to the routine visit were counted against weeks of observation for each participant. 
Diarrhoea incidence per child was calculated as the number of episodes per child year. Rate ratios 
were used to compare person-time rates in the two groups.  
Results 
The incidence of diarrhoea was 3.8 (95% CI; 3.4 – 4.3) in the MMS and 3.5 (95% CI; 3.1 – 4.0) 
in the MV group per child year. The rate ratio was 1.1 (0.9 – 1.3), similar in both strata, except 
that HAART treated children had a lower incidence rate of diarrhoea. The prevalence of 
diarrhoea at 6 months was also similar in the two groups.  
Conclusion 
A 14 multiple micronutrient supplement given in 2RDA doses compared to a 6 multivitamin 
‘standard of care’ supplement given in 1RDA dose did not reduce the incidence nor the 
prevalence of diarrhoea in HIV-infected children aged 1-5 years.  
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Trial registration: NCT00122941 (http://clinicaltrials.gov)     
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Background 
 
HIV-infected children living in low-income countries have an increased risk of morbidity and 
mortality from common childhood diseases.1-4 In addition, they tend to suffer from recurrent 
episodes of diarrhoea and have worse outcomes compared to  HIV-uninfected children.5-7  
 
Infectious morbidity is further compounded by the high prevalence of both macronutrient and 
micronutrient malnutrition8 that tends to co-exist with the disease or occurs as a result of repeated 
infections. Micronutrient deficiencies are associated with reduced immunity9-11 whereas 
infections aggravate micronutrient deficiencies by interfering with utilization, increasing losses, 
in addition to reduced nutrient intake.12 
 
Several studies have shown that micronutrient interventions reduce childhood morbidity in low-
income countries. Vitamin A supplementation reduces severity of infectious disease episodes in 
young children13, 14 while zinc reduces incidence and duration of diarrhoea and respiratory 
infections.15, 16 For many years vitamin A supplementation has been routinely practiced in 
children under 5 years of age whereas zinc has become standard treatment for diarrhoea since 
200517 in children living in low-income countries.  
 
Whereas HIV treatment programmes recommend use of micronutrients in the standard 
recommended dietary allowances, few studies have evaluated their efficacy in HIV-infected 
children. We hypothesised that children supplemented with twice the recommended dietary 
allowance (2RDA) of 14 multiple micronutrients (MMS) would get fewer episodes of diarrhoea 
compared to those receiving one RDA of 6 multivitamins (MV) as the ‘standard of care’ in a 
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period of 6 months. The effect of multiple micronutrient supplementation on diarrhoea morbidity 
was a secondary outcome of this trial. The primary outcome was the effect of multiple 
micronutrient supplementation on survival and the findings have been reported.18 
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Methods 
Design 
In a randomised trial conducted between 2005 and 2008, the participants were assigned to a 14 
multiple micronutrient supplement (MMS) of 2RDA doses of the individual components or the 
‘standard of care’ 6 multivitamin supplement in a 1:1 ratio. 
 
Participants 
We enrolled HIV-infected children aged 1-5 years whose HIV status had been confirmed and 
were coming for follow up at the HIV care clinics in seven hospitals. We only included those 
who were not enrolled in other studies, residing in a radius of 15 kilometres from the facility and 
whose mothers were willing to adhere to the supplement and the study follow up schedule. All 
consecutive patients attending the clinics were offered enrolment. In summary, 847 HIV-infected 
children aged 1-5 years were enrolled in the trial. Eighty five children belonged to the highly 
active anti-retroviral therapy (HAART) stratum and 762 to the non-HAART stratum. In the 
HAART stratum, 43 children were assigned to MMS and 42 the MV group. Of the 762 children 
in the non-HAART stratum, 383 received MMS and 379 were treated with MV (figure 1). The 
baseline characteristics of the participants are presented in table 1. This study was health facility 
based intentionally since most mothers refused home visits because of the stigma that was 
associated with HIV at that time.  
 
Study sites  
The study was conducted at 3 sites in Kampala; the capital city of Uganda and 4 regional 
hospitals situated in the South-western, Central, Eastern and Northern parts of the country. Each 
site had a designated paediatric HIV clinic though at different stages of development. Most of the 
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clinics at the regional hospitals were new and had few patients whereas the sites in the capital city 
were well established. The national referral hospital had the largest clinic with over 5000 HIV-
infected children.  
Ethical considerations 
The study was approved by Makerere University College of Health Sciences Research and Ethics 
Committee, the Uganda National Council for Science and technology and the Regional 
Committee for Medical Research Ethics, Western Norway. Written informed consent was 
obtained from the parents or caretakers of the participants.  
Trial supplements 
The multiple micronutrient supplement consisted vitamin A, B1, B2, B3, B6, B12, folate, C, D, E 
and trace elements; selenium, zinc, copper and iodine in 2RDAs. The multivitamin supplement 
contained vitamin A, B1, B2, B3, C and D in 1 RDA doses as shown in table 2. The formula for 
MMS was based on two times the recommended dietary allowance for a 4 year old age group 
while the MV was based on one RDA dose for a similar age group.19 We used the UNICEF 
recommended multiple micronutrient supplement for pregnant women and other vulnerable 
groups but we excluded iron since previous studies had indicated that iron could be harmful in 
HIV-infected persons.20-22 There were no studies in children that had used a similar supplement 
by the time we conceptualised this study. We anticipated that HIV-infected children would have 
increased micronutrient requirements based on their nutritional state and increased infectious 
morbidity. There were two age bands in the RDA tables where our participants would fall; 1-3 
and 4-8 years of age. We noted that there were minor variations in dosages of some 
micronutrients while others like iodine and vitamin D did not vary. We decided to use the group 
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with the higher requirement, to warrant the highest probability that every child’s requirements are 
met. In addition it was easier to administer a uniform intervention. The multivitamin formula was 
similar to the ‘standard of care’ multivitamins given to HIV-infected children attending health 
care clinics in Uganda. Whereas the standard of care multivitamin was dispensed in tablet form 
the study supplements were manufactured as a powder. We chose to use a powder because it 
would be easier to administer in a reconstituted solution and we also considered the stability of 
the compound (upon the manufacturer’s advice) since it contained many supplements. A daily 
dose was 4 g, measured by a scoop provided by the manufacturer. This was mixed with 10 – 20 
ml of milk or water and administered orally.  
Outcomes 
Every child was assessed for diarrhoea at baseline, monthly (scheduled study clinic visits) and 
during inter-current/sick visits up to six months. The caretakers (mostly the mothers) were 
interviewed about any episodes of diarrhoea occurring within two weeks before the clinic visit. 
They were also asked whether the child had an episode of diarrhoea lasting for 14 days (2 weeks) 
or more in-between the clinic visits. Presence of diarrhoea was defined as passage of 3 or more 
loose/fluid stools in the previous 24 hours. Episodes which had persisted from the previous sick 
or routine visit were not counted again. If there was a diarrhoea-free interval of 3 or more days 
the illness was regarded as a new episode.  
The diarrhoea incidence was calculated as follows: 
1) We counted all new episodes of diarrhoea recorded from enrolment to 6 months 
2) Each recall covered 2 out of 4 weeks since the last visit. This was set as the period of 
observation  
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3) If an inter-current visit occurred the period of observation increased and possibly the 
episode count 
4) Total observation time per child was calculated by adding each individual’s period of 
observation 
5) Incidence rates were calculated by dividing the episodes of diarrhoea in each group with 
the total observation time in weeks 
6) The rate ratio was calculated like this: incidence rate of MMS group divided by the 
incidence rate of MV group.  
  
The prevalence of diarrhoea was determined by dividing the number of children who had 
diarrhoea at the 6 month’s visit with the total number of participants who had information on 
diarrhoea at the 6 month’s visit. The proportion of those who had diarrhoea in the MMS was 
compared with the proportion in the MV group using a two by two table. The Fisher’s exact test 
was used to test for significance of the differences.  
 
Sample size 
The sample size was based on the primary outcome of survival for which 411 participants were 
required in each arm. The assumptions for the sample size calculation are indicated in a previous 
publication.18  
Randomization 
The eligible participants were randomized in a 1:1 ratio in permuted blocks of 4 to 20 to one of 
the study supplements. The randomisation code was generated using the Stata software by an 
independent researcher and sent to the manufactures (NUTRISET) in France. The supplements 
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were packaged in white plastic containers and labelled sequentially by the manufacturers. The 
participants were consecutively enrolled by the study doctor (at each of the sites there was at 
doctor responsible for the study) and the supplements were dispensed by the study nurse in serial 
order.  
 
Masking 
The intervention and standard of care supplement were both similar in colour, consistency, odour 
and packaged in identical containers. The study staff, mothers/ caretakers and investigators were 
all masked to treatment assignment. Serial interviews with the study staff indicated that they 
could never tell the difference between the two. The investigators had no access to the 
randomization code until completion of the study. 
Compliance and adverse events 
Compliance was assessed by weighing the remaining supplement using a light-weight weighing 
scale (Philips HR 2389/B 9.OV/DC) at each routine visit. Information about missed doses in the 
past 2 weeks was also collected. Each study participant took 4 g of the supplement per day (one 
scoop) and this was equivalent to 120 g in 30 days. The proportion of the amount of supplement 
taken against the expected was used as a measure of compliance. The overall compliance was 
derived by adding the monthly measurements divided by the 6 visits. And adverse effects that 
were attributed to the supplement by the mother or the doctor were recorded. 
Quality control 
Overall there were 10 doctors involved in the study. All of them were trained on the study 
protocol, the operating procedures and how to assess and manage HIV-infected children. A 
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majority of them were routinely involved in the care of sick children or HIV-infected children. 
Measurements such as anthropometry were done according to the protocol and standard operating 
procedures. At each site the doctor captured information on different forms (baseline, 6 months, 
monthly and inter-current visit).  
Statistical analysis 
Diarrhoea incidence was calculated as the number of episodes per child year. Rate ratios were 
used to compare person-time rates in the two groups using OpenEpi-Epidemiologic Calculators.23 
The prevalence of diarrhoea at 6 months and hospitalisations in the two groups were compared 
using the Fishers exact test. All tests were two-sided and considered significant if the p-value was 
<0.05. Children whose weight-for-height z-scores were less than -2 standard deviations below the 
mean were considered wasted, height-for-age z-scores less than -2 standard deviations were 
stunted, and less than -2 standard deviations weight-for-age z-scores underweight. Determinants 
for diarrhoea were evaluated by multiple regression in a stepwise fashion. 
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Results 
Out of 847  HIV-infected children randomised to a 2RDA of 14 multiple micronutrients or 6 
multivitamin supplement as ‘standard of care’ at paediatric HIV clinics in Uganda diarrhoea 
incidence was measured for 800 children, excluding 47 (25 in MMS and 22 in MV) who dropped 
out before their first routine follow up visit. Of the 710 children who completed 6 months of 
follow up, 613 were assessed for prevalence of diarrhoea at the 6 months visit (figure 1).  
 
Baseline characteristics 
Baseline characteristics were similar in the MMS and MV groups, (table 1). The majority of the 
participants [705/847 (83.2%)] were from the capital city.   
 
Diarrhoea morbidity 
There were 516 episodes of diarrhoea in 7336 person weeks; 270/3706 in the MMS and 246/3630 
in the MV group. The incidence rate was 3.8 (95% CI; 3.4 – 4.3) in the MMS and 3.5 (95% CI; 
3.1 – 4.0) in the MV group per child year. The rate ratio was 1.1 (0.9 – 1.3). Similarly, there were 
no differences in the HAART and non-HAART stratum except for the low incidence rate of 
diarrhoea in the HAART treated children (table 3). The overall incidence of diarrhoea was 
equivalent to 3.7 episodes per child per year; 4.0 and 3.8 in the non-HAART group, 1.7 and 1.5 
in the HAART stratum. 
 
The prevalence of diarrhoea at the 6 months visit was 53/613 (8.6%); 30/310 (9.7%) in the MMS 
and 23/303 (7.6%) in the MV group. This was not a statistically significant difference (p > 0.99). 
The baseline prevalence was 96/847 (11.3%); 43/426 (10.1%) in the MMS and 53/421 (12.6%) 
the MV group. The 6 months point prevalence was also not different from baseline (p=0.36).  
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Out of 115 hospitalisations, 24 were due to diarrhoea (20.9%); 11 in MMS and 13 in MV arm. 
There were no hospitalisations due to diarrhoea in the HAART stratum. Persistent diarrhoea was 
uncommon neither at baseline (22 cases) nor at 6 months (4 cases).  
 
Age was the only baseline characteristic that was associated with diarrhoea [AOR 2.2 (95% CI: 
1.2 – 4.4)]. Non use of HAART and poor nutritional indices were associated with diarrhoea at 
bivariate but not at multivariate analysis. Previous routine multivitamin supplementation was not 
associated with diarrhoea (table 4). 
 
Compliance and adverse events 
All participants took 85% or more of the study supplements. Adverse effects were reported in 16 
children (1.9%); vomiting in 12 children and diarrhoea in four children. There were equal 
numbers in each arm; 8/426 (1.9%) in the MMS and 8/421(1.9%) in the MV group. These 
symptoms were minor and the supplement was not stopped.  
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Discussion 
In this study, we found no difference in diarrhoea episodes in Ugandan  HIV-infected children 
aged 1-5 years following supplementation with a 14 multivitamin and mineral supplement 
(MMS) compared to the ‘standard of care’ 6 multivitamin (MV) supplement. The incidence rate 
and the prevalence of diarrhoea were similar in the two groups. The incidence of diarrhoea was 
lower in the HAART treated stratum but not significantly different between the two intervention 
groups. Hospitalisations due to diarrhoea were also similar. Overall the incidence of diarrhoea 
was slightly higher than the estimated average of 3.2 episodes per child per year among children 
under five years of age living in low-income countries24 but consistent with another almost 
similar study that included  HIV-infected children.25 Our study did not include the most at risk 
age group (6-12 months) on purpose because infant diagnosis of HIV was not readily available 
and there were very few infants attending the HIV clinics.  
 
One possible explanation for the lack of effect is that the doses of the various components of the 
supplements may have been insufficient to meet the demands of these HIV-infected children. The 
nutritional needs for HIV-infected children remain largely unknown to date. Based on the serum 
zinc concentrations in this cohort of HIV-infected children (more than 50% had low zinc 
concentrations) it is possible that other micronutrient concentrations were low. The possibility of 
severe and multiple micronutrient deficiencies are further supported by other studies from the 
region. Vitamin A deficiency occurred in 83% of infants born to HIV-infected mothers in 
Tanzania.26 In South Africa more than one in two  HIV-infected children had two or more 
micronutrient deficiencies.27 Some authors have suggested that intake of micronutrients in 
multiples of recommended dietary allowance may be required to achieve the normal 
micronutrient concentrations of  HIV-infected persons.28  
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It is also possible that those who were more deficient or had multiple deficiencies could have 
benefited more that the others. This is supported by previous research that has shown that vitamin 
A supplementation in Tanzania children less than 5 years of age reduced acute diarrhoea in 
wasted children and signs of pneumonia in HIV-infected but not uninfected children13. Zinc 
supplementation studies have also shown that the effect on diarrhoea was more pronounced 
among children who were undernourished.29, 30 It is also possible that the micronutrients could be 
more beneficial at reducing severity of illness but not episodes. In our study hospitalisation was 
anticipated to be a measure of severe illness. The lack of effect on this outcome could be due to 
the small number of hospitalisations. Mothers were allowed to return to the clinic whenever the 
child was sick on any day of the 5 days of the week except weekends. This may have facilitated 
early care seeking and reduced the frequency of severe illness and subsequently hospitalisations.  
 
The lack of effect on morbidity by micronutrient supplementation in children has been reported 
by other researchers. In a study of Indonesian infants whose HIV status was not known 
supplementation with 15 multiple micronutrients in daily adequate intake amounts had no effect 
on days of illness due to diarrhoea, respiratory infection or fever during 6 months of 
supplementation31 In a trial of 6-24 months old children with a stratum of 32 HIV-infected 
children (out of 373), a supplement containing 14 multiple micronutrients given in recommended 
dietary intake did not reduce diarrhoea morbidity, prevalence of respiratory symptoms or 
pneumonia.32 In a Zambian study of infants whose HIV status was not known, there was no 
difference in the prevalence and causes of hospital referrals following addition of multiple 
micronutrients to a locally available food.33  
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Furthermore, the supplementation period may not have been long enough to create an impact. 
Micronutrient supplementation studies in adults have indicated that a significant proportion of 
HIV-infected patients may remain deficient despite supplementation.34, 35 To create an effect on 
morbidity micronutrients may need to be given for a longer period and possibly in higher doses.  
 
We are unable to make valid conclusions about the HAART stratum because of the small 
numbers. Children in this stratum were less sick at baseline and could have better micronutrient 
status as demonstrated by their higher zinc status.36  
 
For ethical reasons, this was a facility-based study which could have missed some episodes of 
diarrhoea that occurred unreported. This may limit our ability to make comparisons with other 
studies that used weekly or bi-weekly visits. However, we also limited the time of observation to 
reasonable recall periods and any information bias would be equally distributed in the two 
groups.  
 
Another reason for a non-effect is of course the fact that we used a multivitamin supplement in 
the comparative arm and not true placebo. But this remains speculations.  
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Conclusion 
A 14 multiple micronutrient supplement given in 2RDA doses compared to a 6 multivitamin 
‘standard of care’ supplement given in 1RDA did not reduce the incidence and prevalence of 
diarrhoea or diarrhoea related hospitalisations in HIV-infected children aged 1-5 years.  
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Table 1. Baseline characteristics of HIV infected children aged 1-5years at paediatric HIV 
clinics in Uganda 
 
Baseline Characteristics ART stratum (n=85) Non-ART stratum (n=762) 
 
 MMS
n=43 (%) 
MV 
n=42 (%) 
P value MMS  
n=383 (%)  
MV 
n=379 (%) 
P value 
Age < 24 months 1 (   2.3) 3 (   7.1) 0.36 123 (32.1) 122 (32.2) 1.00 
Sex : Male 20 ( 46.5) 23 ( 54.8) 0.52 201(52.5) 182 (48.0) 0.25 
Site: Kampala 40 ( 93.0) 40 ( 95.2) 1.00 313 (81.7) 311 (82.1) 0.93 
Carer: Mother 24 ( 55.8) 21 ( 50.0) 0.67 278 (72.6) 278 (73.4) 0.87 
Diarrhoea 1 (   2.3) 2 (   4.8) 0.62 42 (11.0) 51 (13.5) 0.32 
Persistent diarrhoea 0 (   0.0) 0 (   0.0) - 11 (26.8) 11 (23.4) 0.81 
Diarrhoea in past 2 weeks 0 (   0.0) 0 (   0.0) - 13 (  3.4) 14 (  3.7) 0.85 
Fever 9 ( 20.9) 8 ( 19.0) 1.00 76 (19.8) 81 (21.4) 0.65 
Cough 27 ( 62.8) 26 (  61.9) 1.00 220 (57.4) 219 (57.8) 0.94 
Cotrimoxazole prophylaxis 43 (100.0) 42 (100.0) - 340 (88.8) 334 (88.1) 0.82 
Routine multivitamins 18 ( 41.9) 13 (  31.0) 0.37 241 (62.9) 219 (57.8) 0.16 
Vitamin A in past 6 months 20 ( 46.5)     16 (  38.1) 0.51 183 (47.8) 175 (46.2) 0.66 
WHO stage III or IV - - - 124 (33.4) 114 (30.1) 0.53 
*CD4+ < 25% 14 ( 38.9) 14 (  42.4) 0.81 203 (64.0) 209 (64.7) 0.87 
*WHZ less than -2  2 (   4.6) 3 (    7.1) 1.00 53(13.8) 50 ( 13.2) 0.75 
*HAZ less than  -2 22 ( 51.2) 23 (  54.7) 1.00 190(49.6) 197 ( 51.9) 0.65 
*WAZ less than -2 5 ( 11.6) 6 (  14.3) 1.00 110 (28.7) 125 (32.9) 0.24 
*CRP >6mg/L 15 ( 48.4) 11 (  36.7) 0.44 122 (46.9) 119 (48.2) 0.79 
*Zinc < 10 mol/L 5 ( 16.1) 14 (  48.3) 0.01 86 (60.1) 84 (63.2) 0.62 
       
*These measurements were less than 847.  
CD4+ cell percentages were available for 709 children; 353 in MMS and 356 in MV arm 
CRP results were available for 568 children; 291 in MMS and 277 in MV arm 
WHZ was available for 816 children; 407 in MMS and 409 in MV arm 
WAZ was available for 809 children; 404 in each arm 
HAZ was available for 798 children; 398 in MSS and 400 in MV arm. 
Zinc results were available for 336 children; 174 in MMS and 162 in MV arm. 
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Table 2. The formulation for the intervention supplements 
Micronutrient Multivitamins  
‘Standard of care’ 1RDA 
Multiple micronutrients 
2 RDA 
Vitamin A (mcg) 400 800 
VitaminB1 (mg) 0.6 1.2 
Vitamin B2 (mg) 0.6 1.2 
Niacin (mg) 8 16 
Vitamin B6 (mg) - 1.2 
Vitamin B12 (mcg) - 2.4 
Vitamin C (mg) 25 50 
Vitamin D (IU) 200 400 
Vitamin E (mg) - 14 
Folate (mcg) - 400 
Selenium (mcg) - 60 
Zinc (mg) - 10 
Copper (mcg) - 800 
Iodine (mcg) - 180 
Iron (mg) - - 
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Table 3. Incidence of diarrhoea in the multiple micronutrient supplementation compared to the 
‘standard of care’ multivitamin group 
 
 
MMS = Multiple micronutrient supplementation arm 
MV = Multivitamin ‘standard of care’ arm  
 
 
 
 
 
 
Group Intervention Number of 
participants 
with at least 
one follow up 
observation 
Episodes of 
diarrhoea 
Observation 
Period in 
weeks 
Rate per 
child/year 
(95% CI) 
Rate ratio 
(95% CI) 
P value 
Overall MMS 
MV 
 
401 
399 
270 
246 
3706 
3630 
3.8 (3.4 – 4.3) 
3.5 (3.1 – 4.0) 
1.1 (0.9 – 1.3) 0.43 
Non-
HAART 
stratum 
MMS 
MV 
359 
358 
255 
233 
3246 
3190 
4.0 (3.6 – 4.6) 
3.8 (3.4 – 4.3) 
1.1 (0.9 – 1.2) 0.44 
HAART 
stratum 
MMS 
MV 
 
42 
41 
15 
13 
460 
440 
1.7 (1.0 – 2.7) 
1.5 (0.9 – 2.6) 
1.1 (0.5 – 2.3) 0.94 
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Table 4. Determinants of diarrhoea in HIV infected children supplemented with 2RDA multiple 
micronutrients or the ‘standard of care’ multivitamins 
 
Variable Number 
in group 
Had an 
episode of 
diarrhoea: 
n, (%) 
P-value Unadjusted 
OR (95% CI) 
Adjusted OR 
(95% CI) 
Intervention 
MMS 
MV 
 
426 
421 
 
111 (26.1) 
101 (24.0) 
 
0.52 
 
0.9 (0.7 – 1.2) 
 
ART stratum 
HAART 
No-HAART 
 
85 
762 
 
13 (15.3) 
199 (26.1) 
 
0.03 
 
0.6 (0.3 – 0.9) 
 
Age 
< 24 months 
 24 months 
 
 
249 
598 
 
86 (34.5) 
126 (21.1) 
 
<0.001 
 
1.6 (1.3 – 2.1) 
 
2.2 (1.2 – 4.4) 
Sex  
Male 
Female 
 
426 
421 
 
114 (26.8) 
98 (23.3) 
 
0.26 
 
1.2 (0.9 – 1.4) 
 
Routine MVs 
Yes 
No 
 
491 
356 
 
135 (27.5) 
77 (21.6) 
 
0.05 
 
1.3 (1.0 – 1.6) 
 
Vit A in past 6mo 
Yes 
No 
 
394 
453 
 
96 (24.4) 
116 (25.6) 
 
0.69 
 
0.9 (0.7 – 1.2) 
 
CD4+ % 
< 25% 
 25% 
 
440 
269 
 
127 (28.9) 
72 (26.8) 
 
0.60 
 
1.1 (0.8 – 1.4) 
 
WHZ 
< -2 z score 
 -2 z score 
 
108 
708 
 
30 (27.8) 
174 (24.6) 
 
0.47 
 
1.1 (0.8 – 1.6) 
 
WAZ 
< -2  
 -2  
 
246 
562 
 
75 (30.5) 
133 (23.7) 
 
0.04 
 
1.3 (1.1 – 1.6) 
 
HAZ 
< -2  
 -2  
 
432 
366 
 
113 (26.3) 
91 (24.9) 
 
0.68 
 
1.1 (0.8 – 1.3) 
 
WHO staging 
I and II 
III and IV 
 
598 
249 
 
141 (23.6) 
71 (28.5) 
 
0.14 
 
0.8 (0.6 – 1.1) 
 
Zinc status 
< 10 mol/L 
 10 mol/L 
 
189 
147 
 
53 (28.0) 
36 (24.5) 
 
0.53 
 
1.1 (0.8 – 1.6) 
 
C reactive protein 
< 6mg/L 
 6mg/ 
 
267 
301 
 
86 (32.2) 
76 (25.2) 
 
0.07 
 
1.3 (0.9 – 1.7) 
 
CTX = Cotrimoxazole      HAZ = Height-for-age z score  
MMS = Multiple micronutrient supplementation  WAZ = weight-for age z score 
MV = Multivitamin       WHZ = weight-for-height z score 
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Stratified and randomised: 
847
Randomised in ART stratum: 85
Lost to follow-up: 1
Withdrew: 0
Transferred: 0
Died: 0
Total excluded: 785
- Other studies: 218
- Inconsistent carers: 172
- Distance >15km: 348
- Declined to consent: 47
Assessed for eligibility:
1632
Randomised in non-ART stratum: 762
Lost to follow-up: 32
Withdrew: 5
Transferred: 6
Died: 19
Lost to follow-up: 0
Withdrew: 0
Transferred: 1
Died: 2
Lost to follow-up: 36
Withdrew: 6
Transferred: 4
Died: 25
Intervention arm: 
383
Comparative arm: 
42
Comparative arm: 
379
Intervention arm:
43
Completed 6 months: 42
Diarrhoea prevalence: 0/39 
Incidence:1.5/child/yr
Diarr. prevalence: 28/310
Incidence: 4.0/child/yr
Diarr. prevalence 23/303 
Incidence: 3.8/child/yr
Diarrhoea prevalence: 2/42 
Incidence: 1.7/child/yr
Completed 6 months: 39 Completed 6 months: 321 Completed 6 months: 308
 
 
Figure 1. Trial profile. 
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Abstract
Background: Low concentrations of serum zinc have been reported in HIV infected adults and are associated with
disease progression and an increased risk of death. Few studies have been conducted in HIV infected children in
Africa. We determined serum zinc levels and factors associated with zinc deficiency in HIV infected Ugandan
children.
Methods: We measured the baseline zinc status of 247 children aged 1-5 years enrolled in a randomised trial for
multiple micronutrient supplementation at paediatric HIV clinics in Uganda (http://ClinicalTrials.gov NCT00122941).
Zinc status was determined using inductively coupled atomic emission spectrophotometry (ICP-AES). Clinical and
laboratory characteristics were compared among zinc deficient (zinc <10.0 μmol/L) and non deficient children.
Logistic regression was used to determine predictors of low serum zinc.
Results: Of the 247 children, 134 (54.3%) had low serum zinc (< 10.0 μmol/L). Of the 44 children on highly active
antiretroviral therapy (HAART), 13 (29.5%) had low zinc compared to 121/203 (59.6%) who were not on HAART.
Overall, independent predictors of low zinc were fever (OR 2.2; 95%CI 1.1 - 4.6) and not taking HAART (OR 3.7; 95%
CI 1.8 - 7.6).
Conclusion: Almost two thirds of HAART naïve and a third of HAART treated HIV infected children were zinc
deficient. Increased access to HAART among HIV infected children living in Uganda might reduce the prevalence of
zinc deficiency.
Background
Zinc deficiency is wide spread in low-income countries
and is responsible for 4% of childhood deaths and 1% of
the burden of disease in Africa, Latin America and Asia
[1]. Populations in sub-Saharan Africa and South East
Asia have the greatest risk of zinc deficiency because of
inadequate zinc intake in about one third of the popula-
tion [2].
Zinc is a component of various metallo-enzymes, pro-
teins and cell membranes; and plays an important role
in immune regulation. Zinc deficiency increases suscept-
ibility to oxidative stress and impaired cell membrane
function [3,4]. In HIV infected adults, low serum zinc
has been associated with more advanced HIV disease
and increased mortality [5-7].
Whereas some studies of HIV infected children in
high-income countries have indicated that micronutrient
deficiencies are uncommon [8], the reverse is true in
low-income countries. The zinc status of HIV infected
children in Uganda has not been reported. In this paper
we report the magnitude of zinc deficiency and asso-
ciated factors in a group of HIV infected children in
Uganda.
Methods
Study sites
This study was part of a baseline assessment of children
enrolled in a multiple micronutrient supplementation
trial carried out between June 2005 and June 2008. This
paper presents data from 3 of 7 clinics involved in the
study, namely the paediatric HIV clinics at the national
referral hospital (Mulago), Mildmay Centre and Nsam-
bya hospital. These centres had laboratory facilities for
blood sampling and freezing before transportation for
analysis at a distant laboratory. Mulago is the national
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Health Sciences, Makerere University, Kampala, Uganda
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referral hospital; Mildmay Centre and Nsambya are pri-
vate, not-for-profit hospitals. All the three are situated
in the capital city, Kampala. The Mulago Hospital Pae-
diatric HIV Clinic is the largest in the country and cares
for more than 8000 patients. The Mildmay Centre,
Uganda, is an HIV/AIDS referral and training institu-
tion, 12 kilometres South of Kampala city centre and
cares for about 1500 HIV infected children, while
Nsambya hospital cares for an equal number of HIV
infected children.
Design and subjects
We here report the baseline zinc levels of children aged
1-5 years who enrolled in the multiple micronutrient
supplementation (MMS) study (ClinicalTrials.gov Identi-
fier: NCT00122941).
The MMS study was a randomised trial of a 14 vita-
mins and minerals versus a six multivitamin supplement
as ‘standard-of-care’ for 6 months, among 847 HIV
infected children, with a highly active anti-retroviral
therapy (HAART) strata comprising 10% of the study
participants. The study enrolled HIV infected children
who had at least attended the clinic once and were com-
ing for follow-up. Those who were enrolled in other stu-
dies were excluded.
Children in the HAART strata had already been
started on anti-retroviral therapy (ART) at the study
clinics before enrolment into the study. The 2006
World Health Organization (WHO) guidelines for
initiating anti-retroviral therapy in children had been
used, in addition to a ‘social criteria’ that was conduc-
tive for initiating ART. Children aged 1 - 3 years were
initiated on ART if their CD4+ T cell count was below
20% or if they had WHO stage 3 or 4 disease. Those
above 3 years of age were initiated on ART if their
CD4+ T cell count was < 15% or if they had WHO
stage 3 or 4 disease [9]. The social criteria meant that
the child had a consistent caretaker who was adherent
to previous clinic appointments, attended at least 2
counseling sessions on adherence to ART and had
consented for initiation of therapy.
Due to cost, zinc was analysed at baseline only for chil-
dren who had sufficient serum collected on both sam-
plings (baseline and at 6-month follow-up). Of the 847
children who participated in the multiple micronutrient
supplementation study, 705 were enrolled at the 3 sites
where zinc analysis was possible. Two hundred and forty
seven children of the 705 (35.0%) had complete clinical
data and laboratory analyses at baseline to be included in
this paper (figure 1). Laboratory data was declared
incomplete as long as a participant did not have one or
more of the tests. Out of the 458 exclusions, 261 children
had haematology and CRP results but no micronutrient
test (zinc inclusive) result, 64 had other micronutrient
tests done except zinc, 89 had baseline zinc results but
no second sample and 44 had missing samples. Overall
insufficient samples contributed 414/458 exclusions
while 44 were due to missing samples.
Ethical issues
Written informed consent from the mothers/caretakers
was obtained in English or Luganda, one of the com-
monly spoken local languages in the study area. Permis-
sion to conduct the study was granted by Makerere
University College of Health Sciences, the Mildmay
Centre, Nsambya and Mulago hospitals Research and
Ethics Committees. Permission was also granted by the
Uganda National Council for Science and Technology
and the Regional Committee for Medical and Health
Research Ethics, Western Norway ("REK Vest”). Coun-
selling for initiation of HAART and adherence was
offered to those who were eligible to start antiretroviral
therapy. Treatment for illness and prophylaxis was
offered according to the WHO and national paediatric
HIV management guidelines.
Procedures
History and physical examination
Mothers/caretakers were interviewed about the child’s
medical history, nutritional history and symptoms.
A detailed physical examination was conducted by one
of the study doctors. Weight was taken using a standar-
dized uniscale 01-410-15 to the nearest 0.1 kg and
height was taken using the Shorr portable infant/child
length/height (Shorr productions, Olney, Maryland,
USA) measuring board to the nearest 0.1 centimetre.
HIV/AIDS clinical disease staging was determined using
705 children enrolled at 3 urban sites 
(Mulago 500, Mildmay 167, Nsambya 38)
247 analysed for zinc
458 excluded due to 
incomplete lab data
Not on HAART
203
On HAART
44
847 HIV infected children 
enrolled in the 
multiple micronutrient supplementation study
Serum zinc 
<10.0 μmol/L
121
Serum zinc 
≥10.0 μmol/L
82
Serum zinc 
<10.0 μmol/L
13
Serum zinc 
≥10.0 μmol/L
31
142 at rural sites
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the World Health Organisation (WHO) classification for
paediatric HIV/AIDS [10].
Laboratory procedures
Three to 5 millilitres (ml) of blood was collected in a 5
ml trace element free vacutainer tube (Becton Dickin-
son, Franklin Lakes, N.J) by venepuncture from the
cubital fossa or dorsum of the hand irrespective of
when the last meal was eaten. The sample was centri-
fuged at 2000 g within one hour of collection. Serum
was transferred into trace element-free cryo-tubes, and
transported within 3 hours to a minus 20°C refrigera-
tor until shipment. Zinc was analysed using Inductively
Coupled Atomic Emission Spectrophotometry (ICP-
AES) [11] at the Clinical Chemistry Laboratory, Hau-
keland University Hospital, Bergen, Norway. The sam-
ples were digested using a microwave oven, nitric acid
and concentrated hydrogen peroxide, as described by
Rahil-Khazen et al [12]. The analytical coefficient of
variation was about 3 %. An additional 2 ml sample
was collected in an EDTA containing vacutainer tube
and analysed for haemoglobin, white cell count and
CD4+ T cell count within 12 hours of collection. A
complete blood count was performed using the Act
5Diff instrument (Beckman Coulter) and CD4 count
was done using a FACScan instrument and MultiSET
software (Beckman Dickinson). Qualitative C-reactive
protein (CRP) was measured using the latex immu-
noassay on one drop of serum (Human Gesellschaft
fur Biochemica und Diagnostica mbH, Germany). Dis-
tinct agglutination indicated a C-reactive protein (CRP)
content ≥ 6 mg/L. This rapid procedure was used in
order to feedback the result to the attending paediatri-
cian/doctor.
Low zinc was defined as a serum concentration below
10.0 μmol/L and an elevated CRP was defined as
≥6 mg/L. We used the WHO definition for anaemia
where by children aged 6 months to 5 years are consid-
ered to be anaemic if their haemoglobin levels are below
11 g/dl [13]. We did not adjust the haemoglobin levels
for ethnicity or altitude.
Statistical issues
Data were analysed using SPSS version 15. Categorical
characteristics were summarised into proportions while
continuous variables were analysed using means and
standard deviations. Demographic, anthropometry and
clinical characteristics were compared among zinc defi-
cient (zinc less than 10.0 μmol/L) and non deficient
children using Fisher’s exact test and odds ratios. All
factors with a p-value of less than 0.20 by bivariate ana-
lysis were retained in the multiple logistic regression
model to determine factors independently associated
with low zinc. Weight for height (WHZ), height for age
(HAZ) and weight for age (WAZ), z-scores were
calculated using the WHO Anthro software and refer-
ence population [14] to assess anthropometric status.
Results
Of the 247 children analysed for serum zinc, 134
(54.3%) had low zinc < 10μmol/L. Their mean (SD) age
was 33.4 (13.8) with a range of 12.0 to 65.5 months.
The male to female ratio was approximately 1:1.
Clinical and haematological findings
Generally the children were unhealthy. More than half
(141/247, 57.1%) had cough, which was the commonest
symptom, followed by skin rash in about half (121/247,
49.0%) and fever in a fifth (94/247, 17.8%) of the children.
More than half of the children (108/247, 53.0%) were
stunted, almost a quarter were underweight (53/247,
21.5%) and a tenth was wasted. Twenty five percent (62/
247) had advanced HIV disease with WHO stage 3 or 4.
Absolute CD4+ T cell count ranged from 46 - 3769 with a
mean (SD) of 1129(615). One third of the children (85/
247) were severely immune-compromised with CD4+ T
cell counts of less than 20%. Qualitative C-reactive protein
was elevated in 100 out of 247 (40.5%) children. The mean
haemoglobin (SD) was 9.9 (1.6) g/dl with a range of 4.6 -
13.7 g/dl. Two thirds of the children (170/247, 68.8%)
were anaemic with haemoglobin of less than 11 g/dl.
There were no differences in sex, age, anthropometry,
morbidity and CD4+ T cell count among those tested
for zinc versus those who were not tested.
Characteristics of children on HAART
The children receiving HAART were older with a mean
(SD) age of 42.3 (10.7) compared to the non-HAART
group with 31.4 (13.7) months. Other descriptive char-
acteristics were similar in HAART treated and HAART
naïve children as shown in table 1.
The proportion of HAART children who were tested for
zinc (44/85, 55.0%) was significantly higher (p = 0.00) than
the non-HAART (203/847, 32.5%) children analyzed for
zinc. The mean serum zinc among children on HAART
was 12.2 (SD 4.1) compared to 9.6 (SD 2.5) among those
not receiving HAART, a statistically significant difference
(OR 2.6; 95%CI 1.6 - 3.5). The mean duration of HAART
was 10.2 months for the 13 zinc deficient and 9.5 months
in children who were not zinc deficient, with a range of
one to 21 months. Of the 44 children, 33 (75%) had
received ART for 12 or more months.
Serum zinc and factors associated with low zinc
concentrations
The mean (SD) serum zinc concentration was 10.0 (2.9)
μmol/L with a range of 5.6 - 29.5 μmol/L. There was no
linear relationship between age, WHZ and haemoglobin
versus zinc status as shown in Figure 2, 3 and 4. In
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addition there was no significant difference in mean age,
anthropometry, haemoglobin and CD4+ cell count
among children with low serum zinc (< 10μmol/L) com-
pared to those with normal zinc levels (table 2).
Factors associated with low serum zinc concentrations
at bivariate analysis were: being HAART naïve, reported
fever, underweight, WHO stage 3 or 4 disease and ele-
vated CRP (table 3). The mean (SD) serum zinc among
CRP negative children was 10.2 (2.5) compared to 9.8
(3.6) in CRP positive children. This difference was not
statistically significant.
In the multivariate model the only significant indepen-
dent predictors of low zinc were: being HAART naïve
and reported fever. Of the 44 children on HAART, 13
(29.5%) had low serum zinc compared to 121 of 203
(59.6%) in the non-HAART group. This difference was
statistically significant [Adjusted OR 3.7 (95% CI 1.8-
7.7)]. When fever was excluded from the model elevated
CRP was a significant predictor of low zinc, illustrating
that fever and CRP are closely related.
Discussion
The prevalence of zinc deficiency in this group of HIV
infected children aged 1-5 years attending paediatric
HIV clinics in Uganda was high (54.3%). This was
higher than what was reported in a previous study of
children aged 6-36 months with persistent diarrhoea
but of undetermined HIV status at Mulago hospital,
Uganda [15]. While we used a cut off of 10 μmol/L to
indicate zinc deficiency, the previous study had used
4.73 μmol/L assuming a normal serum zinc level of
8.99 (SD 2.13) μmol/L measured from a control group
of healthy children. What was regarded as normal is
below the mean (SD) serum zinc of 10.0 (2.9) reported
in our study. An earlier community study in Kampala
had found a serum zinc range of 8.4 - 20.9μmol/L
[mean(SD) 10.1(3.2)] among children aged 4 -14 years
[16]. Based on these two previous studies, it is possible
that the zinc status in our study is similar to zinc
levels in the general population of children in a similar
age group in Uganda. The prevalence was twice as
high in children who had not yet started HAART com-
pared to those receiving HAART. This was not influ-
enced by the duration on HAART. This implies that
HAART may protect against zinc deficiency but will
not completely eliminate it.
Compared to other studies of HIV infected children in
Africa, the prevalence of zinc deficiency was higher than
Age in months
70605040302010
Se
ru
m
 z
in
c 
in
 
m
ic
ro
m
o
l/L
30
20
10
0
Figure 2 A scatterplot of age against zinc levels.
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Figure 3 A scatterplot of weight for height z-scores versus zinc
levels.
Table 1 Characteristics of HIV infected children aged 1-5 years by HAART status at paediatric HIV clinics in Uganda
Variable (mean, SD) HAART (n = 44) No HAART (n = 203) Mean difference (95% CI)
Age in months 42.3 (10.7) 31.4 (13.7) 10.9 (6.6 - 15.2)
Weight for height z score 0.7 (1.4) -0.2 (1.4) 0.9 (0.4 - 1.4)
Weight for age z score -0.7 (1.1) -1.3 (1.3) 0.6 (0.2 - 1.0)
Height for age z score -2.1 (1.4) -2.1 (1.6) 0.0 (-0.5 - 0.5)
Haemoglobin (g/dl) 10.9 (1.2) 9.8 (1.6) 1.1 (0.6 - 1.6)
Absolute CD4+ cell count (cells/μ L 1132 (664) 1128 (607) 6 (-198 - 206)
Serum zinc (μmol/L) 12.2 (4.1) 9.6 (2.5) 2.6 (1.6 - 3.5)
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what was reported in South Africa and Rwanda [17,18].
Our study had a larger sample size and older children
compared to the two studies which enrolled children
from 2 months of age.
We did not find any association between age and zinc
status in our study. All the children enrolled in this
study were above one year of age, very few of whom
were still breastfeeding. Other studies have shown that
micronutrient deficiencies are less likely to occur below
24 months of age [17] and that breastfeeding is protec-
tive [19] against low serum zinc. Further more, there
was no significant difference in mean zinc concentra-
tions between girls and boys. Similar findings were
reported from children whose HIV status was not
known in low-income families in California [20].
Surprisingly, there was no significant association
between zinc status and diarrhoea in the current study,
possibly because there were very few children with diar-
rhoea. Studies in other developing countries have shown
an association between low zinc and diarrhoea [21]. As
expected, the presence of fever was significantly asso-
ciated with low zinc levels. Fever is an indicator of
infection and this may be associated with increased
acute phase proteins and consequently reduced serum
zinc [22]. Other common illnesses such as cough and
skin rash were not associated with low zinc either.
There was a weak association between underweight
and zinc status although a previous Uganda study of
children with persistent diarrhoea [15] and a South
Africa study of HIV infected children [17] did not find
any association between zinc and nutritional status.
Some authors have shown that severely malnourished
children have a higher anti-oxidant activity and this is
associated with low serum zinc [19]. Although anaemic
children were more likely to have low zinc, the associa-
tion was not significant. Other studies in zinc deficient
low-income countries such as India and Cambodia have
reported a close association between zinc deficiency and
anaemia [19,23]. The lack of association in our study
could not be explained.
Advanced HIV disease (WHO stage 3 and 4) was asso-
ciated with low serum zinc but probably confounded by
other factors. Advanced HIV disease is more likely to be
associated with recurrent acute infections and an elevated
acute phase response interpreted as low zinc. Our find-
ings are similar to a South African study where the pre-
valence of zinc deficiency increased with HIV disease
staging [6]. CD4+ T cell count had no association with
zinc status in the current study. This finding is similar to
what was reported in studies of HIV infected adults at
Tufts university and Medical Centre in the nutrition for
health living cohort [24] and in South Africa [6].
Children who were on HAART were less likely to be
zinc deficient. This is further supported by a study in
adults that showed that patients receiving HAART have
better micronutrient indices including zinc than those
not yet on HAART [25]. However, two other studies
indicated that zinc deficiency remains highly prevalent
in HIV infected adults on HAART [7,24].
We acknowledge that infant, child feeding practices
and maternal HIV status influence the diet and mode of
feeding [26], and may subsequently affect zinc intake.
Adult studies have shown that the time of blood
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Figure 4 A scatterplot of haemoglobin against zinc levels.
Table 2 Characteristics of HIV infected children aged 1-5 years by zinc status at paediatric HIV clinics in Uganda
Variable (mean, SD) Serum zinc < 10 μmol/L 95% CI Serum zinc = 10 μmol/L 95% CI
Age in months 32.2 (14.0) 29.8 to 34.6 34.7 (13.6) 32.2 to 37.2
Weight for height
z score
-0.2 (1.4) -0.5 to 0.0 0.1 (1.5) -0.2 to 0.4
Weight for age z score -1.4 (1.3) -1.6 to -1.2 -1.0 (-1.3) -1.2 to -0.7
Height for age z score -2.3 (1.4) -2.5 to -2.0 -1.9 (1.8) -2.3 to -1.6
Haemoglobin (g/dl) 9.7 (1.7) 9.5 to 10.0 10.2 (1.5) 9.7 to 10.5)
Absolute CD4+ cell count (cells/μ L) 1056 (613) 950 to 1162 1214 (610) 1099 to 1330
*On HAART (n,%) 13 (29.5) 31 (70.5)
*Children on HAART are expressed as a percentage (%).
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collection and feeding influence zinc levels [27], factors
not controlled for in this study. The exclusions though
numerous, were not systematic and therefore less likely
to influence the results of our study. Low zinc levels
were associated with fever or CRP implying that infec-
tion and acute phase proteins may have influenced the
zinc status of the study children. Other researchers have
previously confirmed that serum zinc is affected by the
serum protein level and any acute-phase reactions [28].
Although the concentration of serum zinc gives limited
information on the total zinc content in the body, there
is no better way of determining zinc status that has
been established [29]. The generalisability of this study
is limited to the HIV infected children since we did not
have a control group of HIV un-infected children.
Coupled with the already existing poor nutritional and
immunological status, low zinc status in Ugandan HIV
infected children is likely to remain a significant contri-
butor to increased morbidity especially among those not
yet receiving HAART.
Conclusion
While almost two thirds of untreated HIV infected chil-
dren were zinc deficient, zinc deficiency occurred in
only a third of those on HAART. Increased access to
HAART among HIV infected children living in Uganda
might reduce the prevalence of zinc deficiency in this
population.
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Table 3 Factors associated with low zinc in 247 HIV infected Ugandan children aged 1-5 years
Variable No. of children Low zinc < 10μmol/L
(n; %)
Unadjusted OR (95%CI) p-value Adjusted OR (95%CI)
Age < 36 months
Age ≥ 36 months
146
101
86 (58.2)
49 (48.5)
1.5 (0.9 - 2.5) 0.153 1.0 (0.6 - 1.8)
Male
Female
128
119
75 (58.6)
59 (49.6)
1.4 (0.9 - 2.4) 0.162 0.7 (0.4 - 1.1)
On HAART
No HAART
44
203
13 (29.5)
121(59.6)
3.5 (1.7 - 7.1) 0.000 3.7 (1.8 - 7.7)
Reported fever
No fever
44
203
30 (68.2)
104 (51.2)
2.0 (1.0 - 4.1) 0.046 2.2 (1.1 - 4.6)
Current diarrhoea
No Diarrhoea
20
227
15 (75.0)
119 (52.4)
2.7 (1.0 - 7.7) 0.062 2.2 (0.8 - 6.7)
Cough present
No cough
141
106
81 (57.4)
53 (50.0)
1.4 (0.8 - 2.2) 0.249
WHO stage 3 or 4
WHO stage 1 or 2
62
185
42 (67.7)
92 (49.7)
2.1 (1.2 - 3.9) 0.018 1.5 (0.8 - 2.9)
WHZ score < -2
WHZ score ≥ -2
24
223
15 (62.5)
119 (53.4)
1.5 (0.6 - 3.5) 0.519
WAZ score < -2
WAZ score ≥ -2
56
191
38 (67.9)
96 (50.3)
2.1 (1.1 - 3.9) 0.022 1.2 (0.6 - 2.6)
HAZ score < -2
HAZ score ≥ -2
136
111
80 (58.8)
54 (48.6)
1.5 (0.9 - 2.5) 0.124 1.3 (0.8 - 2.3)
CRP < 6 mg/L
CRP ≥ 6 mg/L
147
100
72 (49.0)
62 (62.0)
1.7 (1.0 - 2.9) 0.051 1.6 (0.9 - 2.7)
Hb < 11 g/dl
Hb ≥ 11 g/dl
170
77
98 (57.6)
36 (46.8)
1.6 (0.9 - 2.7) 0.130 1.1 (0.6 - 2.0)
CD4 < 20%
CD4 ≥ 20%
85
162
52 (61.2)
82 (50.6)
1.5 (0.9 - 2.5) 0.139 1.1 (0.6 - 1.9)
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Multiple micronutrient supplementation improves
vitamin B12 and folate concentrations of HIV
infected children in Uganda: a randomized
controlled trial
Grace Ndeezi1,2*, James K Tumwine1, Christopher M Ndugwa1, Bjørn J Bolann3 and Thorkild Tylleskär2
Abstract
Background: The effect of multiple micronutrient supplementation on vitamin B12 and folate has hither to not
been reported in African HIV infected children. This paper describes vitamin B12 and folate status of Ugandan HIV
infected children aged 1-5 years and reports the effect of multiple micronutrient supplementation on serum
vitamin B12 and folate concentrations.
Methods: Of 847 children who participated in a multiple micronutrient supplementation trial, 214 were assessed
for vitamin B12 and folate concentrations pre and post supplementation. One hundred and four children were
randomised to two times the recommended dietary allowance (RDA) of a 14 multiple micronutrient supplement
(MMS) and 114 to a ‘standard of care’ supplement of 6 multivitamins (MV). Serum vitamin B12 was measured by an
electrochemiluminescence immunoassay and folate by a competitive protein-binding assay using Modular E
(Roche) automatic analyzer. Vitamin B12 concentrations were considered low if less than 221picomoles per litre
(pmol/L) and folate if < 13.4 nanomoles per litre (nmol/L). The Wilcoxon Signed Ranks test was used to measure
the difference between pre and post supplementation concentrations.
Results: Vitamin B12 was low in 60/214 (28%) and folate in 62/214 (29.0%) children. In the MMS group, the median
concentration (IQR) of vitamin B12 at 6 months was 401.5 (264.3 - 518.8) pmol/L compared to the baseline of 285.5
(216.5 - 371.8) pmol/L, p < 0.001. The median (IQR) folate concentrations increased from 17.3 (13.5 - 26.6) nmol/L
to 27.7 (21.1 - 33.4) nmol/L, p < 0.001. In the ‘standard of care’ MV supplemented group, the median concentration
(IQR) of vitamin B12 at 6 months was 288.5 (198.8 - 391.0) pmol/L compared to the baseline of 280.0 (211.5 - 386.3)
pmol/L while the median (IQR) folate concentrations at 6 months were 16.5 (11.7 - 22.1) nmol/L compared to 15.7
(11.9 - 22.1) nmol/L at baseline. There was a significant difference in the MMS group in both vitamin B12 and folate
concentrations but no difference in the MV group.
Conclusions: Almost a third of the HIV infected Ugandan children aged 1-5 years had low serum concentrations
of vitamin B12 and folate. Multiple micronutrient supplementation compared to the ‘standard of care’ supplement
of 6 multivitamins improved the vitamin B12 and folate status of HIV infected children in Uganda.
Trial registration: http://ClinicalTrials.govNCT00122941)
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Background
Vitamin B12 and folate deficiency are relatively common
in low income countries compared to high income
countries, particularly in communities where the diet is
predominantly vegetarian [1-4], where major sources of
vitamin B12 such as meat, fish, poultry, milk and forti-
fied breakfast cereals [5] are consumed in small amounts
or are not readily available. Dietary sources of folate, on
the other hand, are more prevalent as they include
green leafy vegetables, fruits and dried beans and peas
[6]. During infancy and childhood folate and vitamin
B12 deficiency have been associated with failure to
thrive, reduced physical activity and cognitive function
and megaloblastic anaemia [7,8]. However many of the
symptoms are non-specific and may result from a vari-
ety of medical conditions.
A significant number of HIV-infected children in low-
income countries remain at risk of increased morbidity
due to immunodeficiency related to HIV infection in
addition to micronutrient deficiencies. Low vitamin B12
status has been associated with poor immunological sta-
tus and HIV disease progression in adults [9]. In follow
up studies of HIV infected pregnant women micronutri-
ent supplementation resulted in improved child growth,
haematological indices and vitamin B12 levels [10].
Food supplementation and multiple micronutrient for-
tification of foods and beverages in children with
unknown HIV status living in low income countries
have shown improved haemoglobin levels and concen-
trations of deficient micronutrients [2,11-14].
We hypothesised that supplementation with two
recommended dietary allowances (RDA) of 14 multiple
micronutrients (MMS) would increase serum vitamin
B12 and folate concentrations compared to a 1 RDA of 6
multivitamin (MV) ‘standard of care’ supplement. We
here report the baseline vitamin B12 and folate status in
Ugandan HIV infected children aged 1-5 years and the
effect of multiple micronutrient supplementation on
serum concentrations of vitamin B12 and folate.
Methods
Design
The study was a randomised controlled trial conducted
between 2005 and 2008 at 7 paediatric HIV clinics in
Uganda. Participants were allocated to the intervention
or ‘standard of care’ supplement in a 1:1 ratio.
Participants
HIV infected children aged 1- 5 years presenting at the
study clinics for follow up visits were eligible for the
trial. Children who had enrolled in other studies or
were unable to adhere to a regular follow up schedule
and those whose mothers or guardians declined consent
were excluded. There were no other micronutrient
supplementation studies going on at the time so the
exclusion for those who were participating in other stu-
dies was done to avoid participant fatigue and interfer-
ence with procedures. Multivitamin supplementation
was routinely practiced at the study clinics but this was
not an exclusion criteria. Eligible participants were con-
secutively enrolled, assigned to the study intervention or
‘standard of care’ supplement and followed for one year.
The study sites have been previously described [15].
Three sites were located in the capital city of Uganda
(Kampala) and these were Mulago (the national referral
hospital), Mildmay Centre and Nsambya hospital. The
other sites were situated in the regional hospitals in the
east, south-west, central and north of the country. For
logistical reasons, transport and storage, it was not pos-
sible to collect samples for biochemical tests from all
the sites. Therefore blood samples for biochemical tests
were only collected from the three Kampala sites. The
samples were subsequently shipped to the clinical chem-
istry laboratory at Haukeland University Hospital, Ber-
gen (Norway), where vitamin B12 and folate were
analysed.
The trial enrolled 847 children at all the seven study
sites. Out of 705 children from whom blood samples
could be stored for micronutrient tests, 261 had no suf-
ficient samples, 230 had other micronutrient tests done
or had either baseline but no result at the second sam-
pling. Because of multiple analyses 214 children had
both baseline and 6 months results for vitamin B12 and
folate concentrations. There were no significant differ-
ences in demographic and clinical characteristics such
as age, sex, anthropometric measurements and other
laboratory measurements like CD4 + cell count among
those who had results for vitamin B12 and folate com-
pared to those who did not.
The study was approved by the College of Health
Sciences Research and Ethics Committee, Makerere
University, Kampala, Uganda; the Uganda National
Council for Science and Technology, and the Regional
Committee for Medical Research Ethics, Western
Norway.
Cotrimoxazole prophylaxis, initiation of ART, manage-
ment of common illnesses and opportunistic infections
was offered using the national guidelines for Paediatric
HIV care.
Intervention
The trial supplements were manufactured in powder
form and packaged by NUTRISET, France using a for-
mula that was determined by the investigators based on
twice the recommended dietary intake for a 4 year old
category [6]. We decided to use 2 RDA based on the
fact that many children were malnourished despite rou-
tine supplementation with multivitamins. Secondly some
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previous studies of HIV infected adults had indicated
that HIV infected persons may require multiples of
RDA in order to achieve normal serum concentrations
of micronutrients. Thirdly, looking at the tables of the
nutritional requirements for children [6] we noted that
there are 2 age bands where our participants belonged,
1-3 and 4-8 years of age. We noticed that there were
minor variations in dosages of some micronutrients
while others like iodine and vitamin D did not vary. We
therefore decided to use the 4 year old category for our
study. In addition it was easier to administer a uniform
intervention. There were no similar studies in the region
and there was no literature to guide us on the micronu-
trient status of Ugandan HIV infected children. Also
there were no food composition tables based on the
local foods so we could not estimate how much micro-
nutrients children get from the usual diet. The MMS
comprised of 800 mcg vitamin A, 1.2 mg vitamin B1, 1.2
mg vitamin B2, 16 mg niacin, 1.2 mg vitamin B6, 2.4
mcg vitamin B12, 50 mg vitamin C, 400 IU vitamin D,
14 mg vitamin E, 40 mcg folate, 60 mcg selenium, 10
mg zinc, 800 mcg copper and 180 mcg iodine. The mul-
tivitamin ‘standard of care’ supplement contained 400
mcg vitamin A, 0.6 mg vitamin B1, 0.6 mg vitamin B2, 8
mg niacin, 25 mg vitamin C and 200 IU vitamin D. The
contents and formula for the MV supplement was based
on the regular multivitamins supplied at the study
clinics as routine care of HIV infected children. The
daily dose was 4 g and this was equivalent to a levelled
scoop supplied by the manufacturer. The powder was
mixed with 10 to 20 ml of milk or water. The first dose
of the supplement was administered at the study clinic
following a demonstration and under observation by the
study nurse. At the time of administering the first dose
we counselled the mother on the importance of com-
pleting the dose and ensuring that the daily dose was
given. Whenever the child vomited during or within 30
minutes of administering the dose a repeat dose was
given. Mothers were given calendar charts and
instructed to tick on the appropriate date whenever a
dose was given. They would return to the clinic with
the container/remaining supplement together with the
calendar charts on routine follow up visits. The remain-
ing amount of supplement was measured using a light
weight scale and the level of compliance determined
using the proportion of the supplement consumed
against the expected. The supply for one month was
140 grams and the expected dose for 30 days was 120
grams. The remaining 20 grams was to cater for vom-
ited doses or in case there was spillage. The mothers
administered the subsequent doses from home and it
was not possible to observe them. The supplements
were given for a period of 6 months when the second
sample of blood was drawn.
Outcomes
The outcome measures were serum vitamin B12 and
folate concentrations pre and post supplementation and
factors associated with low concentrations at baseline.
These were secondary objectives of the trial. Survival
was assessed as the primary objective whose findings
have been previously reported [15].
Randomisation and blinding
The randomisation sequence was generated using the
stata soft ware in variable blocks of 4 to 20. The supple-
ments were manufactured and packaged in 140 g plastic
containers which were sequentially numbered. RB gen-
erated the randomisation sequence at Geneva and sent
it to the manufacturers in France. The randomisation
code was kept at Geneva and by the manufacturers. The
treatment assignment was revealed upon completion of
the study.
Participants were enrolled by the principal investigator
and the other study doctors. The trial nurse at the study
sites dispensed the supplement in serial order. The col-
our, consistency and odour of the intervention and
‘standard of care’ supplement were similar. The princi-
pal investigator, study personnel including doctors and
nurses and the caretakers/participants were all blinded
to treatment assignment.
Clinical and laboratory measurements
At enrolment demographic information, history of the
child’s illness and findings on physical examination
were recorded. Non fasting blood samples were drawn
for CD4+ cell count and micronutrient analysis using
procedures previously described in the same cohort
[15]. Vitamin B12 was measured by electrochemilumi-
nescence immunoassay, and folate by a competitive pro-
tein-binding assay on Modular E (Roche) automatic
analyzer. The coefficient of variation for the assays was
less than 5%. To determine cut off values for low vita-
min B12 and folate, we considered what other research-
ers have used since there were no reference values for
Ugandan children. Vitamin B12 concentrations were
considered low if less than 221 picomoles per litre
(pmol/L), combining both very low (<148 pmol/L) and
marginal (148 - 221 pmol/L) status. Concentrations
equal or > 221 pmol/L was considered to be normal.
Folate concentrations were low if < 13.4 nanomoles per
litre (nmol/L), similarly combining both very low (<6.8
nmol/L) and marginal (6.8 - 13.4 nmol/L) status. Con-
centrations ≥ 13.4 nmol/L were regarded as being nor-
mal [16,17].
Statistical analysis
Change in micronutrient concentrations of each partici-
pant was computed in SPSS as follows: concentration at
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6 months minus concentration at baseline. Medians and
their interquartile ranges were used for summarising the
data. Because vitamin B12 and folate concentrations
were not normally distributed the Wilcoxon Signed
Ranks test was used to measure the difference between
baseline and 6 months in each group. Differences in
categorical variables were tested with the Pearson chi-
square or Fischer’s exact test. Differences were consid-
ered significant if a two-sided p-value was less than
0.05. Multiple regression analysis was performed to
examine factors associated with low vitamin B12 or
folate concentrations at baseline assessment.
Results
Baseline characteristics of participants
Of the 214 children with both baseline and 6 months
results for vitamin B12 and folate, 104 (48.6%) received
MMS while the rest received the ‘standard of care’ MV
supplement. The distribution of children by arm and
strata is presented in figure 1. Males and females were
equally represented. The median age (IQR) was 33.2
months (19.6 - 44.4) in the MMS and 30.3 (19.8 - 45.5)
in the MV group. Baseline characteristics are described
in table 1. There were no significant differences between
the two treatment groups.
Overall, 60 children (28.0%) had low vitamin B12 con-
centrations less than 221.0 pmol/L, and 62 (29.0%) had
low folate concentrations less than 13.4 nmol/L. Among
the children with low vitamin B12 status, 13 (6.0%) had
very low and 47 (22.0%) marginal concentrations (148 -
221 pmol/L). Of the 62 children with low folate status,
3 (1.4%) had very low (<6.8 nmol/L) and 59 (27.6%) had
marginal concentrations (6.8 - 13.4 nmol/L).
Comparisons between baseline and 6 months’ vitamin
B12 and folate concentrations
Baseline median serum vitamin B12 and folate concen-
trations were similar in the two groups. Following sup-
plementation with multiple micronutrients (MMS)
vitamin B12 concentrations increased from a median
(IQR) of 285.5 (216.5 - 371.8) to 401.5 (264.3 - 518.8)
pmol/L at 6 months. This difference was statistically sig-
nificant (p < 0.001). Similarly folate concentrations
increased from 17.3 (13.5 - 26.6) to 27.7 (21.1 - 33.4)
nmol/L and this difference was also significant, p <
0.001 (Table 2). There was no significant difference in
the MV ‘standard of care’ group.
Of the 44 children who were on HAART, 19 received
MMS while 25 received MV. In this stratum the median
(IQR) concentration of vitamin B12 in the MMS arm at
baseline was 262.0 (215.0 - 342.0) compared to 453.0
(261.0 - 594.0) pmol/L at 6 months, p = 0.002. The
median (IQR) folate concentrations increased from 18.6
(13.8 - 23.9) to 25.0 (21.3 - 32.9) nmol/L, p = 0.040.
Although the numbers were small these were significant
differences. There was no significant difference in the
MV group. Median (IQR) baseline vitamin B12 concen-
trations were higher in the HAART stratum [306.5
847 children enrolled
110 in the
‘standard of care’ arm
104 in the
multiple micronutrient arm
85 HAART 
naïve
19 HAART 
stratum
214 paired samples
for vitamin B12 and folate
142 at rural sites
261no/minimal samples
230 0ther micronutrient 
tests
25 HAART 
stratum
85 HAART 
naïve
Figure 1 Study profile.
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(209.3 - 372.8) pmol/L] compared to the non-HAART
stratum [280.0 (218.0 - 386.3) pmol/L], but not signifi-
cantly so. Folate concentrations were almost the same
[16.1 (13.5 - 22.0) nmol/L] in the HAART and [16.0
(12.1 - 24.9) nmol/L] non-HAART stratum. Thirteen
out of 40 children (32.5%) who were on HAART had
CD4+ cell percent < 25 compared to 100/159 (63.5%)
who were HAART naïve, p = 0.001 (Fisher’s exact test).
Median (IQR) duration of anti-retroviral therapy was 9
(6.0 - 14.3) months.
Table 1 Characteristics of 214 Ugandan HIV infected children analysed for vitamin B12 and folate by intervention
group
Number (N) MMS n (%) ’Standard of care’ MV n (%) p-value
Sex: Male 100 49 (49.0) 51 (51.0) >0.99
Age less than 24 months 70 33 (47.1) 37 (52.9) 0.77
Mother as carer 146 73 (50.0) 73 (50.0) 0.56
On HAART 44 19 (43.2) 25 (56.8) 0.50
Routine CTX 193 93 (48.2) 100 (51.8) 0.82
Routine MV 144 68 (47.2) 76 (52.8) 0.66
WHZ < -2 28 14 (50.0) 14 (50.0) >0.99
HAZ < -2 113 56 (49.6) 57 (50.4) 0.89
WHO stage 3 or 4 56 26 (46.4) 30 (53.6) 0.76
CD4+ T cells < 25% 114 50 (43.9) 64 (56.1) 0.20
Elevated CRP (> 6 g/dl) 67 33 (49.3) 34 (50.7) 0.42
Low haemoglobin (< 11 g/dl) 127 61 (48.0) 66 (52.0) 0.89
Low vitamin B12 (< 221 pmol/L) 60 29 (48.3) 31 (51.7) 0.96
Low folate (< 13.4 nmol/L) 62 25 (40.3) 37 (59.7) 0.13
MMS = multiple micronutrient supplementation
HAART = Highly active anti-retroviral therapy
CTX = Cotrimoxazole
MV = ‘standard of care’ multivitamins
WHZ = Weight for height z-score
HAZ = Height for age z-score
WHO = World Health Organisation
CD4+ = Cluster of differentiation 4
CRP = C-reactive protein
Table 2 Biochemical and haematological measurements at baseline and at 6 months of supplementation by
intervention group
Multiple Micronutrient Supplementation
group (n = 104)
Comparative ‘standard of care’ multivitamins
group (n = 110)
Measurement Median (IQR) P-value Median (IQR) p-value
Vitamin B12 (pmol/L)
Baseline 285.5 (216.5 - 371.8) <0.001 280.0 (211.5 - 386.3) 0.78
6 months 401.5 (264.3 - 518.8) 288.5 (198.8 - 391.0)
Change 90.5 (-0.8 - 203.5) 10.0 (-73.8 - 83.8)
Folate (nmol/L)
Baseline 17.3 (13.5 - 26.6) <0.001 15.7 (11.9 - 22.1) 0.44
6 months 27.7 (21.1 - 33.4) 16.5 (11.7 - 22.1)
Change 8.0 (-0.3 - 17.1) -0.6 (-3.5 - 5.8)
Haemoglobin (g/dl)
Baseline 10.0 (8.7 - 11.2) 0.04 9.8 (8.8 - 11.2) <0.001
6 months 10.9 (9.4 - 11.7) 10.6 (9.6 - 11.7)
Change 0.3 (-0.4 - 0.9) 0.6 (-0.2 - 1.4)
CD4+ count (cells/μL)
Baseline 1201 (822 - 1556) 0.16 1033 (728 - 1406) 0.52
6 months 1039 (725 - 1358) 1043 (704 - 1484)
Change -137 (-348 - 254) 35 (-278 - 352)
Wilcoxon Signed Ranks test was used to measure the difference between baseline and 6 months.
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Vitamin B12 and folate status at 6 months of
supplementation
Overall, 42 (19.6%) children had low concentrations of
vitamin B12 at 6 months, 9 (4.2%) with very low and 33
(15.4%) with marginal concentrations. Nine children
(1.4%) were in the MMS and 33 (78.6%) in the MV
group. This was a statistically significant difference. The
odds ratio was 4.5 (95% CI; 2.0 - 10.0). Folate concen-
trations were low in 44/214 (20.6%) children at 6
months of follow up; almost all of them had marginal
concentrations. Five children (11.4%) were supplemen-
ted with MMS and 39 (88.6%) MV; Odds ratio 10.8
(95% CI; 4.1 - 28.9). Low vitamin B12 and folate concen-
trations were more frequent in the MV supplemented
group.
Other clinical and haematological findings
Eight of the 214 children had signs of neurological dis-
ease, 6 with delayed or loss of developmental milestones,
3 of whom had low or marginal vitamin B12 status.
There was a significant increase in the haemoglobin sta-
tus in both groups as shown in table 2. There was no
significant change in the CD4 cell counts in either the
MMS or MV group.
HAART strata and initiation of HAART during the study
Of the 44 children on HAART at enrolment, 15 (34.1%)
and 10 (22.7%) had low vitamin B12 and low folate con-
centrations, respectively. The prevalence of low micro-
nutrient status of these two was not significantly
different between the HAART and non-HAART treated
children. Of the 170 HAART naïve children, 21 started
HAART during the study; 13 in MMS and 8 in MV
group. This difference was not significant, p = 0.35.
Seven of the 21 children who initiated HAART during
the study had low vitamin B12 concentrations at
enrolment.
Factors associated with low vitamin B12 or folate
concentrations
Vitamin B12 status was not closely associated with most
of the baseline characteristics (Table 3). However being
male, age less than 24 months and a haemoglobin < 11
g/dl were associated with low folate concentrations. At
multivariate analysis only age and the male sex
remained significantly associated with low serum folate
concentrations.
Discussion
This paper describes the vitamin B12 and folate concen-
trations of HIV-infected Ugandan children aged 1-5
years and the effect of 2RDA of 14 multiple micronutri-
ents that contained vitamin B12 and folate versus the
‘standard of care’ multivitamins in 1RDA without
vitamin B12 and folate. Almost a third of the children
had low vitamin B12 and low folate concentrations at
baseline. Very low serum concentrations were uncom-
mon. MMS containing vitamin B12 and folate improved
both vitamin B12 and folate concentrations compared to
the ‘standard of care’ multivitamins.
Vitamin B12 and folate concentrations in our study are
comparable or slightly lower than what has been
reported in children living in other low-income coun-
tries [1,2,4,17]. Our findings are also comparable to
what other studies in HIV infected adults reported
before the HAART era. These studies showed that low
vitamin B12 concentrations were relatively common with
a prevalence ranging between 10 and 35% [18-22].
There are few studies that have examined vitamin B12
and folate in HIV infected children in Africa. The preva-
lence of low vitamin B12 concentrations in our study was
much higher than the prevalence of 5% reported in South
African HIV infected children [23]. Contrary to our find-
ings a study of HIV infected children in New York showed
elevated vitamin B12 and folate status [24]. Our study
included younger children, the majority of whom were
symptomatic and not on HAART compared to the New
York study. In our study the lack of differences between
the HAART and non-HAART stratum in baseline vitamin
B12 or folate concentrations could be explained by the
short duration of HAART compared to other studies.
Twice the recommended dietary allowance of multiple
micronutrients improved vitamin B12 and folate status
compared to the ‘standard of care’. This is not surpris-
ing since the standard of care supplement did not con-
tain vitamin B12 and folate. This implies that the
standard of care multivitamin is not enough and many
more micronutrients may be required to correct micro-
nutrient deficiencies. A significant number of children
still had low concentrations of vitamin B12 and folate at
the end of 6 months, implying that the duration of sup-
plementation needed to be extended.
Low vitamin B12 could be related to folate deficiency
or to low vitamin B12 binding proteins. Although we did
not find an association between low vitamin B12 and
white blood cell count this does exclude the possibility
that low vitamin B12 concentrations could be related to
neutropenia.
We observed that there was an association between
low folate concentrations and low haemoglobin which
indicates that the anaemia could partly be attributed to
low folate concentrations. In both treatment groups the
haemoglobin improved compared to baseline levels. We
could not conclusively attribute the anaemia to low
folate concentrations since we did not measure red
blood cell folate concentrations. Measuring both serum
folate and Red cell folate would have yielded more diag-
nostic information of folate deficiency. However sub-
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normal serum folate is a useful indicator of folate status
that warrants reporting. In a landscape of multiple defi-
ciencies, such as HIV-infected children in a low-income
country, there is always the potential for other deficien-
cies to alter the response, for instance, iron deficiency
(the supplement did not contain iron). Folate deficiency
has been reported in almost one in two anaemic HIV
infected patients [25]. Other authors have reported asso-
ciations between anaemia, gender and folate deficiency
in children whose HIV infection status was not known
[26].
Neither MMS nor the ‘standard of care’ MV improved
the immunological status of the study children. In fact
there was a slight deterioration in the CD4+ cell counts
among the HAART naïve MMS group. This was contrary
to findings of a trial in HAART treated HIV infected
adults living in the USA where multiple micronutrient
supplementation was associated with improved CD4+
cell count compared to a placebo [27]. The lack of effect
on CD4+ cell count in our study could be explained by
the natural immunological deterioration or it may be
apparent due to the small numbers in the HAART
group. It is also possible that the supplementation was
not long enough to show an impact on CD4+ cell count
since one in five children still had low vitamin B12 and
folate concentrations at 6 months of follow up.
Table 3 Factors associated with low vitamin B12 and folate among HIV infected children in Uganda
Baseline characteristics Number N Low vitamin B12 status
a n (%) Un adjusted OR (95% CI) Adjusted OR (95%CI)
Vitamin B12 status
Age < 24 months 70 19 (27.1) 0.9 (0.6 - 1.5)
Age ≥ 24 months 144 41 (28.5)
Male 100 33 (33.0) 1.4 (0.9 - 2.1) 1.6 (0.8 - 3.1)
Female 114 27 (23.7)
Weight for height z score < -2 28 7 (25.0) 0.9 (0.4 - 1.7)
Weight for height z score ≥ -2 182 52 (28.6)
Haemoglobin < 11 g/dl 127 37 (29.1) 1.1 (0.7 - 1.7)
Haemoglobin ≥ 11 g/dl 87 23 (26.4)
CD4+ < 25% 114 33 (28.9) 1.1 (0.6 - 2.1)
CD4+ ≥ 25% 85 23 (27.1)
On HAART 44 15 (34.1) 1.3 (0.8 - 2.1)
HAART naïve 170 45 (26.5)
Routine CTX prophylaxis 193 56 (29.0) 1.5 (0.6 - 3.8)
No routine CTX prophylaxis 21 4 (19.0)
Previous routine multivitamins 144 40 (27.8) 1.0 (0.6 - 1.5)
No routine multivitamins 70 20 (28.6)
Folate status Low folate
Age < 24 months 70 27 (38.6) 1.6 (1.1 - 2.4) 2.2 (1.1 - 4.5)
Age ≥ 24 months 144 35 (24.3)
Male 100 36 (36.0) 1.6 (1.0 - 2.4) 2.1 (1.1 - 4.0)
Female 114 26 (22.8)
Weight for height z score < -2 28 7 (25.0) 0.8 (0.4 - 1.7)
Weight for height z score ≥ -2 182 54 (29.7)
Haemoglobin < 11 g/dl 127 45 (35.4) 1.8 (1.1 - 2.9) 1.9 (0.9 - 4.6)
Haemoglobin ≥ 11 g/dl 87 17 (19.5)
CD4+ < 25% 114 36 (31.6) 1.2 (0.7 - 1.9)
CD4+ ≥ 25% 85 22 (25.9)
On HAART 44 10 (22.7) 0.7 (0.4 - 1.3)
HAART naïve 170 52 (30.6)
Routine CTX prophylaxis 193 58 (30.1) 1.6 (0.6 - 3.9)
No routine CTX prophylaxis 21 4 (19.0)
Previous routine multivitamins 144 44 (30.6) 1.2 (0.7 - 1.9)
No routine multivitamins 70 18 (25.7)
aLow vitamin B12 < 221 pmol/L,
Low folate < 13.4 nmol/L
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In our setting it is possible that low concentrations of
vitamin B12 and folate may be related to consumption
of marginal or low levels of vitamin B12 and folate since
twice the recommended dietary intakes increased serum
concentrations as opposed to the multivitamin supple-
ment which did not contain vitamin B12 or folate. Some
authors have shown that Vitamin B12 deficiency is rare
in HIV infected persons consuming vitamin B12 well
above the recommended nutrient intakes [28]. In
Uganda one third of children aged between 6 and 24
months are likely to be getting diary products in their
diet and very few are likely to be getting other animal
source foods [29].
We are not certain whether our findings are similar to
children in the general population since we had no con-
trol group of HIV uninfected children. A study of both
HIV-infected and exposed uninfected children in Brazil
showed no differences in micronutrient status [30].
However another study indicated that HIV infected chil-
dren had significantly lower folate levels than the refer-
ence children while vitamin B12 was similar [31].
We were unable to measure serum homocysteine and
methyl malonic acid concentrations which are more reli-
able indicators of vitamin B12 deficiency because of the
limited amount of blood that we could draw from the
children as we had multiple micronutrients to test for.
We also did not conduct absorption studies to examine
the impact of malabsorption on baseline micronutrient
and post-supplementation status. This paper does not
describe the dietary habits of the study children and
whether they had an impact on the outcome.
Conclusion
Low vitamin B12 and folate concentrations are common
in Ugandan HIV infected children aged 1-5 years. Twice
the recommended dietary allowance of 14 multiple
micronutrients as opposed to the 6 multivitamin ‘stan-
dard of care’ supplement improved the vitamin B12 and
folate status of HIV-infected children in Uganda.
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